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Preface and Declaration
This thesis presents results from investigations conducted within 4 broadly defined areas :
1) To investigate the effect of acute brain injury on the distribution of the microtubule- 
associated proteins tau, MAP2 and MAP5 in oligodendrocytes.
2) To asses the mechanisms underlying the accumulation of tau immunoreactivity in 
oligodendrocytes following acute brain injury.
3) To determine if increased tau immunoreactivity within these cells reflected increased 
synthesis or protein modification.
4) To compare the distribution of tau, MAP2 and MAP5 within oligodendrocytes with that 
in neurons following acute brain injury.
Results from these studies are presented and discussed separately. The thesis comprises 
my own original work and has not been presented previously as a thesis in any form. Dr. 
K. Yatsushiro performed the permanent middle cerebral artery occlusions. In vitro studies 
were carried out in collaboration with Dr. S.C. Barnett who kindly supplied the 
oligodendrocyte cultures. In situ hybridisation studies were carried out in collaboration 
with Dr. P. Dickinson. Both the electron microscopy and confocal microscopy were 
performed by Prof. I.R. Griffiths.
Abstract
With the growing evidence supporting glia-neuronal signalling it is becoming increasingly 
apparent that it is crucial to gain an understanding of the mechanisms underlying the 
degeneration of both neurons and glia to fully understand the pathogenesis of acute and 
chronic degenerative diseases of the brain. Breakdown of the cytoskeleton is thought to 
represent a common pathway mediating irreversible neuronal damage in a variety of both 
acute and chronic neurodegenerative conditions. One of the most well documented 
alterations to the cytoskeleton, occurring in various neurodegenerative disorders including 
Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy, is the 
formation of neurofibrillary tangles. The formation of neurofibrillary tangles is thought to 
involve alterations in the microtubule-associated protein tau, the protein being 
hyperphosphorylated compared to its normal form. Tau is traditionally believed to be a 
neuron-specific protein where it is predominantly located within the axonal compartment. 
Supporting this specific localisation of tau, immunoreactivity was found only within axons 
in histologically normal rat or human brain tissue throughout the investigations carried out 
in this thesis. However, the novel finding of this thesis was the presence of tau 
immunoreactivity within oligodendrocytes in both rat and human brain tissue following 
acute brain injury. The studies described in this thesis were aimed at characterising the 
increased tau immunoreactivity present in oligodendrocytes in animal models of acute brain 
injury, in human post-mortem brain tissue from patients who died following a stroke or 
head injury and in an oligodendrocyte cell line.
! In the initial study of the thesis tau-positive oligodendrocytes were present 4 h following
j  glutamate-induced toxicity in the rat. In order to confirm that the induction of tau
I immunoreactivity in these cells following injury was not a phenomenum characteristic to
the rat, human post-mortem brain tissue from acute brain injured patients was examined
i
for the presence of tau-positive oligodendrocytes. Tau-positive oligodendrocytes were 
detected within areas of tissue, as defined by decreased haematoxylin and eosin staining, 
affected by brain injury, but not in tissue obtained from control patients who had no 
previous history of neurological or psychiatric disorders. Tau-positive oligodendrocytes 
were detected as early as 2 h following head injury, suggesting that this is a rapid response 
o f these cells to acute brain injury. In support o f this, the induction o f tau 
immunoreactivity in oligodendrocytes was detected as early as 40 min following the 
induction of permanent focal cerebral ischaemia in the ra t
xiv
Glutamate toxicity has been shown to be involved in neuronal degeneration following 
ischaemic brain injury, and tau-positive oligodendrocytes were detected 4 h following 
intracortical perfusion of 1M monosodium glutamate, both within the resulting cortical 
lesion and in the white matter immediately underlying this area. This result implicated 
glutamate in the mechanisms underlying the accumulation of tau in oligodendrocytes 
following injury. However, the ability of NaCl to induce a similar response in 
oligodendrocytes suggested that mechanisms other than glutamate toxicity may be 
involved. Using pure oligodendrocyte cultures exposed to monosodium glutamate or 
NaCl it was shown that alteration of tau in these cells was a direct effect, not mediated 
through neuronal degeneration. Taken together the results of these studies indicated that 
some aspect of the brain injury in vivo other than glutamate receptor activation may be 
involved in the alteration o f tau in oligodendrocytes. In order to investigate further the 
mechanisms which may be involved in this oligodendrocyte response, the effects of 3 
pharmacological agents on the density of tau-positive oligodendrocytes following focal 
cerebral ischaemia in the rat were determined. Pre-treatment with the spin trap agent a- 
phenyl-tert-butyl-nitrone reduced the number of tau-positive oligodendrocytes by 55% in 
the subcortical white matter of the ischaemic hemisphere compared to untreated animals at 
40 min after middle cerebral artery occlusion. In contrast, pre-treatment with glutamate 
receptor antagonists dizocilpine or 2,3-dihydroxy-6-nitro-7-sulpfamoyl-benzo(F) 
quinoxaline, failed to reduce the number of tau-positive oligodendrocytes following 40 
min of ischaemia. Thus free radial mediated mechanisms were involved in the induction 
of tau immunoreactivity in oligodendrocytes following ischaemic brain injury.
In both the animal models of brain injury and the human post-mortem brain tissue obtained 
from patients who died following a stroke or head injury, tau-positive oligodendrocytes 
were detected with a range of antibodies to different epitopes of the protein. This 
suggested that there may be increased levels of the full-length protein. In order to 
investigate whether this increased immunoreactivity was due to increased protein 
synthesis, in situ hybridisation studies were performed in rat brain tissue obtained from the 
focal cerebral ischaemia model. However, these in situ hybridisation studies failed to 
detect increased tau mRNA within the ipsilateral white matter up to 4 h after the induction 
o f focal cerebral ischaemia. This suggests that increased tau immunoreactivity in 
oligodendrocytes does not reflect increased de novo synthesis of the protein.
In contrast to the accumulation of full-length tau in oligodendrocytes, neuronal tau was 
dephosphorylated and/or degraded following acute brain injury in the rat. 
Dephosphorylation of tau in neurons was detected as early as 20 min following the 
induction of focal cerebral ischaemia in the rat. In addition, degradation of tau in neurons
xv
but not in oligodendrocytes suggests that tau present in neuronal perikarya may be more 
susceptible to ischaemic brain damage than that in oligodendrocytes. However these 
results demonstrate that tau present in both neuronal perikarya and oligodendrocytes 
undergoes rapid alteration following ischaemic challenge. Glutamate excitotoxicity 
induced changes in tau similar to those occurring following focal cerebral ischaemia in the 
rat suggesting that while the accumulation of tau in oligodendrocytes is initiated through 
free radical mediated mechanisms, dephosphorylation and/or degradation of tau in neurons 
appears to be mediated through glutamate mediated mechanisms.
The results presented in this thesis provide compelling evidence that tau is present in 
oligodendrocytes and therefore can no longer be considered as a neuron-specific protein. 
Moreover these results show that tau undergoes rapid alteration within oligodendrocytes in 
response to acute brain injury which is initiated through free radical mediated mechanisms. 
Alterations in the distribution of microtubule-associated proteins in neurons following 
injury are thought to represent altered cytoskeletal integrity which may result in irreversible 
neuronal damage. It is possible to speculate therefore that alterations to tau in 
oligodendrocytes, following acute brain injury may also represent early stages of 
cytoskeletal breakdown within these cells. Oligodendrocytes have been until recently 
considered to be relatively unresponsive to ischaemic brain injury, and neuroprotective 
agents have been evaluated solely on their ability to reduce neuronal damage. One of the 
most successful strategies involves the blockade of glutamate receptor activation which 
was without effect in the reduction of the induction of tau immunoreactivity in 
oligodendrocytes following focal cerebral ischaemia. The results of this thesis may 
therefore have important consequences for the development of new therapeutic strategies, 
since protection of neuronal elements without the protection of glial cells would lead to 
delayed neuronal death rather than complete protection of the brain following acute brain 
injury.
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CHAPTER 1 INTRODUCTION
1.1  General introduction
Until recently neurons were believed to be the most important cells in the functioning of the 
central nervous system (CNS) with neuroglia providing a purely supportive role. With this 
view much attention has been directed at elucidating the mechanisms underlying neuronal 
degeneration, in both acute and chronic degenerative diseases of the brain. Assuming that 
similar mechanisms underlie neuronal degeneration in both acute and chronic disorders, 
animal models of acute brain injury have been used to gain insight into such mechanisms in 
order to uncover suitable targets for therapeutic intervention. As a result, neuroprotective 
agents have been evaluated on their ability to reduce the extent of neuronal death following 
acute brain injury.
Glutamate is a major neurotransmitter in the CNS and is essential for neuronal signalling 
under normal conditions (Palmer and Gerhon, 1990; Salt and Herrling, 1991). In acute 
brain injury, including stroke and head injury, excessive glutamate receptor activation, 
subsequent calcium influx and free radical formation plays a pivotal role in neuronal 
degeneration (see section 1.2.3). It is now widely accepted that both astrocytes and 
oligodendrocytes possess glutamate receptors (for review see Gallo and Russell, 1995), 
suggesting that receptor activation in these cells may also occur during the presence of 
elevated extracellular glutamate concentrations. In neurons glutamate toxicity whether via 
calcium release and/or free radical toxicity, has been shown to be mediated largely through 
the activation of N-methyl-D-aspartate (NMDA) receptors and therefore many of the most 
effective neuroprotective agents have been directed towards NMDA receptor blockade. 
Astrocytes and oligodendrocytes however appear to lack NMDA receptor subtypes and 
glutamate toxicity has been shown to be mediated through non-NMDA receptors in these 
cells (Gallo and Russell, 1995; Patneau, et. al. 1994; Puchalski, et. al. 1994; Yoshioka, et. 
al. 1994). In light of this it is possible to envisage that although neurons are protected 
successfully by NMDA antagonists, glial cells remain at risk in conditions where there are 
high concentrations of extracellular glutamate.
The role of astrocytes in the uptake of glutamate and other neurotoxic substances and the 
proliferation of these glial cells following acute brain injury has been well documented. In 
contrast however, oligodendrocytes have been considered to be relatively unresponsive to 
acute brain injury. With the exception of the undisputed role of these cells in the pathology 
o f multiple sclerosis, the elucidation of possible roles for oligodendrocytes in the 
pathogenesis of both acute and chronic neurodegenerative conditions has therefore on the 
whole been neglected. However, the discovery that these glial cells possess glutamate
1
receptors suggest that oligodendrocytes may have a function in neuron-glial signalling and 
therefore play an important role in disease pathology (see section 1.5.5). A limited number 
of investigators have provided evidence that in addition to astrocytes and neurons, 
oligodendrocytes may have the ability to respond rapidly to ischaemic, hypoxic and 
traumatic brain injury (see section 1.5.7).
Cytoskeletal breakdown is thought to represent a final common pathway of neuronal 
degeneration in a variety of both acute and chronic degenerative conditions. Accumulation 
o f tau within neuronal perikarya and altered distribution of the microtubule associated 
proteins tau, MAP2 and MAP5, may illustrate alterations in cytoskeletal integrity within 
these cells. Abnormal cytoskeletal profiles have recently been detected in both 
oligodendrocytes and astrocytes in various chronic degenerative diseases such as multiple 
system atrophy (MSA) and progressive supranuclear palsy (PSP) (see section 1.4.4). The 
distribution and density of these oligodendrocytes in MSA closely parallels the severity of 
the disease, in addition these cells can occur in areas where neuronal degeneration is absent 
This suggests that the formation of these cytoskeletal inclusions in oligodendrocytes may 
represent an early and important event in the pathogenesis of this chronic degenerative 
disease.
Together these findings suggest that oligodendrocytes, once thought to be relatively inactive 
in disease, may play an important role in the progression of both acute and chronic disease 
of the CNS. In order to fully understand the pathogenesis of acute and chronic brain injury 
and to highlight areas for new therapeutic intervention, it is crucial to determine the response 
of these cells to brain injury, the possible mechanisms underlying such responses and the 
consequence of these responses to the structural integrity of the neuron. Any similarities 
between mechanisms underlying neuronal and oligodendroglial degeneration may lead to a 
target for drug intervention protecting both neuronal and glial elements of the CNS essential 
for effective and prolonged neuroprotection. The main focus of this thesis therefore was to 
examine the effect of acute brain injury on one particular cytoskeletal protein; tau in 
oligodendrocytes and the mechanisms through which such effects are mediated.
1 .2  Acute brain injury
1.2.1 Stroke
Stroke results from a reduction of blood flow to a given area of the brain, normally caused 
by the blockage of a major artery, however, spontaneous intracerebral haemorrhage or 
decreased cardiac output are also minor causes of stroke. Cerebrovascular disease, accounts 
for approximately 10% of all deaths in the United Kingdom surpassed only by cancer and
2
heart disease. The incidence of stroke increases with age, however strokes can occur in all 
age groups (Bamford, et. al. 1990). For those that survive a stroke lasting for 24 hr, 50% 
remain permanendy disabled with only 10% returning to normal activity.
Structural damage resulting from stroke or hypoxia can be limited to neurons (selective 
neuronal necrosis) or may also affect glia, nerve fibres and blood vessels (cerebral 
infarction) (Nedergaard, 1988). It is now widely accepted that neurons followed by 
astrocytes and oligodendrocytes are most vulnerable to hypoxia and stroke. The degree of 
infarction is dependant on the reduction of cerebral blood flow and the duration of 
hypoperfusion. A threshold for infarction of 35 % of normal cerebral blood flow or 
17ml/100mg tissue has been found in sustained ischaemia (Jones, et. al. 1981). Normally 
infarction occurs within the territory of a given arterial supply, the extent of which is 
dependant on the efficiency of collateral blood supply to the affected area. Through the use 
of post-mortem brain tissue, the evolution of ischaemic brain damage has been well 
documented in man (Adams and Graham, 1988). At post-mortem, recent infarcts result in 
soft very swollen brain tissue and can be anaemic or haemorrhagic depending on whether or 
not some blood flow has been restored or if blood vessel necrosis has occurred. 
Histological assessment by haematoxylin and eosin (H&E) staining shows dead neurons 
present in the grey matter, recognised by intensely eosinophilic cytoplasm and a poorly 
stained nucleus with haematoxylin 4-6 h after cessation of blood flow. Areas of ischaemic 
brain damage are extremely difficult to define at survival times of less than 4 h following the 
onset of stroke. Within 12-25 h the infarct has a sharply delineated boundary due to 
decreased H&E staining of neuropil caused by a combination of the swelling of astrocyte 
processes and axons. The next stage of development occurs within 24 h and involves 
proliferation of microglia and astrocytes this proliferation extends to lipid phagocytes 1-2 
weeks later which phagocytose the affected tissue. The grey matter becomes shrunken and 
granular and if the patient survives for several months following stroke the dead tissue is 
removed by phagocytosis and the infarct presents as a shrunken cystic lesion.
1.2.2 Head injury
Trauma is the largest cause of death of under 45 yr olds in the United Kingdom with head 
injury being largely responsible. In non-missile head injury a sudden acceleration or 
deceleration of the head is usually involved with or without skull fracture. The brain moves 
within the skull resulting in a number of shearing forces and impact of the brain against the 
bony protruberances of the skull. The majority of head injured patients make an uneventful 
recovery, however, others sustain significant irreversible brain damage to the extent that 
may leave them dependant on family members or institutions for the rest of their lives. In 
the UK alone 1 in 300 families has a member permanently disabled by head injury.
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Brain damage resulting from head injury is classified by describing the damage as focal or 
diffuse or as primary or secondary. Primary damage involves fracture of the skull, cerebral 
contusions and diffuse axonal injury while secondary damage includes that due to 
intracranial haematoma, raised intracranial pressure, brain swelling, hypoxic brain damage 
or infection. Diffuse axonal injury is now widely accepted to represent the most important 
factor in the outcome of patients following non-missile head injury (Graham, e t  al. 1995) 
often responsible for concussion up to and including post-traumatic coma (Blumbergs, et. 
al. 1989; Gennarelli, 1993). In this type of injury there is widespread disruption of axons 
due to the shearing stresses of acceleration/deceleration injury resulting in discrete lesions in 
the dorsolateral quadrant of the rostral brain stem and in the corpus callosum as well as 
diffuse damage to axons throughout the brain. Axonal damage can be detected 
histologically by H&E staining or silver staining and immunologically with anti-amyloid 
precursor protein antibodies (Gentleman, et. al. 1993; 1995; McKenzie, et. al. 1995) or 
anti-neurofilament antibodies (Christman, et. al. 1996; Grady, et. al. 1993). In patients 
surviving only a short time following head injury axonal swellings and axonal bulbs can be 
detected, however as survival time increases (several weeks) the most conspicuous feature 
is the presence of multiple clusters of microglia with a few axonal bulbs still detectable 2 
months following injury.
Approximately 90% of fatal head injured patients show ischaemic cell change of varying 
degrees at post-mortem (Graham, et. al. 1978) suggesting that ischaemic brain damage 
plays pivotal role in patient outcome after head injury. 40% of these patients spoke 
following head injury implying that cerebral ischaemia may represent a secondary and 
therefore treatable event (Bullock and Teasdale, 1990). Ischaemic brain injury may 
therefore be crucial in the degree of brain damage sustained following both moderate and 
severe head injury. Cerebral ischaemia may be caused by intracranial haematoma or 
systemic insults such as hypoxia and hypotension which may result in raised intracranial 
pressure and therefore reduced cerebral perfusion. Further supporting a role for ischaemic 
brain damage in outcome after head injury, a body of evidence now exists showing that 
events at the time of the primary injury may leave the brain susceptible to ischaemic injury. 
This may occur through altered metabolism and function or by alteration of normal vascular 
reactivity, such that mild ischaemic insults which would normally be tolerated, may cause 
major ischaemic brain damage (Jenkins, et. al. 1989; Wei, et. al. 1980).
Figure 1. Photomicrograph of neurons displaying ischaemic cell change. Post-mortem 
tissue obtained from the cingulate cortex of a patient surviving 5 d following a stroke stained 
with H&E. Note the triangulation of the nuclei present in neurons and the eosinophilic 
cytoplasm of these cells. Neuropil staining is reduced, probably through swelling of axons, 
dendrites and astrocytic processes. This reduction in H&E staining of the neuropil clearly 
delineates the boundary between areas of tissue affected by ischaemic brain damage and 
histologically normal tissue. Scale bar = 100|im.
1.2.3 M echanism s of acute b ra in  in jury  
Glutamate toxicity
There is a large body of evidence supporting a role for glutamate excitotoxicity in the 
pathogenesis of cerebral ischaemia. In experimental models of cerebral ischaemia there is a 
marked, immediate rise in extracellular glutamate concentration, irrespective of the cause of 
the ischaemic episode (Beneviste, et. al. 1984; Bullock, et. al. 1990; Butcher, et. al. 1990; 
Faden, et. al. 1989). The largest elevation of 20 fold in the cerebral cortex and 80 fold in 
the caudate nucleus occurred following focal cerebral ischaemia in the rat (Butcher, et. al. 
1990; Graham, et. al. 1990). This elevation peaks within 40 min after middle cerebral 
artery occlusion (MCAO) in the rat and probably results due to an increase release of 
glutamate from neurons and reduced uptake into both neurons and astrocytes (Drejer, et. al. 
1985). This release appears to be dependent on the severity of blood flow reduction, 
elevation being triggered by blood flows below 20ml/100g/min (Shimada, et. al. 1989).
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Levels of glutamate released within 10-30 min of focal cerebral ischaemia have been shown 
to be comparable with a glutamate concentration (60-500|iM) which is toxic to neurons in 
vitro (Choi, 1987).
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Figure 2. Extracellular glutamate levels are elevated following permanent MCAO in the 
rat. Microdialysis probes were placed in the cerebral cortex and dialysates collected every 
20 min. Extracellular glutamate concentrations were increased approximately 20-fold 40 
min after MCAO. Arrow respresents the onset of focal cerebral ischaemia by permanent 
occlusion of the middle cerebral artery (MCA). O represent sham operated c o n tro ls^  
represent proximal occlusion of the MCA; A represent distal occlusion of the MCA. 
Reproduced from Butcher, et. al. (1990).
Since the initial discovery of the toxic potential of glutamate by Lucas and Newhouse in 
(1957), when they described the degeneration of retinal neurons in neonatal mice injected 
systemically with glutamate, it is now widely accepted that high extracellular concentrations 
of glutamate are neurotoxic (Rothman and Olney, 1986; Choi, 1991). Glutamate acts on 4 
major types of receptor, the NMDA receptor, the 2-amino-3-hydroxy-5-methylisoxazole-4- 
propionic acid (AMPA) receptor, the kainate receptor and metabotropic receptors 
(Collingridge and Lester, 1989; Monaghan, et. al. 1989; Watkins, et. al. 1990). The 
NMDA, kainate and AMPA receptors are linked to receptor activated ion channels while 
metabotropic subtypes are thought to be linked to phosphoinositide metabolism as a second 
messenger system (Schoepp, et. al. 1990). Under normal conditions, AMPA and kainate 
receptors which are permeable to Na+ and K+ (there are also some reports of Ca++
6
permeability, see below) are responsible for fast excitatory synaptic transmission in the 
CNS since NMDA receptors are blocked through a voltage dependant blockade by Mg++ 
(MacDermott and Dale, 1987; Mayer and Westbrook, 1987).
Glutamate toxicity has been shown to involve both a sodium chloride and a calcium 
dependant component (Dessi, e t  al. 1994). Cellular swelling following glutamate toxicity 
is thought to result from the influx of Na+ through the activated NMDA receptor channel, 
which subsequently leads to an influx of Cl- and water through this channel due to the 
osmotic properties of these ions. Excessive activation of NMDA receptors leads to toxic 
levels of intracellular calcium (Choi, 1987; 1991; MacDermott, et. al. 1986; Michaels and 
Rothman, 1990). Depolarisation frees the Mg++ channel block allowing the passage of 
Ca++ through the receptor mediated channel, voltage-gated calcium channels and results in 
the mobilisation of intracellular Ca++ stores. Although, originally believed to be 
impermeable to Ca++, a large body of evidence has accumulated showing that certain 
configurations of non-NMDA receptor subunits form ionophores permeable to Ca++ 
(Hollman, et. al. 1991; Murphy and Miller, 1989; Murphy, et. al. 1992; Ogura, et. al. 1990; 
Ozawa, et. al. 1991). Activation of non-NMDA receptors therefore may also contribute to 
calcium influx in pathological circumstances. Although the exact mechanisms involved in 
glutamate excitotoxicity are not fully understood, most evidence to date suggests that the 
influx of Ca++ is probably largely responsible (Siesjo, et. al. 1991; Miller, et. al. 1992).
Calcium plays an important role in many normal cell functions including the control of 
membrane permeability, modulation of neurite extension and synapse formation, triggering 
neurotransmitter release and the regulation of gene expression such as the induction of 
immediate early genes. In addition Ca++ modulates the activities of various enzymes 
including calcium-dependant phosphatases, kinases and proteases and therefore plays a role 
in the maintenance of neuronal structure, since cytoskeletal proteins are substrates for these 
enzymes (for review see Siesjo, 1988). Intracellular and extracellular Ca** concentrations 
o f neurons are around 10"7 and 10"3M respectively (Choi, 1988) the intracellular 
concentration being strictly controlled by an ATP-dependent Ca++/Na+ exchange (Mayer 
and Miller, 1990) for normal cellular function. Under pathological conditions such as 
ischaemia or head injury however, where excessive glutamate receptor stimulation is 
thought to occur, the resultant influx of Ca++ results in the loss of calcium homeostasis. 
Calcium "overload" in the cell results in abnormal activation of proteases, such as calpain, 
resulting in the breakdown of cytoskeletal proteins, activated nucleases result in DNA 
fragmentation, while activated lipases result in membrane damage and the production of free 
radicals. Together these events ultimately result in cell death (Siesjo, 1988; Siesjo and 
Bengtsson, 1989).
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In addition to the increase in glutamate release, the most compelling evidence for a role of 
glutamate receptor activation in the pathogenesis of cerebral ischaemia is the large number of 
studies carried out, in various species, which show significant reduction in infarct size 
following treatment with glutamate receptor antagonists (for review see McCulloch, e t  al. 
1991). It is now widely accepted that glutamate antagonists reduce the volume of infarcted 
tissue following cerebral ischaemia independent of the species or model of ischaemia 
involved. The non-competative NMD A antagonist dizocilpine (MK801) and the 2,3- 
dihydroxy-6-nitro-7-sufomyl-benzo(F)quinoxaline (NBQX) have shown the largest and 
most reproducible reduction in infarct volume (Gill, et. al. 1992; Park, et. al. 1988). In the 
rat, pretreatment with MK801 reduced the volume of ischaemic brain damage by more than 
50%, a similar reduction was also seen when administered up to 2 h following the onset of 
ischaemia (Gill, et. al. 1992; Park, et. al. 1988). Pre-treatment with MK801 (0.5mg/kg) 30 
min prior to MCAO in the rat significantly reduced the volume of infarcted tissue (Park, e t  
al. 1988). Similarly pre- or post- treatment of rats with NBQX reduced the volume of 
infarcted tissue following MCAO in the rat (Gill, et. al. 1992) however this reduction was 
not a great as that o f MK801. NBQX is selective antagonist at the AMPA and kainate 
prefering receptors with little or no affinity for the NMDA receptor complex (Sheardown, 
et. al. 1990).
Free radical m ediated toxicity
Free radicals are atoms that have an orbital with an unpaired electron and are formed under 
normal conditions during reduction and oxidation reactions. Some free radicals are highly 
reactive and are able to extract an electron from neighbouring molecules in order to fill the 
vacancy in their orbital. Reactions such as these can damage a variety of critical biological 
molecules including DNA, proteins and lipids (Halliwell & Gutteridge, 1985). Superoxide 
radicals (C^’)* hydrogen peroxide (H2 O2 ) and the hydroxyl radical (OH‘) are produced 
through the reduction of molecular oxygen to water by oxidative phosphorylation. Free 
oxygen can accept ions from transition metals such as iron that can exist in many different 
valence states and therefore donate, or accept, electrons in redox reactions resulting in 
radical formation. Neither the superoxide radical or hydrogen peroxide is very reactive, and 
it is the hydroxyl radical, formed from hydrogen peroxide in a reaction catalysed by a 
transition metal such as iron, which is thought to be the mediator of radical toxicity. The 
hydroxyl radical has the ability to combine with most biological molecules, and therefore 
results in widespread oxidative damage (for review see Olanow, 1992).
Under normal conditions, a series of naturally occurring antioxidant defense mechanisms, 
prevent or limit free radical production and tissue damage (Rose and Bode, 1993). In 
pathological conditions such as ischaemia and trauma, an imbalance of the equilibrium of
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production and protection, favouring free radical production is defined as a state of free 
radical stress. Cellular injury appears to increase the availability of metal ions, therefore 
once cellular injury has begun, damaging radical reactions tend to be amplified, especially 
during reperfusion when oxygen is exposed to an excess of metal ions (Choi, 1988; Hall 
and Braughler, 1989; Siesjo, et. al., 1989). For several biochemical, physiological and 
anatomical reasons the nervous system may be particularly susceptible to free radical injury 
compared to other organs of the body. These include a high rate of metabolic activity, high 
concentrations of readily oxidisable substrate, in particular membrane lipid polyunsaturated 
fatty acids, and low levels of intrinsic free radical scavengers such as catalase and 
glutathione peroxidase. Membrane disruption and destabilisation of calcium homeostasis 
have been proposed as major mechanisms by which free radicals induce neuronal damage 
(Boobis, et. al. 1989; Braughler, et. al. 1985; Orrenius et. al. 1989; Siesjo, et. al. 1981). 
However, the mechanisms of free radical release, the mode of action of radicals, including 
the molecular targets and the sequence of events that lead to cell degeneration remain largely 
undefined.
Although the concept of free radical mediated brain damage is widely accepted, it has proved 
difficult to obtain definitive evidence of free radical-mediated damage following ischaemia. 
Watson et. al. (1984) provided some evidence of diene conjugation in unsaturated fatty 
acids, which is generally accepted as the first structural manifistation of free radical damage, 
however, other studies failed to show significant levels of lipid peroxidation. Negative 
results obtained could be explained by the fact that lipid peroxidation is neither a prominent 
nor early sign of free radical damage (Halliwell, 1987). Superoxide ions and OH* have 
been shown to be generated in trauma and ischaemia (Hall, et. al. 1993; Kontos, 1989; Sen 
and Phillis, 1993; Zini, et. al. 1992). An important role for free radicals in ischaemic brain 
damage was suggested by Floyd, et. al. (1990) and by Oliver, et. al. (1990) who described 
the presence of oxidated proteins in gerbils subjected to transient ischaemia, however no 
oxidated proteins were detected in the dog (Folbergrova, et. al. 1993). Pretreatment with 
free radical scavangers such as dimethylthiourea and allopurinol and the enzymes 
superoxide dismutase or catalase have been shown to moderately reduce the extent of 
ischaemic brain damage (Liu, et. al. 1989; Martz, et. al. 1989). However the most 
compelling evidence implicating a role for free radical release in the genesis of ischaemic 
brain injury comes from studies showing significant reductions in brain damage following 
both transient (Folbergrovd, et. al. 1995; Phalmark and Siesjo, 1996; Phillis and Gough- 
Helfman, 1990) and permanent focal (Cao and Phillis, 1994) cerebral ischaemia by the spin 
trap agent a-phenyl-tert-butyl-nitrone (PBN).
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PBN is one of the most widely used compounds for the detection of reactive free radicals in 
vitro. Spin trap agents are nitrone or nitroso compounds with which all forms of free 
radicals can react producing long lived nitroxide compounds. PBN is rapidly absorbed 
when injected intraperitoneally in rats, with the plasma level peaking within 15 min. Brain 
levels of PBN peak around 30 min after administration and decrease steadily over the next 8 
h (Chen, et. al. 1990). The brain concentration of PBN is much higher than that in the 
blood due to the lipophilicity of the compound (Cheng, et. al. 1993). PBN has been shown 
to facilitate post-ischaemic reperfusion (Schultz, et. al. 1995) and improve energy status 
following transient ischaemia in the rat (Folbergrova, et. al. 1995) both of which could be 
involved in the mechanisms of tissue salvage following ischaemic injury.
Interaction o f glutamate toxicity and free radical damage 
Both glutamate excitotoxicity and free radical release have been implicated in the 
pathogenesis of cerebral ischaemia as described above and have until recently been 
independently investigated. However, observations suggest that the mechanisms of free 
radical damage and glutamate excitotoxicity may be at least partially interdependent. 
Glutamate toxicity has been shown to be markedly reduced in vitro (Bondy and Lee, 1993; 
Dykens et. al. 1987; Murphy, et. al. 1990; Miyamoto, et. al. 1989; Nakao, et. al. 1996) by 
various antioxidant agents and in vivo using PBN (Nakao, et. al. 1996; Schulz, et. al. 
1995) suggesting that oxygen-free radicals contribute to glutamate toxicity. Both the 
glutamate antagonist MK801 and the antioxidant dimethylthiourea have been shown to 
reduce ischaemic brain oedema in rats indicating that both excitatory and free radical 
mediated mechanisms are involved in this process. Combination therapy with these two 
agents failed to show any significant additive effect in oedema reduction (Oh and Betz, 
1991) further suggesting that glutamate toxicity and oxidative stress may be acting through 
similar mechanistic pathways.
Increased extracellular glutamate has been shown to inhibit the uptake of cystine from the 
surrounding medium into neurons through the action of the cystine/glutamate transporter 
(Bannai, 1986). Cystine is metabolized to cysteine within the cell which is a precursor for 
glutathione synthesis, reduced cystine uptake therefore results in glutathione depletion 
within these cells. Glutathione is an intrinsic free radical scavanger (for review see Bast,
1991) therefore its depletion renders the cell vulnerable to oxidative stress (Murphy, et. al. 
1990; Miyamoto, et. al. 1989). Similar mechanism have been postulated to mediate 
glutamate excitotoxicity in oligodendrocyte cell cultures (Oka, et. al. 1993; Yonezawa, et. 
al. 1996) (see below). Free radicals have been shown to inhibit the uptake of glutamate into 
astrocytes (Volterra, et. al. 1994a; 1994b). Astrocytes are responsible for the uptake of 
glutamate and other substances that are toxic to the neuron (Hertz, et. al. 1992; Schousboe,
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et. al. 1988), therefore inhibition of glutamate uptake will have profound effects on the 
extracellular glutamate levels in pathological conditions. In addition, free radical generating 
systems such as xanthine/xanthine oxidase, have been shown to cause increased release of 
glutamate from rat hippocampal slices in vitro (Pellegrini-Giampietero, et. al. 1990). 
Together these results give evidence for the existence of a "vicious circle" between glutamate 
toxicity and oxidative stress in the pathological conditions such as cerebral ischaemia.
1 . 2 . 4  Animal models of acute brain injury
As described above stroke and head injury are multi-factorial insults, it is impossible 
therefore to encompass all the events in a single animal model. However many models have 
been devised in an attempt to explore individual events. These models include fluid 
percussion, cortical impact, optic nerve stretch, subdural haematoma, glutamate toxicity and 
global and focal ischaemia. For the purpose of this thesis however I will focus on a model 
of permanent focal cerebral ischaemia and a model of glutamate toxicity, as these models 
were used in the studies reported here.
Permanent focal cerebral ischaemia
Models of focal cerebral ischaemia in the rat have gained increasing recognition due to their 
relation to events occurring in human stroke. In humans the most common cause of stroke 
is temporary or permanent occlusion of a major artery, usually the middle cerebral artery 
(MCA) (Brierly and Graham, 1984). Permanent and transient occlusion of the MCA in the 
rat can be carried out by a variety of methods (for review see Ginsberg and Busto, 1989). 
The subtemporal approach of Tamura, et. al. (1981) and electrocoaggulation of the MCA 
described briefly in section 2.6.2, has become the gold standard method of permanent 
proximal occlusion of the MCA. In the rat this results in reduced blood flow within the 
territory supplied by the MCA including most of the caudate nucleus, the lateral segment of 
the globus pallidus, much of the cerebral cortex, the internal capsule and adjacent subcortical 
white matter. Permanent occlusion results in cerebral infarction within this area. At the 
periphery of this region there is an area where blood flow is reduced, but is not below 
critical levels termed the "penumbra" (Nedergaard, 1988; Tamura, et. al. 1981; Siesjo,
1992). The boundary between viable and non-viable tissue in this model is well defined 
making volumetric analysis possible. This model is therefore favoured for the volumetric 
quantification of neuroprotection given by drugs and has been used in such investigations in 
the rat and other animal species (for review see McCulloch, et. al.1991).
Histological assessment of brain tissue can not accurately be performed less than four hours 
following MCA occlusion (MCAO), however immunological staining using an antibody 
directed towards MAP2 can be used to delineate ischaemic damage at shorter survival
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periods (Dawson and Hallenbeck, 1996). Following 4 hr MCAO conventional H&E 
staining of tissue reveals swollen or lysed cells in the core of the MCA territory, they appear 
light due to their inability to stain with haematoxylin. In surrounding areas where blood 
flow is reduced shrunken and pyknotic neurons are apparent. Twenty-four hr following 
MCAO all of this territory may become infarcted (Graham, et. al. 1993). Most of the 
swollen cells disappear 24-48 hr after MCAO, small eosinophilic cells are found in the 
penumbra, and the lesion area is clearly delineated from normal tissue.
Glutam ate toxicity in vivo
Glutamate toxicity is involved in neuronal death following cerebral ischaemia (see section 
1.2.3), and many in vitro models of excitotoxicity have been employed to decipher the 
pathological progression of neuronal degeneration. However in vitro experiments lack the 
cellular complexity of the intact adult CNS, therefore various animal models have been 
devised to examine the effects of glutamate toxicity. These models allow the examination of 
the progression of neuronal death and the effect of glutamate antagonists on neuronal 
survival without the complications of reduced energy metabolism and blood flow present in 
ischaemia (for review see Meldrum, 1990). In such studies, selective excitatory amino acid 
receptor agonists are used to produce excitotoxic lesions, which avoids significant uptake by 
intrinsic mechanisms and interference with CNS metabolism. However in this thesis the 
use of monosodium glutamate was chosen for the induction of a cytotoxic lesion in the rat 
cortex to examine the effects of glutamate toxicity on cytoskeletal proteins. This model of 
glutamate toxicity has been described previously (Fujisawa, et. al. 1993a; 1993b; 1996; 
Landolt, et. al. 1993) and involves reterograde dialysis of glutamate into the cortex resulting 
in histological alterations consistent with excitotoxic neuronal damage (see section 3.1). 
The perfusion of 1M monosodium glutamate results in a sizeable lesion which extends in 
anterior and posterior directions and is characterised by an area of pallor as shown by 
haematoxylin and eosin staining. The histopathological features of the lesion include loss of 
H&E stained neurons, triangulation of the nucleus, and shrinkage of neurons and neuropil. 
A sharp boundary between the area of the lesion and histologically normal tissue can be 
readily detected in H&E stained sections (Fig. 15). In contrast, intracortical perfusion of the 
control solution, 1M sodium chloride, results in a smaller area of pallor on H&E stained 
sections compared to that resulting from glutamate perfusion. The boundary between the 
area of pallor and histologically normal tissue in the NaCl perfused brains was less well 
delined than in glutamate infused animals (Fig. 15). Within the core of a sodium chloride 
induced lesion, the number of H&E stained neurons are reduced compared to histologically 
normal tissue, while towards the edge of the lesion nuclei are triangulated.
1.3  Structure and function of the neuronal cytoskeleton
1.3.1 Components of the neuronal cytoskeleton
As mentioned above, cytoskeletal proteins are excellent substrates for calcium activated 
proteases therefore leaving the cytoskeletal vulnerable to ischaemic injury. Cytoskeletal 
breakdown is though to represent a final common pathway of irreversible neuronal 
degeneration in a variety of both chronic and acute degenerative diseases of the brain. 
Before I go on to discuss the effect of acute brain injury on these structural proteins I will 
briefly discuss the structure and function of the neuronal cytoskeleton. The cytoskeleton is 
a highly dynamic structure, involved in many essential cellular processes including cell 
movement, process elongation and intracellular transport. The cytoskeleton is unique to 
eukaryotic cells and consists of three major classes of cytoskeletal fibres: microfilaments; 
neurofilaments and microtubules (for review see Ludin and Matus, 1993).
M icrofilam ents
Microfilaments consist of actin fibres which are polymers of actin protein with a diameter of 
6nm. Actin therefore plays a pivotal role in the shape and growth of axons and dendrites. 
At the leading edge of the elongating process is the growth cone which, through controlled 
polymerisation and rearrangement of the actin fibres is responsible for process extension. 
Microfilaments are not readily detectable in mature differentiated neurons, however actin is 
present concentrated beneath the axolemma.
Interm ediate filam ents
Intermediate filaments (7-1 lnm in diameter) are polymers of several intermediate filament 
(IF) proteins, which vary according to cell type, but are restricted to six classes of IF 
protein. Neurons of the central nervous system contain class IV proteins - the neurofilament 
proteins, NF-H (heavy chain; 115kDa), NF-M (medium chain; llOkDa) and NF-L (light 
chain, 60kDa). Axonal neurofilaments are connected together by numerous side arms in a 
rope like manner, in contrast to microtubules and microfilaments which are globular. 
Neurofilaments are present in axons often in association with microtubules, together they 
provide strength and rigidity to the axon.
M icrotubu les
Microtubules, so called as they are made of tubulin, are long cylindrical structures with a 
diameter of approximately 22nm. They are composed of tubulin heterodimers which consist 
of an a -  and 6-monomer, alined longitudinally to form protofilaments which in turn join 
laterally to form a tube. In the neuron, microtubules are highly organised and have a 
defined polarity with respect to the microtubule organising centre, thus defining the polarity
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of the cell. This results in a fast growing end called the plus end which is guanosine 
triphosphate-dependent and a slow growing end called the minus end (Wiesenberg, et. al. 
1976). They are very stable, but generally dynamic structures, which go through periods 
of growth at the plus end that are interrupted by episodes of sudden collapse (Mitchison and 
Kirschner, 1984). In addition to tubulin, microtubules contain minor protein components 
called the microtubule associated proteins (MAP). These are a heterogeneous group of 
proteins originally described to co-assemble with microtubules, but have now been shown 
to be a major determinant of microtubule function. Microtubules are essential for the 
formation and structural maintenance of neurites. The highly complex morphology of 
neurons correlates with the abundance of microtubules in this cell type (Bray, et. al. 1978; 
Matus, et. al. 1986). Axons and dendrites lack the capability for protein synthesis, 
therefore in addition to pre-synthesised proteins, organelles and ribosomes carrying mRNA 
essential for protein synthesis have to be transported to the axons and dendrites to allow 
local protein synthesis. These functions are all mediated through the microtubule 
framework of the cell in conjunction with motor proteins (Bloom, 1992).
1.3.2 The microtubule associated proteins
The MAPs appear to be the major determinants of microtubule function and all share the 
ability to bind to polymerised tubulin in vitro. In the neuron they can be separated into 2 
groups. Firstly, the motor proteins such as kinesins and dyneins which are responsible for 
intracellular transport of organelles and proteins from the cell body to the axons and 
dendrites. This is an ATP dependant function essential for neuronal survival since axons 
and dendrites cannot synthesize proteins (Bloom, 1992). Secondly, the sfructural MAPs: 
MAP1A/B; MAP2a/b/c; MAP4 and tau, all of which share the ability to promote tubulin 
polymerisation and stabilise microtubules in vitro (Tucker, 1990; Weingarten, e t  al. 1975) 
suggesting that they may regulate the state of assembly of tubulin in neuronal processes and 
influence the stability of microtubules. MAP expression is developmentally regulated and 
persists in areas of the brain in which neurons continue to divide, suggesting that they may 
play a role in neuronal plasticity (Burgoyne, 1986; Matus, 1988; Viereck, et. al. 1989). The 
structural MAPs of interest in this thesis are described in more detail below.
M AP 2
MAP2 consists of several isoforms, produced through alternative splicing of a single gene 
transcript, referred to as: MAP2a (280kDa); MAP2b (270kDa) and MAP2c(70kDa). 
MAP2c mRNA encodes a polypeptide lacking amino acids 152-1514 of the MAP2 sequence 
(Doll, et. al. 1990). MAP2 has 2 domains: a 200kDa N-terminal projecting arm that forms 
regularly spaced lOOnm lateral projections from the microtubule surface and a C-terminal 
microtubule binding domain. It has been proposed that the projection domains of these 
molecules are involved in the arrangement of microtubules by acting as mechanical struts 
m aintaining regular spacing between microtubules (W eishaar and Matus, 1993). 
Alternatively, it is possible that the projection domain may play a role in the interaction of 
tubulin with MAP2 during microtubule assembly (Fellous, et. al. 1994). The tubulin 
binding domain of both the high and low molecular weight proteins contains a series of 3 or 
4 imperfect 18 amino acid repeats each separated by 13-14 amino acids (Kindler and 
Gamer, 1994), which act in conjunction with adjacent sequences to affect microtubule 
binding affinity (Lewis, et. al. 1988). MAP2 is a phosphoprotein and the degree of 
phosphorylation affects the affinity of the protein for microtubules. Extensive 
phosphorylation reduces its ability to stimulate microtubule assembly and to bind to 
preformed microtubule (Bums, et. al. 1984; Murthy and Flavin 1983) and this may be a 
means whereby MAP2 can modulate neuronal plasticity. MAP2a is present at very low 
levels in embryonic and newborn brain, but becomes the major MAP in adult brain. In 
contrast, MAP2c is the major MAP in embryonic brain, persisting in adult brain where 
differentiation continues (Binder, et. al. 1984; Burgoyne and Cumming, 1984; Przyborski 
and Cambray-Deakin, 1995). In normal brain MAP2a and b are predominantly localised in 
the cytoplasm of dendrites and cell bodies where they are found associated with 
microtubules (Bernhardt and Matus, 1984; Caceres, et. al. 1988). In contrast, MAP2c is 
also found in axons of the developing brain (Riederer and Matus, 1985). This differential 
pattern of distribution can be explained by the compartmentalisation of MAP2 mRNA 
through selective transport which allows regulation of MAP2 synthesis (Tucker, et. al.
1989). MAP2a and b mRNA is found localised in dendrites (Gamer, et. al. 1988; Landry, 
et. al. 1994) while MAP2c mRNA is present in cell bodies (Papadrikopoalou, et. al. 1986). 
The use of antisense oligonucleotides has provided evidence for the involvement of MAP2 
in neurite extension and the maintenance of existing neurites (Caceres, et. al. 1992; Sharma, 
et. al. 1994).
15
MAPS (M APIB)
The earliest structural MAP to appear in the developing brain is MAP5 which is already 
present in axons at the time of their emergence from the cell body (Tucker and Matus, 1988; 
Tucker, et. al. 1988). In contrast to MAP2 and tau, MAP5 lacks the 3-4 repeat region at the 
C-terminus, however microtubule binding is mediated through 2 repeat regions. The first 
consists of a motif composed of 2 basic amino acids followed by 2 acidic amino acids 
(Noble, et. al. 1989) near the N-terminus. The second is a set of 12 imperfect repeats of 15 
amino acids each near the C-terminus. MAP5 mRNA is detected in perikarya of developing 
neurons suggesting that synthesis occurs in the perikarya and the protein is subsequently 
therefore transported into the processes (Tucker, et. al. 1989). The expression of MAP5 is 
most prominent in extending axons (Calvert and Anderton, 1985; Black, et. al. 1994) 
however, protein levels decrease following termination of neurite outgrowth (Tucker and 
Matus, 1988), with the exception of areas of the brain where neuronal growth is continuous 
(Tucker and Matus, 1988; Viereck, et. al. 1989). Phosphorylation of MAP5 occurs during 
brain development and appears to correlate with axon growth (Calvert, et. al. 1987; Fischer 
and Romano-Clarke, 1990) suggesting that the function of MAP5 in axonal growth may be 
regulated by phosphorylation (Tucker, 1990; Gordon-Weeks, 1991). In PC12 cells 
stimulated with nerve growth factor, neurite extension was inhibited by the presence of 
MAP5 anti-sense oligonucleotides providing direct evidence for a role of MAP5 in process 
extension (Brugg, et. al. 1993).
Tau
The microtubule associated protein tau has gained much interest since the discovery, using 
immunohistochemical studies, that tau is the major component of neurofibrillary tangles 
(NFTs) found in Alzheimer's disease (AD) (Delacourte and Defossez, 1986; Grundke- 
Iqbal, et. al. 1986; Kosik, et. al. 1986) (see section 1.4.3). Tau was the first MAP to be 
isolated and shown to stimulate microtubule assembly in vitro (Weingarten, et. al. 1975) 
and molecular cloning of tau has now confirmed that there are at least six isoforms arising 
from alternative splicing of a single transcript encoded by a single gene located on the long 
arm of chromosome 17 (Druben, et. al. 1984; Himmler, et. al. 1989; Neve, et. al. 1986). 
Multiple isoforms of tau exist, ranging in size from 352-441 amino acids in the human brain 
(Goedert, et. al. 1988; 1989; Himmler, 1989; Himmler, et. al. 1989; Kanai, et. al. 1989; 
Kosik, et. al. 1989a; Lee, et. al. 1988), due to the differential expression of 0, 1 or 2, 29 
amino acid inserts in the N-terminal region and the expression of 3 or 4 imperfect tandem 
repeats, 31 or 32 amino acids in length in the C-terminal region of the protein (Lee, et. al. 
1988; Goedert, et. al. 1989a; Himmler, 1989) shown in Fig. 3. Tau expression is 
developmentally regulated, the shortest form containing three repeats and no N-terminal 
insert, being present in very low levels in adult brain although is abundant in fetal brain
(Goedert, et. al., 1989a,b). The longest tau transcript containing 4 repeats and a 58 amino 
acid insert is abundant in adult but not fetal brain. The switch from the short to longer 
forms of protein has been shown to occur in neurons in vitro when process extension is 
complete and synapses are forming, suggesting that this pattern of expression is probably 
involved in the maturation of neuronal processes (Smith, et. al. 1995; Pizzi, et. al. 1995a).
Recently an additional form of tau has been identified named "big tau", because of its higher 
molecular weight (110-120kDa). This isoform was originally found in the PNS (Geogrieff, 
et. al. 1991; Oblinger, et. al. 1991) and peripheral neuron-like cell lines (Drubin, et. al. 
1988) and has recently been reported to be present in a wide range of peripheral tissues (Gu, 
et. al. 1996). Cloning of big tau cDNA showed that, compared to tau found in brain tissue, 
this tau contains additional inserts of 237 and 66 amino acids present in the middle of the 
protein (Couchie, et. al. 1992) or of 254 amino acids present in the N-terminal portion 
(Goedert, et. al. 1992), respectively in the mouse and rat. In addition big tau is transcribed 
from an 8kb mRNA, as opposed to the 6kb mRNA that encodes normal tau, generated 
through alternative splicing from the same gene, located on chromosome 17, that encodes 
normal tau. Another larger protein, 83kDa, reacting with tau antibodies has been detected 
within astrocytes (Couchie, et. al. 1988). Together this data suggests that there may be 
multiple isoforms of big tau present in neuronal and non-neuronal cells.
Tau is believed to be an elongated molecule with very little a-helix or B-sheet structure 
(Cleveland, et. al. 1977b; Lee, et. al. 1988) and a highly assymetrical shape (Hirokawa, et. 
al. 1988). The most striking feature of the tau sequence is the presence of three or four 
imperfect tandem repeats of 31 or 32 residues located at the C-terminal which is thought to 
represent the microtubule binding domain (Brandt and Lee, 1993; Butner and Kischner, 
1991; Lee, et. al. 1989). Ionic interactions between the basic residues of the tau protein 
within this repeat region and the acidic residues at the C- terminal of tubulin is partially 
responsible for the binding of tau to microtubules (Butner and Kischner, 1991). Tau 
isoforms containing four repeat regions have been shown to be more effective at binding 
microtubules than those with three repeats probably due to increased ionic interactions with 
tubulin (Goedert and Jakes, 1990). Recently however, studies carried out in vitro have 
implicated other regions of the tau protein in microtubule binding. Using fragments of tau, 
the regions flanking this repeat sequence have been shown to increase the affinity of tau for 
microtubules (Butner and Kischner, 1991; Gustke, et. al. 1994; Trinczek, et. al. 1995). In 
addition, Goode and Feinstein (1994) have demonstrated that intermediate regions between 
the repeat sequences have a higher affinity for microtubules than any of the repeat regions 
themselves. Together this data suggest that a complex interaction between tau and 
microtubules exists which cannot be explained purely through ionic interactions.
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C-terminalN-terminal
F igu re  3. Schematic representation of the six tau isoforms found in human brain. 
Isoforms are formed through alternative splicing of a single tau transcript and exist due to 
the presence or absence of 1 or 2 inserts at the N-terminal (closely hatched shading) and the 
presence of 3 or 4 repeats in the C-terminal region (hatched shading). The number of amino 
acids in each isoform is indicated at the right of each diagram and are termed 4R, 58, 4R, 
29, 4R, 0, 3R, 58, 3R, 29, 3R, 0, from top to bottom according to the nomenclature of 
Goedert and Jakes, (1990).
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Tau contains many potential phosphorylation sites and exists as a phosphoprotein in vivo 
which contributes to the complex pattern of bands after SDS-PAGE. Phosphorylation of 
tau is the only post-translational modification of the protein known to date and is thought to 
be of functional importance, as it leads to a reduced affinity of tau for microtubules (Brandt 
and Lee, 1994; Lindwall and Cole, 1984; Trinczek, e t  al. 1995). Fetal forms of tau which 
are more phosphorylated than adult forms have a decreased affinity for microtubules. 
Hyperphosphorylated tau present in NFTs (Gustke, et. al. 1992) lacks the ability to bind to 
and stabilise microtubules, however this ability can be restored following dephosphorylation 
of the protein (Iqbal, et. al. 1994). It has also been postulated that phosphorylation may be 
involved in the compartmentalisation of tau within cells (Kosik, 1990). Tau present in 
perikarya is phosphorylated which prevents microtubule binding and therefore allows tau to 
move rapidly by diffusion to the axon. However, once reaching the initial segment of the 
axon tau is dephosphorylated and becomes associated with microtubules, therefore entering 
the slow transport system that exists within axons, subsequntly leading to its predominant 
location within the axon.
1.3.3 Normal distribution of tau in the CNS
Within the normal CNS the predominant localisation of tau within the axonal compartment 
of neurons is widely accepted (Binder, et. al. 1985; Brion, et. al. 1988; Kowall and Kosik, 
1987; Migheli, et al. 1988; Papasozomenos and Binder, 1987; Trojanowski, et. al. 1989). 
However the presence of tau in other cell types remains controversial. Tau has been 
detected  in neuronal perikarya, oligodendrocytes and astrocytes follow ing 
dephosphorylation of tissue sections or using phosphorylation independent antibodies 
(Migheli, et al. 1988; Papasozomenos and Binder, 1987). In support of its presence in 
oligodendrocytes, tau was detected in primary ovine oligodendrocyte cultures using western 
blot analysis, immunohistochemistry and in situ hybridisation (Lopresti, et. al. 1995). In 
contrast, Vouyiouklis and Brophy (1995) have failed to show the presence of tau in rat 
primary oligodendrocytes cultures using an antibody directed towards neuronal tau. 
Discrepancies between these two studies may reflect differences in the species from which 
the oligodendrocyte culture were derived. In addition, the absence of tau in 
oligodendrocytes in situ may suggest that cultured oligodendrocytes have different 
properties to those in situ. Electron microscopy studies of the rat brain showed that tau 
immunostaining is found associated with microtubules in axons and in the cytoplasm of cell 
bodies (Migheli, et. al. 1988). In agreement with the immunohistochemical studies, in situ 
hybridisation showed that tau mRNAs occurred in neurons and that different neuronal 
subtypes express different isoforms (Goedert, et. al. 1989a; Kosik, et. al. 1989a). 
However, tau mRNA was not detected in glial cells supporting the predominant localisation 
of the protein in neurons. Within the neuron, tau mRNA is localised within the cell body
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and proximal part of the axon, this distribution being thought to be due to the interaction of 
mRNA with microtubules (Litman, et. al. 1993; 1994). Recently however, tau mRNA has 
been detected in ovine oligodendrocyte cultures in vitro (Lopresti, et. al. 1995) supporting 
the idea that tau protein may be present in non-neuronal cells within the CNS.
1 . 3 . 4  Cellular functions of tau
Information about the cellular functions of tau originated from studies employing purified 
microtubule preparations. These studies showed that tau promotes microtubule assembly 
(Cleveland, et. al. 1977a; Wiengarten, et. al. 1975) and is able to decrease the rate of 
transition between microtubule elongation and shortening (Dreschel, et. al. 1992; Pryer, et. 
al. 1992). Further evidence supporting a role for tau in microtubule binding has evolved 
from the use of cell lines lacking endogenous tau microinjected or transfected with human 
tau cDNA. In HeLa, 3T3 and rat fibroblast cells, tau expressed from transfected cDNA 
associated with microtubules, altered the post-translational modification of tubulin, induced 
microtubule bundling and protected microtubules against drug-induced depolymerisation 
(Drubin, et. al. 1984; Drubin and Kirschner, 1986; Lee and Rook, 1992; Lewis, et. al. 
1989; Takemura, et. al. 1992). In CHO cells however, although tau expressed from 
transfected tau cDNA protected against drug-induced depolymerisation, tau had no effect on 
the monomer-polymer equilibrium (Barlow, et. al. 1994). Transfection of tau cDNA into 
fibroblasts was shown to change the organisation of microtubules and induced microtubule 
bundle formation similar to that of microtubule domains in nerve cells (Lewis, et. al. 1989; 
Kanai, et. al. 1992), although, no morphological changes were reported in these cells. In 
contrast to transfected fibroblasts, sf9 cells transfected with tau expressed in a baculovirus, 
produced neurite-like processes in which microtubule bundles were formed and orientated 
as in axons with their plus end distal to the cell body (Baas, et. al. 1991; Knops, et. al. 
1991). Inhibition of tau expression with antisense oligonucleotides inhibited the 
development of axon-like structures in cultured neurons (Caceres and Kosik, 1990) and in 
differentiated neuronal cultures resulted in the loss of axon-like structures (Caceres, et. al. 
1991). Together these reults suggest that tau is actively involved in the elongation and 
maintenance of neuronal processes.
As well as its presence in neuronal perikarya and axons, tau has also been shown to be 
localised within the nucleus of human neuroblasts (Loomis, et. al. 1990; Wang, et. al.
1993). Nuclear tau has not yet been identified in mature neuronal cells suggesting that this 
may play a role in neuronal differentiation. The nucleus lacks microtubules therefore these 
results together with the non-microtubule associated localisation of tau to ribosomes 
(Papasozomenos and Binder, 1987) suggests that tau may have additional roles rather than 
purely binding to and stabilising microtubules. It is possible to speculate that tau may target
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ribosomes to microtubules for transport in the somatodendritic compartments of neurons to 
facilitate local protein synthesis within axons and dendrites.
As discussed in the previous section (1.3.3), tau has recently been identified in 
oligodendrocyte cultures. Localisation of tau at the tips of oligodendrocyte processes 
suggests that, as in neurons, tau may be involved in process elongation in these cells. 
Oligodendrocytes have abundant microtubules in their cytoplasm which have been 
postulated to be key elements in the transportation of myelin basic protein (MBP) mRNA 
and other myelin components along cellular processes to the site of myelination (Barbarese, 
1991; Brophy, et. al. 1993; Colman, et. al. 1982; Trapp, et. al. 1987). Co-localization of 
tau with MBP within oligodendrocytes (Lopresti, et. al. 1995) suggests that tau may interact 
directly with MBP possibly cross-linking MBP, its RNA and the microtubule.
1.4 Cytoskeletal breakdown in brain degeneration
1.4.1 Acute brain injury
In cerebral ischaemia and traumatic brain injury (TBI), increased extracellular glutamate 
concentrations and the subsequent elevation of intracellular Ca++ are thought to trigger a 
cascade of neurochemical events resulting in irreversible neuronal damage. Breakdown of 
the cytoskeleton due to the activation of calcium activated proteases, such as calpain, is 
thought to be one of these events. Many elements of the cytoskeleton are substrates for 
calpain including NF (Banik, et. al. 1987; Schlaeffer and Zimmerman, 1985), MAP2 
(Johnson, et. al. 1991) and tau (Kampfl, et. al. 1996). The majority of studies investigating 
the effects of ischaemia and TBI have concentrated mainly on the distribution of NF, tubulin 
and MAP2 following injury.
Selective degradation of the neurofilament proteins NF68, NF150 and NF200 has been 
shown to occur following both permanent and reversible cerebral ischaemia in the rat 
(Nakamura, et. al. 1992; Ogata, et. al. 1989). Decreased NF 150 and NF200 
immunoreactivity could be detected as early as 10 min following the induction of cerebral 
ischaemia, at which time degradation of other cytoskeletal components such as actin, tubulin 
and NF68 was not apparent suggesting that these neurofilament proteins are extremely 
sensitive to ischaemic injury (Ogata, et. al. 1989). The loss of NF68 immunoreactivity 
within the CA1 region of the hippocampus has been suggested to lead to the selective 
vulnerability of this area to transient global ischaemia in the rat (Nakamura, et. al. 1992). 
Similarly decreased NF68 and NF200 immunoreactivity was decreased in the rat 3 h 
following cortical impact (Postmantur, et. al. 1994). In contrast to these studies however, 
NF68, NF150, and NF200 immunoreactivity were increased 1-72 h following fluid
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percussion induced TBI in the rat (Yaghmait and Povlishock, 1992). It is possible to 
speculate that the discrepancies between these studies may reflect the type and severity of 
brain injury used. Decreased NF immunoreactivity was detected following severe cortical 
impact (Postmantur, et. al. 1994) however fluid percussion resulted in a mild TBI and an 
increase in NF immunoreactivity (Yaghmait and Povlishock, 1992). Interestingly increased 
NF68 immunoreactivity has been used to show early reactive changes in axons in human 
diffuse axonal injury. Axonal swellings can be detected using NF68 early following head 
injury before significant morphological changes can be detected using routine histological 
staining methods (Christman, et. al. 1994; Grady, et. al. 1993).
In both transient and permanent models of cerebral ischaemia in the gerbil, MAP2 and 
tubulin immunoreactivity have been reported to be particularly sensitive to ischaemic damage 
(Hatakeyama, et. al. 1988; Kitagawa, et. al. 1989; Yanagihara, et. al. 1990). In the rat 
however, decreased MAP2 immunoreactivity was not detected following transient cerebral 
ischaemia (Geddes, et. al. 1995; Tomoika, et. al. 1992). Loss of MAP2 immunoreactivity 
within dendrites and neuronal perikarya was however reported following permanent focal 
cerebral ischaemia (Dawson and Hallenbeck, 1996). Routine histological stains fail to allow 
accurate estimation of lesion size less than 4 h following MCAO in the rat, however 
decreased MAP2 immunoreactivity was clearly delineated lh  following MCAO allowing 
quantitative analysis of lesion size (Dawson and Hallenbeck, 1996) showing that loss of 
MAP2 immunostaining can be used as a sensitive marker of early ischaemic brain damage 
induced by MCAO in the rat. Similarly, MAP2 immunoreactivity has also been reported to 
be decreased in both neuronal perikarya and dendrites following TBI (Postmantur, et. al. 
1996a; 1996b; Taft, et. al. 1992) within 3 h of injury. MAP2 is associated with dendrites 
and may therefore reflect the sensitivity of this neuronal compartment to brain damage. 
Antigenic changes in tubulin and MAP2 are consistent with changes in dendrite structure 
observed at the electron microscope level in the gerbil following transient cerebral ischaemia 
(Tomioka, et. al. 1992; Yamamoto, et. al. 1986).
In contrast, although tau has gained great interest through its presence in NFTs, few studies 
have investigated changes in tau following cerebral ischaemia. Tau has been reported to 
accumulate within neuronal perikarya following transient cerebral ischaemia in the rat 
(Geddes, et. al. 1994) with a loss of immunoreactivity in the axon, suggesting redistribution 
of the protein from the axon to the cell body. Two and 6 h following permanent focal 
cerebral ischaemia in the rat, increased tau immunoreactivity was detected using a 
phosphorylation dependent antibody but not with TP70 a polyclonal antibody raised against 
the C-terminal of tau, immunoreactivity of which is independent of phosphorylation state. 
This study indicated that dephosphorylation of existing tau protein in neuronal perikarya,
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rather than accumulation (Dewar and Dawson, 1995). Discrepancies between these two 
studies may reflect the different models of cerebral ischaemia employed. In contrast to that 
present in NFTs (see section 1.4.1), tau present in perikarya following both types of 
cerebral ischaemic injury is dephosphorylated at the Tau 1 epitope (Dewar and Dawson, 
1995; Geddes, et. al. 1994). This suggests that different mechanisms may underly changes 
in tau occurring in acute and chronic degenerative diseases, however the possibility that tau 
becomes phosphorylated over time cannot be ruled out.
Glutamate excitotoxicity is involved in the pathogenesis of cerebral ischaemia and has also 
been implicated in Alzheimer's disease, however its involvement in the alterations of 
microtubule associated proteins which occur in these conditions at present remains unclear. 
Increased MAP2 immunoreactivity was within perikarya following exposure of neuronal 
cultures to high concentrations of glutamate (Bigot and Hunt, 1990, Bigot, et. al. 1991), 
suggesting that mechanisms other than glutamate excitotoxicity may be involved in the 
decreased MAP2 immunoreactivity seen following cerebral ischaemia or TBI. In support of 
this, pre-treatm ent of animals with MK801 failed to prevent decreased MAP2 
immunoreactivity following TBI in the rat (Lewen, et. al. 1996). The effects of glutamate 
toxicity on the neuronal distribution of tau remain controversial with some groups reporting 
the accumulated protein to have antigenic and biochemical properties similar to tau present in 
neurofibrillary tangles (Mattson, 1990; Sautiere, et. al. 1992; Sindou, et. al. 1994), while 
others report the tau protein to be dephosphorylated at the Tau 1 epitope (Bigot and Hunt, 
1990; Davis, et. al. 1995; Pizzi, et. al. 1993; 1994; 1995a), which is phosphorylated in 
Alzheimer's disease. Dephosphorylation of the protein following glutamate toxicity is in 
accordance with the dephosphorylation of tau seen following cerebral ischaemia, suggesting 
that glutamate may be involved in the mechanism underlying neuronal alterations to tau seen 
following cerebral ischaemia but not NFT formation. Discrepancies regarding the nature of 
accumulated tau within neurons following glutamate exposure in vitro, compared to those 
observed in vivo may be partially explained by the maturity of the neuronal cultures. Cells 
are cultured from immature tissue and immature tau differs from the adult forms of the 
protein being similar to those present in neurofibrillary tangles (Bramblett, et. al. 1993; 
Watanabe, et. al. 1993; Yoshida and Ihara, 1993). Variation in the stage of culture maturity 
may therefore influence the data obtained from such experiments. This highlights the care 
that should be exercised when extrapolating data obtained in vitro to events occurring in the 
intact adult CNS where the cellular milieu is more complex.
Together these studies show that the neuronal cytoskeleton undergoes marked alteration 
rapidly following acute brain injury. It is possible to speculate that altered distribution of 
cytoskeletal proteins following ischaemic or traumatic brain injury may reflect loss of
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cytoskeletal integrity which may subsequently result in irreversible neuronal damage. The 
rapid alteration of cytoskeletal proteins following acute brain injury has important 
implications for the development of effective neuroprotective strategies, since irreversible 
brain damage may be triggered extremely early following injury.
1.4.2 Chronic neurodegenerative diseases
Alzheimer's disease, originally described by Alois Alzheimer in 1907, is the most common 
cause of dementia in the elderly. It is characterised by the progressive loss of memory and 
other cognitive functions, however diagnosis can only be confirmed by the presence of 
extracellular and intracellular fibrous deposits in the post-mortem brain. These deposits are 
amyloid plaques and NFTs respectively. Abnormal processing of the amyloid precursor 
protein (APP) is thought to lead to amyloid deposition (Price and Sisodia, 1994; Yankner, 
1996 for reviews) and much research has concentrated on the role of this protein in the 
pathogenesis of AD since the discovery of familial forms of AD showing mutations in the 
APP gene. However recent studies have shown that the distribution and abundance of 
NFTs, rather than amyloid deposits, closely correlates with the severity of dementia in life 
(Arriagada, et. al. 1992). The density of NFTs is greatest in the nerve cells of the cerebral 
cortex, hippocampal formation and some subcortical nuclei, which are the areas most 
commonly affected in the disease. Neuronal loss results in decreased synapse numbers and 
therefore disruption of neurotransmission occurs. The nucleus of Meynert is severely 
affected by NFT formation and its disruption leads to loss of cholinergic terminals within 
the neocortex, which is thought to be involved in the cognitive impairment displayed by 
these patients. In addition to their presence in AD, NFTs have also been, reported to be 
present in degenerating neurons of patients suffering from other chronic degenerative 
conditions such as progressive supranuclear palsy (PSP) (Vermersch, et. al. 1994) and 
Parkinson's disease (Vermersch, et. al. 1993). In PSP neurofibrillary lesions are present 
in the absence of amyloid deposits suggesting that NFT formation may represent a common 
pathway in neurodegeneration present in a variety of chronic disorders of the brain.
1 . 4 . 3  Neurofibrillary tangles
Neurofibrillary lesions are found in cell bodies and apical dendrites as NFTs and in distal 
dendrites as neuropil threads. All the lesions consist of abnormal paired helical filaments 
(PHF) as their major fibrous component and straight filaments as a minor component. In 
electron micrographs PHF consist of two strands twisted in a helix with a periodicity of 
approximately 80nm and a width that varies from 8-20nm (Crowther and Wischnik 1985). 
The straight filaments are found as a minor component in PHF preparations, they are 15nm 
wide and appear to lack the variation in width of the PHF. In contrast to those present in 
AD, NFTs in PSP are composed mainly of straight filaments with a diameter of 13-22nm
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(Montpetit, et. al. 1985). Despite the morphological differences, the biochemical properties 
of these two structures are very similar (Vermersch, et. al. 1994).
Immunohistochemical studies have suggested the presence o f MAP2 (Six, et. al. 1992), 
MAP5 (Geddes, et. al. 1991; Ulloa, et. al. 1994a), ubiquitin (Morishima-Kawashima, et. 
al. 1993) and APP (Perry, et. al. 1993) in PHF. However the major constituent shown by 
both immunohistochemical and biochemical procedures, is tau protein (Brion, et. al. 1985; 
Grundke-Iqbal, et. al. 1986; Goedert, et. al. 1988; Wischik, et. al. 1988). Labelling of 
PHF with antibodies directed towards both the N- and C- terminal of tau protein suggests 
the presence of full length tau (Brion, et. al. 1991a; Goedert, et. al. 1992). More recently 
biochemical analysis showed that PHF tau runs as 3 major bands of 60, 64 and 68 kDa and 
a m inor band of 72 kDa following sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Alkaline phosphatase treatment at high temperature resulted 
in the presence of 6 bands following SDS-PAGE showing that PHF contains all 6 tau 
isoforms in an abnormaly phosphorylated state (Brion, et. al. 1991b; Greenberg, et. al.
1990). PHF tau is hyperphosphorylated, i.e. it is phosphorylated at more sites than normal 
tau and for each site a higher percentage than normal of tau molecules are phosphorylated. 
Sites identified through the use of phosphorylation dependant antibodies include threonine 
residues 185,205 and 231 and serine residues 202, 396 and 404 (Biemat, et. al. 1992; 
Goedert, et. al. 1993; 1994; Otvos, et. al. 1995). Some of these sites are phosphorylated in 
fetal tau, therefore hyperphosphorylation of tau appears to occur through an exaggeration of 
normal phosphorylation mechanisms. Much research has therefore been concentrated on 
determining possible candidates for this abnormal phosphorylation. MAP kinase, GSK3 
and cdc-2 kinase and calcium calmodulin dependant kinases have all been implicated in this 
process (Steiner, et. al. 1990; Goedert, et. al. 1995). The hyperphosphorylation of tau and 
subsequent lack of affinity for microtubules is thought to contribute to the formation of 
PHF. However, whether tau accumulation within neuronal perikarya occurs before or after 
phosphorylation is as yet undetermined. Loss of Tau 1 immunostaining (Tau 1 recognises 
tau dephosphorylated at ser 202) has been reported to occur prior to NFT formation 
(Bancher, et. al. 1989) suggesting that phosphorylation occurs before PHF formation. 
However, tau has also been shown to form PHF without prior phosphorylation (Crowther, 
et. al. 1994) and fragments of tau containing the repeat region which does not encompass 
the phosphorylation sites have also been shown to form filaments similar to PHF (Crowther 
et. al. 1992; Wilie, et. al 1992). In addition, phosphorylated tau transfected into COS-1 
cells failed to form PHFs (Baum, et. al. 1995). The PHF core consists of the repeat region 
of tau leaving the N- and C-terminals in a disorganised pronase sensitive state which 
becomes pronase resistant following hyperphosphorylation (Crowther, et. al. 1992; 
Vincent, et. al. 1994). Recently Mena, et. al. (1996) have suggested that PHF formation
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occurs in two stages. Firstly, the formation of tau complexes truncated at the C-terminal of 
the protein. Secondly, these complexes then bind together to form PHFs. It is probable 
therefore that phosphorylation is not the only factor involved in PHF formation.
The formation of PHF in neurons is thought to be involved in the degeneration of neurons 
in AD. Accumulation of NFT accompanies a decrease in the number of microtubules, 
decreased affinity for microtubule binding and altered microtubule morphology resulting in 
loss of microtubule function (Lu and Wood, 1993). As well as decreased affinity of PHF 
tau for microtubules, the presence of PHF tau appears to inhibit the binding of normal tau to 
microtubules possibly through binding to normal tau itself leaving it unavailable for 
microtubule binding (Alonso, et. al. 1994). Within neurons presenting NFTs there is often 
an accumulation of degraded mitochondria, lysosomes and multivesicular bodies. These 
organelles are transported along the axon by interaction with microtubules in an ATP 
dependant manner. This loss of vital functions is thought to lead to rapid degeneration of 
the cell.
In addition to genetic factors such as APP mutations leading to abnormal amyloid deposition 
(Price and Sisodia, 1994; Yankner, 1996 for reviews) factors including head injury 
(Roberts et. al. 1991), free radical damage (Evans, 1993; Friedlich and Butcher, 1994) and 
glutamate excitotoxicity (Choi, et. al. 1988; Greenamayre and Young, 1989) have been 
implicated to play a role in the pathogenesis of AD. Clinical investigations have shown that 
treatment of patients with antioxidant nutrients such as vitamin E and C, selenium and zinc 
have indicated a reduction in the progression of the disease (McLachlan, et. al. 1991). 
Furthermore age related increases in oxidatively-inactivated enzymes in the brain and 
impaired memory in aged gerbils has been reduced by the spin trap agent PBN (Carney, e t  
al. 1991). It has been postulated that abnormal energy production in the disease may result 
in increased susceptibility of cells to excitotoxic injury (Greenamyre, 1991). Thus 
excitotoxicty would occur at physiological levels of glutamate.
At present however, it is unknown if free radical damage and/or glutamate toxicity are 
involved in the mechanisms underlying NFT formation. As discussed in section 1.4.1, 
glutamate toxicity has been shown to increase tau in neuronal perikarya (Bigot and Hunt, 
1990; Davis, et. al. 1995; Mattson, 1990; Pizzi, et. al. 1993; 1994; 1995; Sautiere, et. al. 
1992; Sindou, et. al. 1994), however the antigenic properties of the accumulated protein 
remains controversial. Some groups report the presence of tau similar to that of PHF tau 
(Mattson, 1990; Sautiere, et. al. 1992; Sindou, et. al. 1994) while others report accumulated 
tau to be dephosphorylated at the Tau 1 epitope (Bigot and Hunt, 1990; Davis, et. al. 1995).
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1.4.4 Glial fibrillary tangles
Argyrophilic oligodendroglial inclusions were first described by Papp, et. al. (1989) and 
since this time they have been used routinely in histological assessment of multiple system 
atrophy (MSA). These inclusions are most commonly detected within the cytoplasm, but 
have also been detected in the nucleus of the cell (Papp and Lantos, 1992). MSA is a 
chronic neurodegenerative condition comprising a combination of striatonigral degeneration 
(Adams, et. al. 1964), olivopontocerebellar atrophy (Duvoisin, 1984) and autonomic failure 
(Shy and Drager, 1960). Although glial inclusions have been used as a diagnostic marker 
for this disease for many years, it is only recently been recognised that the formation of 
these cytoplasmic inclusions may play a pivotal role in the disease pathogenesis. The 
density and distribution of oligodendroglial inclusions rather than neuronal degeneration 
correlates with the areas of affected brain and the severity of the disease (Papp and Lantos,
1994). Inclusion bearing cells are found mainly within regions in which myelinated fibres 
were affected by MSA lesions (Abe, et. al. 1992; Papp and Lantos, 1994) and also in areas 
of grey matter where little or no neuronal loss was detected, suggesting that neuronal 
degeneration is not required to induce inclusion formation within oligodendrocytes. The 
presence of these inclusion bearing cells in areas of tissue which appear normal, suggests 
that the formation of oligodendrocyte inclusions may be an early event in the degeneration 
characteristic of MSA (Abe, et. al. 1992; Papp and Lantos, 1994). Although the presence 
of oligodendroglial inclusions has been used in the diagnosis of MSA similar inclusions 
have also been described in post-mortem brain tissue of patients dying as the result of AD, 
PD and PSP (Iwatsubo, et. al. 1994; Nishimura, et. al. 1995; Yamada and McGeer, 1990). 
There are relatively few oligodendroglial inclusions compared to NFTs in AD and are 
therefore unlikely to be involved in the pathogenesis of this disease (Nishimura, et. al.
1995). In PSP, glial inclusions are found mainly within astrocytes, although 
oligodendroglial inclusions are detected in some cases (Iwatsubo, et. al. 1994; Nishimura, 
et. al. 1995; Yamada and McGeer, 1990). Cytoplasmic inclusions found within astrocytes 
in PSP are distinct from those occuring in MSA in that they can not be stained using 
ubiquitin antibodies (Yamada, et. al. 1992).
Neither the ultrastructure nor the biochemical composition of oligodendroglial inclusions is 
well defined. Some studies however have reported that these inclusions contain fibrils 
between 20 and 30nm in diameter, however whether these fibrils are microtubules or 
another form of cytoskeletal component remains controversial (Abe, et. al. 1992; Kato, et. 
al. 1991). In support of the presence of microtubules, oligodendroglial inclusions have 
been reported to stain positive for a  and B-tubulin subunits (Abe, et. al. 1992; Aria, et. al. 
1992; Kato, et. al. 1991). Independent of cell type or the underlying disease, 
immunohistochemical studies have shown that all forms of glial inclusion can be stained
2 7
with antibodies directed against tau (Murayama, et. al. 1992; Iwatsubo, et. al. 1994; 
Nishimura, et. al. 1992; Yamada and McGeer, 1990; Yamada, et. al. 1992) and antibodies 
directed towards PHF tau (Iwatsubo, et. al. 1994). Together this data suggests that tau may 
undergo similar modification in both neuronal and glial cells in chronic neurodegenerative 
conditions. Immunohistochemical studies have also shown the presence of MAP5 with 
oligodendrocyte inclusions present in MSA.
Figure 4. Photomicrograph showing NFT and GFT morphology. A) shows NFTs 
present in the hippocampus of a 85 year old female diagnosed with Alzheimer's disease at 
post-mortem stained with Bielschowsky modified silver stain. B) shows the morphological 
appearance of oligodendrocyte cytoplasmic inclusions, stained with an anti-ubiquitin 
antibody, from the pons of a 52 year old female who died with MSA. Scale bar = 50p.m.
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1.5  The neuroglial cells
1.5.1 Introduction
Recognition and characterisation of glial cells occurred long after the description of neurons. 
Neuroglia were first described by Virchow in 1846 as "nerve glue" which following the 
advent of electron microscopy on tissue from the central nervous system fixed by perfusion 
was found to consist of perikarya and processes. Knowledge of the morphologies of these 
cells emerged with the development of metallic impregnation techniques. The "astrocyte" 
was then identified and separated from other neuroglia and thus became the second element 
of the central nervous system next to the neuron (Cajal, 1913, 1916). In 1897 and 1899 
Robertson was the first to identify the "mesoglia" cell, so named due to its different 
morphology compared to the commonly accepted neuroglial cell. This cell type was later 
characterised and named the "oligodendroglia" (del Rio-Hortega, 1919; 1921) comprising 
the third element of the central nervous system. Since these original characterisations the 
glial cells have been separated into the macroglia, consisting of the astrocytes and 
oligodendroglia and the microglia. Unlike neurons, macroglia have only one type of 
process and have the ability to divide throughout life.
1.5.2 Astrocytes
Of the 3 types of glial cells the astrocyte has been the most extensively studied. At the light 
microscope level astrocytes are recognised as star shaped cells whose processes extend into 
the surrounding neuropil. In white matter these cells have many fibrils and are referred to as 
fibrous astrocytes, however those in the grey matter have fewer fibrils and are thus called 
protoplasmic astrocytes. The astrocyte contains all normal organelles found in eukaryotic 
cells, however these are more sparse than in other glia. The most prominent cytoplasmic 
components of the astrocyte are filaments 8 nm in diameter which occur in the perikarya and 
extend into the processes. These filaments closely resemble intermediate filaments found in 
neurons, however their dimensions are smaller and they regularly appear as closely packed 
bundles. Glial fibrillary acidic protein (GFAP, MW 47kDa) one of the intermediate filament 
proteins is known to be the major component of these filaments (Eng and Bigbee, 1978). In 
the CNS, GFAP is unique to astrocytes and therefore antibodies raised against this protein 
are routinely used as specific cellular markers to distinguish these cells from other glia and 
neurons (Martin, et. al., 1991). Astrocytes can therefore be identified in the CNS at the 
light microscope level by both immunological and morphological assessment (see Fig. 5).
2 9
1.5.3 M icroglia
Although microglia were detected in the early 1900's it was 1932 before del Rio Hortega 
classified the microglia. These cells are small compared to astrocytes, have an elongated or 
triangular nucleus and display many fine spine-like branches. Microglia are found in both 
white and grey matter, but are more abundant in grey matter, where they are often situated 
near neurons or blood vessels. In the normal adult brain microglial cells appear to be 
inactive, however become activated by any inflammatory or degenerative process. Once 
activated they move to the site of injury, where they turn into macrophages and remove the 
debris. At this time, the cells may assume a rounded or rodlike shape as they fill with lipids 
and cell constituents. They then transport the debris to the vicinity o f blood vessels for 
clearance from the brain tissue.
1.5.4 Oligodendrocytes
As mentioned above the oligodendrocyte was first described by Robertson (1899) however 
it was decades later before this cell received its name and definitive description by del Rio 
Hortega (1921; 1928). The cell was described as having a small soma with sparse 
cytoplasm and in contrast to the astrocyte which shows an elaborate array of processes these 
cells have few (between 2-10) processes thus leading to the name oligodendrocyte meaning 
’’cell with few branches”. Since its original identification the oligodendrocyte has become 
well characterised both at the light and electron microscope level. Del Rio Hortega separated 
oligodendrocytes into two major classes according to the anatomical position: 1) 
perineuronal - where the cell body is adjacent to a neuron and located in the grey matter, 2) 
intrafascicular - oligodendrocytes positioned between nerve fibres in white matter. Electron 
microscopy has confirmed del Rio Hortega's descriptions (Stensaas and Stensaas, 1968), 
the mature oligodendrocyte is a small cell (10-20pm) in diameter with a dense nucleus and 
cytoplasm (Peters, et. al. 1976) due to the presence of heterochromatin and an unknown 
dense material occupying the cytosol. Oligodendrocytes can display different morphological 
profiles involving their cytoplasmic density and the clumping of nuclear chromatin, 
described as light, medium and dark (Mori and Leblond, 1970). These authors speculated 
that in the corpus callosum of young rats the different morphologies may reflect cells in 
different stages of maturation, with the larger light ones being the most actively dividing 
cells and the most mature being the small dark ones. There are no unique organelles within 
the oligodendrocyte cytoplasm, however they contain an abundance of ribosomes both free 
and associated with membranes. In contrast to astrocytes, oligodendrocytes lack GFAP 
containing filaments, however have an abundance of microtubules similar to those present in 
neurons.
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At the light microscope level oligodendrocytes are morphologically distinct from astrocytes 
as they display a small perikarya with little cytoplasm. In contrast to astrocytes 
oligodendrocyte processes are not readily detected in situ. In vitro, oligodendrocytes can be 
easily identified by surface antigens which change through each stage of maturation. 
However, successful immunological markers for oligodendrocytes in tissue sections have 
been more difficult to develop. Oligodendrocytes have an abundance of transferrin which 
although is not unique to oligodendrocytes allows immunological detection of these cells at 
levels below the threshold for detection in other cell types. Anti-transferrin antibodies are 
therefore used routinely in conjunction with anti-GFAP status and morphology to identify 
oligodendrocytes in situ (Conner and Finne, 1986; Martin, et. al. 1991) (see Fig. 5).
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Figure 5. Rat corpus callosum showing astrocytes immunostained with GFAP (a) and 
oligodendrocytes stained with transferrin (b). In situ astrocytes and oligodendrocytes can 
be easily distinguished by both immunological and morphological criteria. Astrocytes 
contain abundant intermediate filaments which consist mainly of GFAP, which in the CNS 
is unique to astrocytes. Immunohistochemical staining of tissue with antibodies raised 
against GFAP therefore provides a cellular marker for astrocytes (a). Oligodendrocytes 
contain an abundance of transferrin, therefore antibodies directed against this protein can 
serve as a good cellular marker in the CNS (b). Staining with these markers distinguishes 
these cells immunologically and also displays the cellular morphology of these cells. The 
oligodendrocyte has a small soma with sparse cytoplasm and processes are not readily 
detectable in situ. In contrast however, astrocytes have a larger soma and display an 
elaborate array of cellular processes (arrows). Scale bar = 50pm.
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1 .5 .5  Oligodendrocyte function
M yelination
Myelination is the most well documented function of oligodendrocytes and detailed 
discussion of this process is outwith the scope of this thesis, however see McLaurin and 
Yong, (1994) for review. During development, axons in the CNS become ensheathed with 
myelin produced by oligodendrocytes, each cell being capable o f myelinating many 
segments of different axons (Bunge, et. al. 1962; Bunge, 1968; Mathews and Duncan, 
1971). Myelin is a highly complex and specialised extension of the oligodendrocyte plasma 
membrane, with each cell capable of making approximately three times its weight in 
membrane each day during active myelination (Norton and Poduslo, 1973). Myelin is 
composed mainly of lipids, none of which are unique to oligodendrocytes, however 
cerebroside is the most characteristic of oligodendrocytes and is often used as a cellular 
marker (Raff, et. al. 1978). Lipid accounts for approximately 70% of myelin the rest of 
which consists of protein, the major ones being proteolipid protein (PLP) and myelin basic 
protein (MBP) which account for 50% and 30% of total myelin protein respectively (Lees 
and Brostoff, 1984). More minor protein components include myelin-associated 
oligodendrocyte basic protein, 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) and 
myelin associated glycoprotein.
As the oligodendrocyte process encircles its axon, the cytoplasm is eliminated forming a 
compacted multilamellar sheath. Each cell generating myelin only provides myelin for a 
segment of the axon which therefore results in a discontinuous sheath with areas of axon 
uncovered called the nodes of Ranvier. At the node of Ranvier there is a high concentration 
of ion channels and this is the only point where the axon comes into contact with the 
extracellular fluid. As the nerve impulse passes along the axon they "jump” from node to 
node. This feature permits signal transmission to occur at a greater velocity, frequency and 
efficiency than unmyelinated fibers. Demyelination during disease such as multiple 
sclerosis therefore results in impaired signal transmission, leading to devastating 
neurological symptoms.
Inhibition o f  neurite outgrowth
Using video time lapse cinematography, Schwab and colleagues have provided evidence for 
a role of oligodendrocytes and myelin in the inhibition of neurite outgrowth. Astrocytes 
were shown to be a good substrate for neurite extension while contact with 
oligodendrocytes or myelin resulted in growth cone collapse (Schwab, et. al. 1988). 
Biochemical analysis has revealed two groups of proteins of molecular weights 35kDa and 
250kDa that are uniquely found tightly bound to mem brane proteins of CNS
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oligodendrocytes and have been implicated in the inhibitory action of oligodendrocytes to 
neurite extension (Schwab, et. al. 1993). These proteins are expressed late in development 
and may therefore play a role in guiding late developing CNS tracts in order to avoid 
abnormal sprouting and regulate axon number (Cadelli, et. al. 1992; Chiquet, 1989; Collelo 
and Schwab, 1994). The continued expression of these factors on oligodendrocytes 
following brain injury may therefore be a key feature in the failure of axonal regeneration. 
Biochemical analysis of these proteins has revealed two groups of proteins of molecular 
weights 35kDa and 250kDa that are uniquely found tightly bound to membrane proteins of 
CNS oligodendrocytes (Schwab, et. al. 1993).
N euronal-glia l signalling
The presence of glutamate receptor subtypes on oligodendrocytes and astrocytes (see section 
1.5.7) raises the possibility that neurotransmitters released at the synapse or along axons can 
not only influence neurons, but also glial cells that are intimately associated with neuronal 
elements (for review see Finkbeiner, 1993). This raises the suggestion that signalling may 
occur between neurons and glia, via excitatory amino acids. In support o f glutamate 
mediated signalling between neurons and glia, Dani, et. al (1992) showed that glial cells 
receive signals during neuronal activity in hippocampal organotypic cultures possibly 
mediated through glutamate. Excitatory amino acid receptor activation may result in the 
release of growth factor, neuropeptides, or neurotransmitters from glia (Parpura, et. al.
1994) and the release of such substances from glia may participate in activity-dependant 
plasticity in the adult brain (Kang and Schuman, 1995). Glutamate receptor activation has 
also been shown to increase c-fos and c-jun (immediate early genes) expression and inhibit 
proliferation of oligodendrocyte progenitors through non-NMDA receptor activation (Liu 
and Almazan, 1995; Pende, et. al. 1994). Repetitive axonal stimulation or treatment of the 
axons with glutamate in neonatal rat optic nerve also stimulated this response in 
oligodendrocytes (Mack, et. al. 1994). Immediate early genes encode transcription factors 
that regulate the expression of late genes which may result in permanent phenotypic 
alterations (Sheng and Greenberg, 1990).
Most studies to date have concentrated on the role of astrocytes in glia-neuronal signalling, 
for example K+ buffering. During neuronal activity K+ levels increase immediately 
surrounding the neuron, which may lead to prolonged depolarisation if not removed. 
Glutamate receptor activation in astrocytes during neuronal activity leads to increased 
intracellular Ca++ within these cells resulting in K+ uptake through the activity of the 
Na+/Ca++ exchanger and Na+/K+ pump (for review see Barres, et. al 1991). These Ca++ 
signals can be propagated as waves through astrocyte gap junctions (Giaume, et. al. 1991). 
Recently Nedergaard (1994) showed that Ca++ signals can pass from astrocytes to neurons
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through gap junctions suggesting that neurons can signal to glia which in turn can signal 
back to neurons. Due to the presence of glutamate receptors on oligodendrocytes it is 
possible to speculate that these cells also have the capacity to respond to neuronal signals 
such as glutamate release. Glutamate receptor activation on these cells results in increased 
intracellular calcium suggesting that oligodendrocytes may also be capable of K+ buffering.
1.5.6 The oligodendrocyte cytoskeleton
In contrast to astrocytes, mature oligodendrocytes in vivo do not contain intermediate 
filaments, they do however contain large amounts of microtubules. Similarly to those found 
in neurons (see section 1.3.1) these microtubules are 25 nm in diameter and consist of 
tubulin dimers. They are arranged randomly throughout the perikaryal cytoplasm although 
in the processes they are arranged parallel to one another as in axons and dendrites of 
neurons. Since myelination involves the extension of long processes requiring substantial 
changes in the shape of the oligodendrocyte and given what is known about neuronal 
cytoskeletal functions it seems likely that the cytoskeleton of oligodendrocytes may play an 
important role in process extension. In support of this theory, tubulin has been identified as 
a constituent of myelin isolated from rat brain (Gozes and Richter-Landsberg, 1978). 
This protein is synthesized prior to myelination and has therefore been suggested to be 
involved in the formation and maintenance of myelin shape. In addition, purified MBP 
can form complexes with tubulin and actin (Modesti and Barra, 1986). Using cell culture 
both MBP and CNP have been shown to associate with the cytoskeleton of 
oligodendrocytes. CNP and MBP are synthesized on free ribosomes (Colman, et. al. 1982; 
Gillespie, et. al. 1989) and have to be transported into the processes for myelin formation. 
It is possible to speculate therefore that microtubular networks within these cells are 
essential for the transportation of the machinery required for myelin formation into the 
processes. In immature cells with many processes, CNP appears to localise with 
filamentous actin which is more abundant than microtubules at this stage. In more mature 
oligodendrocytes, where the number of processes is decreased and the diameter thickened, 
filaments appear to be lost and microtubules predominate to which MBP is found to 
colocalize (Wilson and Brophy, 1989). It is possible to speculate that actin filaments are 
responsible for the direction of growth however microtubules are involved in the elongation 
and thickening of processes.
The microtubule associated proteins as discussed in sections 1.3.2 play an important role in 
microtubule function in neurons. In neurons these proteins appear to be developmentally 
regulated and are thought to be involved in the formation and extension of axons and 
dendrites. Although traditionally believed to be neuron specific, MAP2, MAP4, MAP5 and 
tau have recently been identified in oligodendrocyte cultures (Diaz-Nido and Avila, 1989;
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Fischer, et. al. 1990; Lopresti, et. al. 1995; Ulloa, et. al. 1994b; Vouyiouklis and Brophy, 
1995). MAP2c expression in neurons is present during development which regresses and is 
replaced by the higher molecular weight isoforms. In oligodendrocytes a novel MAP2c 
isoform containing four repeat sequences is present in progenitor cells. This expression of 
MAP2c is higher in pre-oligodendrocytes than progenitors but decreased again when 
reaching the final stages of maturation suggesting that MAP2c is required with the 
transitional pre-oligodendroglial stage (Vouyiouklis and Brophy, 1995). MAP2c is 
therefore unlikely to be involved in stabilizing myelin processes but important in initiating 
the extension of processes. The heterogeneous nature of MAP2c may represent various 
phosphorylation states of the protein (Vouyiouklis and Brophy, 1995). Similarly to 
neurons, MAP5 expression is developmentally regulated and its appearance coincides with 
the development of pre-oligodendrocytes from progenitors (Vouyiouklis and Brophy,
1995), when the cells start to develop a network of extensive processes. MAP5 found in 
oligodendrocytes colocalizes with tubulin (Fischer, et. al. 1990) and has a phosphorylation 
pattern distinct from that in neurons (Ulloa, et. al. 1994). In contrast to neurons, however 
MAP5 levels appear to remain elevated in mature oligodendrocytes. Together these results 
suggest a role for MAP5 in the stabilization of the cytoskeleton and extension of processes 
in mature oligodendrocytes. The presence of the microtubule-associated protein tau in 
oligodendrocytes remains a controversial issue. Many groups have failed to detect the 
presence of tau in non-neuronal cells using antibodies directed towards neuronal tau (Brion, 
et. al. 1988; Trojanowski, et. al. 1989; Vouyiouklis and Brophy, 1995). However, tau has 
been reported in oligodendrocytes of rat brain tissue before (Migheli, et. al. 1988) and after 
enzymatic dephosphorylation of the tissue (Papasozomenos and Binder, 1987). It should 
be noted however, that tau was not detected in intrafasicular oligodendrocytes following 
dephosphorylation of the tissue and was only detected in perineuronal oligodendrocytes 
(Papasozomenos and Binder, 1987). Lopresti, et. al. (1995) failed to detect tau within 
oligodendrocytes of rat brain tissue with Tau 1 however did detect tau in these cells using 
Tau 5, an antibody raised against glial tau. In addition Lopresti et. al. (1995) provided 
evidence for the presence of tau protein and tau mRNA in oligodendrocyte cultures and that 
tau appears to colocalize with MBP. This raises the possibility that tau may be involved in 
the transportation of MBP to the site of myelination.
1 . 5 . 7  The effect of ischaemic injury on oligodendrocytes
Research to date has mainly concentrated on the mechanisms underlying neuronal death in 
both acute and chronic degenerative disorders of the brain. However in light of the growing 
evidence showing the importance of glia in the maintenance of neuronal integrity it is 
essential to gain an understanding of events occuring within these cells under pathological 
conditions. The role of astrocytes in glutamate uptake and their proliferation following
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cerebral ischaemia has been well documented (Hertz, et. al. 1992; Petito and Babbiak, 1982; 
Schousboe, et. al. 1988). In contrast however the reaction of oligodendrocytes to ischaemia 
is not well known.
Oligodendrocytes are relatively resistant to ischaemia (Brierly and Graham, 1984), but can 
be selectively damaged following cardiac arrest (Plum, et. al. 1962) or severe hypotension 
(Ginsberg, et. al. 1976). Using a model of transient cerebral ischaemia in the rat Petito 
(1986) showed that in addition to neurons and astrocytes, oligodendrocytes can also 
respond rapidly to ischaemic injury. Medium-light oligodendrocytes increased in size 3 ,30 
and 180 min following ischaemia. These cells showed increased microtubules and 
tubovascular profiles and accounted for approximately 50% of all glial cells within 2 h of 
injury, however the number present decreased to 6.5% by 3 h. In contrast, dark cells 
thought to represent the most mature oligodendrocytes, showed little change following 
cerebral ischaemia. Petito suggests that cell loss may represent a transition of medium-light 
oligodendrocytes to intermediate glia which have some characteristics o f both 
oligodendrocytes and astrocytes. This may represent an "active" oligodendrocyte. Further 
evidence showing that oligodendrocytes are capable of responding rapidly to injury in vivo 
was provided by Ludwin, (1984) who showed that medium oligodendrocytes proliferate 24 
h following TBI in the mouse. The density of responsive cells was greatest in the cortex 
immediately surrounding the wound and decreased in as the distance from the wound 
increased. Proliferating oligodendrocytes were also detected in the white matter immediately 
below the wound and across the midline of the corpus callosum similar to the spread of 
oedema in this model.
Recently rat neonatal oligodendrocytes and human oligodendroglioma cells have been 
shown to increase ferritin synthesis following 6 h of hypoxia in vitro (Qi and Dawson, 
1992; 1994; 1995). This increase in ferritin synthesis was seen in conjunction with a 
decrease in MBP levels but no change in structural proteins such as actin. The increased 
synthesis of ferritin occurs at a post-transcriptional level, and has been suggested to be part 
of a protective response of oligodendrocytes to hypoxic injury (Qi, et. al. 1995). Ferritin is 
a natural iron chelator (Balia, et. al. 1992) and may therefore play an important role in the 
protection of oligodendrocytes and myelin from free-radical mediated damage. Iron is a 
catalyst for the production of OH' from H2O2  therefore chelation of iron would protect the 
cells from the damaging effects of OH*. Exposure of the same cultures to hydrogen 
peroxide induced ferritin synthesis (Qi, et. al. 1995). Together these results show that 
oligodendrocytes can respond rapidly to hypoxic injury in vitro which involves free radical 
mediated mechanisms.
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The studies described above suggest that oligodendrocytes may play a more active role in 
the pathogenesis of brain damage resulting from cerebral ischaemia than originally believed. 
The mechanisms underlying the changes described following ischaemic injury are however 
unknown. As described above glutamate toxicity and free radical mechanisms have been 
implicated in ischaemic injury, however whether these mechanisms are involved in the 
responses of oligodendrocytes to ischaemia is not known. Electrophysiological studies 
have shown that mature oligodendrocytes respond directly to glutamate exposure in vitro 
(Ballanyi and Kettenman, 1990; Butt and Tutton, 1992; Patneau, et. al. 1994; Puchalski, et. 
al. 1994). Molecular analysis of glutamate receptor subunit expression in progenitors, 01 
and 04 positive oligodendrocytes revealed the expression of AMPA and kainate preferring 
subunit transcripts (Patneau, et. al. 1994). Neither mature oligodendrocytes nor their 
progenitors appear to express NMDA receptors (Patneau, et. al. 1994; for review Gallo and 
Russell, 1995). Electrophysiology studies showed that the currents elicited by glutamate 
receptor activation were coincident with cells expressing both AMPA and kainate preferring 
receptors. This was shown by their different affinities for these receptor agonists, AMPA 
and kainate and the sensitivity to the AMPA modulator cyclothiazide (Patneau, et. al. 1994). 
Cyclothiazide acts to block the rapid desensitisation of AMPA receptors following glutamate 
activation and produces marked potentiation of the response to kainate (Patneau, et. al. 
1993; Yamada and Tang, 1993).
Glutamate induced injury has been reported to be mediated through non-NMDA receptors in 
oligodendrocytes in a Ca++ dependant manner (Patneau, et. al. 1994; Puchalski, et. al. 
1994; Yoshioka, et. al 1995). Contrasting studies however, report that glutamate induced 
injury in oligodendrocytes is mediated, not through glutamate receptor activation, but 
through the actions of free radicals. Similarly to the transport system present in neurons 
increased extracellular glutamate concentrations lead to the depletion of cystine and therefore 
glutathione within these cells rendering them vulnerable to oxidative stress (Oka, et. al. 
1993; Yonezawa, et. al. 1996). In support o f this, primary cultures of bovine 
oligodendrocytes were shown to be susceptible to oxygen radicals derived from 
glucose/glucose oxidase and hypoxanthine/xanthine oxidase reactions (Kim and Kim,
1991). In this study cytotoxicity was measured by tryptan blue exclusion and lactate 
dehydrogenase leakage, showing that oxygen radicals induce significant membrane damage 
to oligodendrocytes within 2 h of exposure.
Calcium influx is involved in neuronal degeneration and in glutamate receptor mediated 
toxicity described above. It has previously been shown that complement activated injury to 
oligodendrocytes characteristic of demyelinating diseases such as multiple sclerosis, is 
accompanied by a significant rise in intracellular calcium (Scolding, et. al. 1989).
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Oligodendrocytes posses myelin-specific calcium dependant enzymes, including a basic 
protein kinase (Petrali and Sulakhe, 1982) and a neutral protease responsible for MBP 
hydrolysis (Banik, et. al. 1985). These enzymes may render oligodendrocytes more 
susceptible to changes in intracellular calcium than other glial cells (Scolding, et. al. 1990). 
Moreover, there is evidence that the effects of anoxia on white matter tracts may reflect 
calcium-mediated injury to the oligodendrocyte and myelin unit (Stys, et. al. 1990; 1992; 
Waxman, et. al. 1994). Calcium ionophores have been shown in vitro to cause cell body 
swelling, the appearance of cytoplasmic granules and the gradual disintegration of 
oligodendrocyte processes, leading to cell lysis (Scolding, et. al. 1992) and in vivo to cause 
demyelination o f white matter tracts (Smith and Hall, 1994). In addition, MBP has been 
shown to be a substrate for the calcium activated protease calpain further implicating a role 
for calcium in the degeneration of the oligodendrocyte-myelin unit (Banik, et. al. 1994).
Together these studies provide evidence that oligodendrocytes can respond to glutamate, 
free radicals and Ca++, all of which have the potential to cause degeneration of these cells. 
In light of this it is possible to envisage that during ischaemia and TBI, where the levels of 
all these substances are elevated, oligodendrocytes may become stimulated and/or undergo 
degeneration. Due to the importance of these cells in maintaining neuronal integrity 
oligodendroglial injury or death may have profound consequences for neuronal function and 
survival. Glutamate excitotoxicity is thought to be predominantly mediated through NMDA 
receptor activation. Although the use of animal models of acute brain injury have shown 
significant protection of neuronal elements by NMDA antagonists, compounds such as these 
will not protect oligodendrocytes since glutamate toxicity is mediated through non-NMDA 
receptors and/or free radical damage in these cells. It is possible to speculate that protection 
o f neurons without a similar protection of glial cells may result in delayed neuronal 
degeneration rather than neuron protection since the degeneration of glial elements would 
ultimately result in neuronal death. An understanding of the mechanisms underlying glial 
responses to ischaemic brain injury is therefore pertinent to highlighting new areas of 
therapeutic intervention.
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1.6. Aims of the thesis
Animal models of acute brain injury have been utilised to determine the mechanisms 
underlying neuronal degeneration in pathological circumstances. Glutamate toxicity and free 
radical mediated mechanisms are two such pathways which have been shown to be involved 
in neuronal degeneration following ischaemic brain injury. Assuming that similar 
mechanisms underly neuronal degeneration in both acute and chronic degenerative disorders 
these factors have also been implicated in the pathogenesis of chronic degenerative 
conditions. Although traditionally considered to be relatively resistant to ischaemic brain 
damage, oligodendrocytes have recently been shown to be susceptible to both glutamate and 
free radicals in vitro, suggesting that oligodendrocytes may also be susceptible to ischaemic 
brain damage. Breakdown of the neuronal cytoskeleton is thought to be one of the 
neurochemical events triggered by elevated extracellular concentrations of glutamate and free 
radicals resulting in irreversible neuronal death. Changes in the neuronal cytoskeleton 
resulting from acute brain injury have been well documented, although the mechanisms 
underlying these changes for the most part remain unclear. In contrast to the intensive 
investigations of neuronal responses to acute injury, the response of oligodendrocytes to 
ischaemia has been largely ignored.
The main aims of this thesis were therefore : 1) to investigate the distribution of the 
cytoskeletal proteins tau, MAP2 and MAP5 in oligodendrocytes in various rat models of 
acute brain injury and in human post-mortem brain tissue from patients who died following 
head injury or a stroke and to compare this to changes occurring in neurons and 2 ) to 
determine the mechanisms through which changes in oligodendrocyte and neuronal 
cytoskeletal proteins occur.
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CHAPTER 2 MATERIALS AND METHODS
PART 1 : ANALYTICAL END POINTS
A variety of different techniques were employed to assess tau protein in animal models of 
acute brain injury; human post-mortem brain tissue or oligodendrocyte cultures. These 
included : immunohistochemistry; western blotting and in situ hybridisation.
2.1 Immunohistochemistry
2.1.1 Description of antibodies
Tau was detected using six different antibodies : Tau 1; AT8 ; B19; TP70,TP007 and AD2 
which have been previously characterised by others (Fig. 6 ). The monoclonal antibody 
Taul labels a dephosphorylated epitope between residues Ser 199 and 204 (Binder, et. al. 
1985; Papasozomenos and Binder, 1987). AT8  is a monoclonal antibody which labels tau 
phosphorylated at residue 200 (Biemat, et. al. 1992). B 19 is a polyclonal antibody raised 
against full length tau (Brion, et. al. 1991b). TP70 is a polyclonal antibody directed against 
a synthetic peptide corresponding to residues 428-441 at the C-terminal of the tau protein 
(Brion, et. al. 1993). TP007 is a polyclonal antibody raised to a synthetic peptide 
corresponding to the 16 most N-terminal residues of human tau protein (Davis, et. al.
1995). Taul, B19, TP70 and TP007 were the kind gift of Professor B.H. Anderton
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(Institute of Psychiatry, London).
Figure 6. Schematic representation of the epitopes to which the tau antibodies used in 
this study bind. Residue numbers correspond to those of the longest human isoform of tau 
containing 4 C- terminal repeats (hatched area) and 2 N-terminal inserts (shaded area). 
T au l and AT8  recognise tau dephosphorylated and dephosphorylated between residues 
199-204 respectively. AD2 immunoreactivity is dependant on the phosphorylation of tau 
at residues 396 and 404. In contrast, detection of tau with B19, TP70 and TP007 is 
independent of the phosphorylation state of the protein.
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AD2 is a phosphorylation dependant antibody raised against tau proteins found in AD. 
The epitope for this antibody includes Ser-396 (phosphorylated) and the participation of 
Ser-404 (phosphorylated) (BueeScherrer, et. al. 1996).
MAP2 was labelled using a monoclonal antibody which recognises MAP2a, b and c (clone 
HM-2; Sigma). MAP5 was labelled using an anti-MAP5 monoclonal antibody (clone 
AA6 ; Sigma).
Anti-transferrin was used as a cell marker for oligodendrocytes (Conner and Fine, 1986; 
Martin, et. al. 1991) and was detected using a polyclonal anti-transferrin (1:300) antibody 
from DAKO. GFAP was used as a cell marker for astrocytes (Martin, et. al. 1991) and 
was detected using a polyclonal anti-GFAP antibody (1:750) from DAKO.
2.1.2 Dephosphorylation of tissue prior to immunostaining
In some experiments, dephosphorylation of the tissue was performed prior to tau 
immunostaining using the method previously described by Papasozomenos & Binder 
(1987). Tissue sections were incubated with 130mg/ml of type VTI-L alkaline phosphatase 
from bovine intestinal mucosa (Sigma) in lOOmM Tris-HCl, pH 8  for 2.5 h in a shaking 
water bath at 32°C. To inhibit proteolysis, ImM phenylmethylsulfonyl fluoride, 10fJ.g/ml 
pepstatin and 10pg/ml leupeptin were included in the incubation fluid. For controls, 
lOOmM sodium pyrophosphate was included in the incubation solution as a competitive 
inhibitor of alkaline phosphatase. The dephosphorylation reaction was quenched by 
bathing the sections in ice-cold Tris saline (50mM Tris-HCl, 0.2M sodium chloride, 
pH7.6), and immunostained immediately as described below. Tau 1 immunoreactivity is 
localised within the axon in histologically normal tissue, how ever following 
dephosphorylation Tau 1 immunoreactivity was also detected within neuronal perikarya 
indicating that tau present in neuronal perikarya is phosphorylated at the Tau 1 epitope 
therefore preventing antibody binding (Fig. 7). Dephosphorylation of tissue prior to 
immunostaining was performed in situations where Tau 1 immunoreactivity was 
decreased, to determine whether this was due to phosphorylation of existing protein or 
due to protein loss.
2.1.3 Single label immunohistochemistry
The immunohistochemical procedures described below were performed on free floating 
ra t brain sections, modification of this procedure for immunostaining of human post­
mortem brain tissue and cell cultures are described in sections 2.5 & 2.7 respectively. 
Sections were rinsed in phosphate buffered saline (PBS) and incubated in PBS containing 
0.2% Triton X-100 for 30 min. After rinsing with PBS the endogenous peroxidase activity
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Figure 7. Photomicrographs showing the pattern of Tau 1 immunoreactivity in the 
parietal cortex and subcortical white matter of the rat before and after dephosphorylation. 
Tau 1 recognises tau protein dephosphorylated between residues 199-204 and therefore 
immunoreactivity is localised to axons in both grey matter and white matter. No neuronal 
perikarya or glial cells are detected in normal brain tissue. Following dephosphorylation 
of the tissue, in addition to axonal staining, Tau 1 immunoreactivity became apparent 
within neuronal perikarya of grey matter. In white matter however, immunoreactivity 
remained predominantly localised to axons, suggesting the absence of tau in glial cells 
rather than tau being masked by phosphorylation. Thus tau is compartmentalised within 
the neuron; phosphorylated at the Tau 1 epitope within neuronal perikarya but 
dephosphorylated at this epitope in the axonal compartment of both grey and white matter. 
Scale bar = 50pm.
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was blocked by incubating in 3% hydrogen peroxide (Sigma) for 20 min. To block non­
specific binding, sections were incubated in PBS containing 10% normal horse serum and 
1% bovine serum albumin (BSA; Sigma) for monoclonal antibodies (Tau 1, AT8 , MAP 2 
and MAP5) or PBS containing 10% normal goat serum and 1% BSA for polyclonal 
antibodies (B19, TP70 & TP007) for 1 h. Dilution curves were carried out to determine 
the optimum dilution for each antibody i.e. that which produced the best signal to 
background ratio. Incubation with primary antibody in appropriate blocking solution (Tau 
1, 1:1000; AT8 , 1:50; MAP2, 1:750; MAP5, 1:1000; B19 1:750; TP70, 1:2000; TP007, 
1:500) was overnight at 4°C. Following two rinses with PBS, monoclonal antibody 
binding was detected by incubating sections with a biotinylated horse anti-mouse IgG 
secondary antibody preadsorbed against rat serum (1:100; Vector Labs.) for 1 h, while 
polyclonal antibody binding was detected using a biotinylated goat anti-rabbit IgG 
secondary antibody (1:400; DAKO). All sections were then incubated with an ABC 
com plex (Vector Labs.) for one hour and peroxidase visualised w ith 3'-3'- 
diaminobenzamine (lOmg DAB tablet (Sigma); 0.024% hydrogen peroxide in 50mM Tris 
HC1 pH7.4). Sections were then mounted onto poly-L-lysine coated slides, dehydrated 
through graded alcohols, cleared and coverslipped ready for microscopic examination. 
Negative controls were included in each experiment, in which the primary antibody was 
omitted from the procedure. Non-specific immunoreactivity was not detected in these 
sections (Fig. 8 ).
2.1.4 Double label immunohistochemistry (chromagen)
Sections were stained as described above for single label immunohistochemistry using 
Taul, however antibody binding was visualised using the purple chromagen VIP (Vector 
Labs.). Following this procedure the sections were washed in water followed by PBS and 
then incubated with PBS containing 10% goat serum and 1% BSA for lh. Incubation with 
the second primary antibody (GFAP or transferrin) was for lh  at room temperature in 
blocking solution. Sections were then rinsed in PBS (2x10 min) and incubated with 
species specific anti-rabbit biotinylated secondary antibody (1:400) for 1 h. All sections 
were then incubated with an ABC complex for one hour and peroxidase visualised with a 
grey chromagen SG (Vector Labs.). Negative controls were included in each experiment, 
where the prim ary antibody was omitted from the procedure. N on-specific 
immunoreactivity was not detected in these sections (Fig. 8 ).
2.1.5 Double label immunohistochemistry (fluorescence)
Double label experiments were also carried out using immunofluorescence techniques. 
Free floating sections were treated as described above however it is unnecessary to block 
endogenous peroxidase activity since this is not involved in the visualisation of antibody
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binding using this technique. Non-specific binding was prevented by incubating sections 
in PBS containing 10% normal horse serum / 10% normal goat serum and 1% BSA for lh. 
Primary antibodies were added together Tau 1(1:1000) + anti-GFAP (1:750) or Tau 1 + 
anti-transferrin (1:750) in blocking solution, overnight at 4°C. Sections were rinsed in 
PBS and incubated with a biotinylated horse anti-mouse secondary antibody (1:100 in 
PBS) for 30min (this binds to the Tau 1 antibody only). Following two rinses in PBS 
sections were incubated in PBS containing streptavidin-FITC conjugate (1:75, Sigma) and 
Texas Red labelled goat anti-rabbit IgG antibody (1:100, Vector Labs.). Sections were 
rinsed in PBS and water and mounted onto poly-L-lysine coated slides and coverslipped 
using citifluor anti-fading agent (Citifluor, Labs.). The FITC conjugate binds to the 
biotinylated secondary antibody and therefore detects Tau 1 antibody binding. FITC 
absorbs light of wavelength 495nm and emits at 525nm and herefore can be visualised as 
green light using a blue filter. The Texas red labelled goat anti-rabbit binds to the 
transferrin or GFAP polyclonal antibody (rabbit IgG) and absorbs light at 596nm and 
emits at 620nm and therefore can be visualised as red light using a green filter.
Figure 8 . Typical examples of negative controls for single (A) and double (B) label 
immunohistochemistry using DAB, VIP or SG as chromagens. Negative controls in 
which the primary antibody was omitted were carried out for every immunohistochemical 
experiment: A) shows a rat brain section processed for single label immunohistochemistry 
using DAB as the chromagen as described in section (2.1.3); B) shows a rat brain section 
processed for double label immunohistochemistry using Vector VIP and SG as 
chromagens as described in section (2.1.4). Non-specific immunoreactivity was not 
detected in these tissue sections. Scale bar = 50p.m.
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2.2 Western blot analyses
2.2.1 Preparation of cell cultures
Cell cultures were removed from -70°C and thawed on ice prior to use (for details of 
cultures used see section 2.7). 250(il of sample buffer (2% SDS, 5% mercaptoethanol, 
10% glycerol in 62.5mM Tris pH 6 .8 ) was added to each culture flask and a suspension of 
lysed cells made using a rubber spatula. Once all cells were lysed and dissociated from 
the flask the suspension was transferred to a sterile eppendorf, heated to 100°C for 5 min, 
centrifuged at 13000rpm for 5 min and returned to ice. Bromophenol blue was added to 
each tube and a 30|il aliquot loaded onto the gel. Remaning homogenates were stored at - 
70°C until further use.
2.2.2 Preparation of whole brain homogenate
An adult rat was killed by an overdose of halothane, decapitated and the brain was rapidly 
dissected and frozen in liquid nitrogen. Whole brain homogenates were prepared by 
homogenising the brain sample in 5mls of sample buffer and centrifuged at 13000rpm at 
4°C for 30 min. The supernatant was retained and heated at 100°C for 5 min, spun at 
13000rpm for 5 min, the supernatant harvested and placed on ice. For protein 
qauntification, brain proteins were precipitated with tri-chloroacetic acids as follows. An 
appropriate volume of brain homogenate was made up to 1ml with distilled water in an 
eppendorf tube, and sodium deoxy cholate was added to a concentration of 1%. The 
samples were vortexed and ice-cold tri-chloracetic acid was added to a final concentration 
of 10%. The samples were vortexed and placed on ice for 30 min to precipitate the protein 
which was pelleted by spinning briefly in a microcentrifuge. The protein pellet was 
resuspended in a small volume of 1M Tris/HCl pH 8  and a sample removed for protein 
analysis as described by Lowry et. al. (1951), using bovine serum albumin as a standard. 
The remaining brain samples were then diluted in 5x sample buffer.
2.2.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
The denatured proteins were separated by discontinuous slab gel electrophoresis 
(Laemmli, 1970). The resolving gel, consisted of 12% acrylamide, 0.32% bis acrylamide, 
0.38M Tris/HCl pH 8 .8 , 0.1% SDS and was polymerised using 0.1% ammonium 
persulphate and 0.04% TEMED. The gel was cast between 2 glass plates in an ATTA gel 
setter to give a gel approximately 13 cm in length. While polymerising the top surface of 
the gel was covered with isopropanol. Once polymerised the isopropanol was removed 
and the stacking gel, consisting of 4.8% acrylamide, 0.13% bis acrylamide, 0.1% SDS, 
0.14M Tris/HCl pH 6 .8 , 0.1% ammonium persulphate and 0.04% TEMED, poured above
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the resolving gel and a 14 well comb inserted. Once solidified the gel was placed in an 
electrophoresis rig, the comb removed and the rig filled with electrophoresis buffer 
(190mM glycine, 25mM Tris and 0.1% SDS). 30|il of each of the cell homogenates and 
2 0 |ig  of brain homogenate were loaded onto the gel alongside pre-stained molecular 
weight markers (14-220kDa; Amersham). Proteins were electrophoresed at 200mV for 2- 
3  h until the dye front had reached the bottom of the gel and all molecular weight markers 
could be seen. Proteins were then transferrrd to PVDF membrane (Millipore) by means 
of semi-dry electroblotting.
2.2.4 Semi - dry electroblotting
After electrophoresis, the resolving gel was separated from the stacking gel and twelve 
sheets of 3mm filter paper (Watmann) and one sheet of PVDF membrane were cut to fit 
the gel. The filter paper was soaked in semi-dry transfer buffer (60mM Tris, 50mM 
glycine, 1.6mM SDS, 30% methanol) for 15 min and 6  sheets placed on the electroblotter, 
ensuring there were no air bubbles. The PVDF membrane was soaked in methanol and 
placed on top of gel, and the gel sandwiched with the remaining six sheets of filter paper. 
Transfer was carried out at 200mA for 45 min. Efficient transfer was confirmed by the 
appearance of the pre-stained molecular weight standards on the PVDF membrane sheet, 
the positions of these were highlighted with pencil. Following transfer the PVDF 
membrane was soaked in methanol and cut ready for Western blotting. The gel was 
placed in Coomassie stain (10% glacial acetic acid; 50% methanol; 0.25% Coomassie 
Brilliant Blue R) and agitated overnight at 4°C. The following day the gel was placed in 
destain (7% acetic acid; 25% methanol) during western blot procedure, to confirm equal 
protein loading of cell samples.
2.2.5 W estern blot (Enhanced chemiluminescence-ECLTM)
Non-specific binding was prevented by incubating the PVDF blots in blocking solution 
(3% non-fat dried milk in Tris buffered saline pH8  containing and Tween-20 (TBS-T : 
lOmM Tris; 150mM NaCl; 0.05% Tween-20)) for lh  at room temperature. Blots were 
rinsed in TBS-T (1 x 10 min, 2 x 5  min) and incubated with primary antibody (Tau 1, 1; 
500 or TP70, 1: 3000) in blocker overnight at 4°C. Following rinses in TBS-T (1 x 15 
min, 2 x 5  min) blots were incubated with HRP labelled sheep anti-mouse IgG (1:5000; 
Amersham), or donkey anti-rabbit IgG (1:2000; Amersham) in blocker for Tau 1 or TP70 
respectively, at room temperature for lh. Blots were rinsed in TBS-T ( 6  x 10 min), 
incubated in ECL reagent (equal volumes of each detection reagent; Amersham) for 1 min, 
blotted dry with filter paper, wrapped in Saranwrap and exposed to blue light sensitive 
autoradiography film (Fuji) for 1-10 min depending on the amount of antigen present. 
Films were developed using an automatic processor. The light produced by ECL peaks
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after 5-20 min and has a half life of 60 min therefore exposure to film must be within 20 
min of the reaction for maximum signal detection.
2.3 In situ hybridisation
2.3.1 Core materials and solutions
Di-ethyl pyrocarbonate (DEPC) minimises RNase activity, therefore all solutions were 
made using DEPC treated sterile distilled water (SDW). This was prepared by treating 
distilled water with 0.01% DEPC overnight and sterilising by autoclaving at 151b/in2 for 
15 min. Glasswear (once cleaned by soaking in 6 % sulphuric acid and 6 % potassium 
dichromate overnight) and plastics were soaked in DEPC SDW prior to sterilisation by 
baking at 180°C or autoclaving at 151b/in2 fo r 15 m in respectively . 3- 
Aminopropyltriethoxy-silane (APES) coated slides were prepared using DEPC treated 
glass slides. Slides were soaked in 5% Decon 90 (Decon Labs. Ltd.) overnight, washed 
well, wrapped in foil and oven dried. Once dry slides were soaked in 0.25% APES 
(Sigma) in methylated spirit for 2 min in a fume hood. Slides were then rinsed in DEPC 
SDW for 2 min and oven dried in foil and stored at room temperature.
2.3.2 Preparation of tau DNA for riboprobe production 
Amplification o f tau cDNA
cDNA encoding full length adult rat tau (Kosik, et. al. 1989a) was kindly gifted by Dr. K. 
Kosik. Two copies of this adult rat cDNA were cloned into a pGEM3 vector head to tail 
at the EcoRI site. Competent cells, kindly prepared by Dr. P. Dickinson, were transformed 
with plasmid to amplify the tau cDNA. Briefly, transformations were performed in sterile 
40ml polypropylene tubes pre-chilled on ice. 25ng of tau cDNA was aliquoted and made 
up to a final volume of 100JJ.1 with Tris EDTA buffer (TE) pH 8  (lOmM Tris HC1 pH 8  /  
ImM EDTA pH8 ). An aliquot of competent cells was thawed and a lOOfil aliquot added 
to the tau DNA, swirled gently and incubated on ice for 30 min. The competent culture 
was heat shocked at 42°C for 45 s and rapidly transferred to ice for 2 min. 800pl of SOC 
medium (see appendix for preparation) was added to the DNA and incubated at 37°C at 
lOOrpm for 1 hr in an orbital incubator. 2x 200|il aliquots were then plated out onto Luria- 
Bertrani agar indicator plates (see appendix for preparation) using a sterile bent glass rod. 
Once all liquid had been absorbed, the plates were inverted and incubated at 37°C 
overnight.
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Single white colonies were removed from the indicator plates and the plasmid DNA 
isolated and purified from bacterial cells using a modified technique based on the alkaline 
lysis procedure (Bimboim and Doly, 1979). Single colonies of cells were incubated 
overnight at 37°C in Terrific Broth (see appendix for preparation) in an orbital incubator at 
lOOrpm. 4.5ml aliquots of cells were spun for 1 min, the supernatant removed and the 
pellet resuspended in 200|il of GTE buffer (50mM glucose, 25mM Tris, lOmM EDTA, 
pH 8 ). The cell suspension was then mixed with 300ml 0.2M NaOH/1% SDS (SDS 
denatures bacterial proteins and NaOH denatures DNA) and incubated on ice for 5 min. 
The solution was then neutralised by mixing with 300|il of 3M potassium acetate pH4.8 
on ice. This causes plasmid DNA to reanneal, while the chromosomal DNA and bacterial 
proteins are precipitated with the SDS and form a complex with the potassium. This is 
removed by centrifuging at 13000rpm for 10 min at room temperature and removing the 
supernatant to a clean tube. The solution was then incubated with RNase A (DNase free) 
at 37°C for 20 min to remove any RNA present. The supernatant was then extracted by 
adding 400|il of chloroform, mixing for 30 s, centrifuging for 1 min and removing the 
aqueous phase into a clean tube. This step was then and the two aqueous phase added 
together. The DNA was then precipitated from the solution by adding an equal volume of 
100% isopropanol and centrifuging for 10 min at 13000rpm at room temperature. The 
supernatant was removed and the pellet washed with 500pl 70% ethanol by spinning at 
13000rpm for 15 min, the ethanol was then removed and the pellet vacuum dried. The 
pellet was dissolved in 32jil SDW and DNA precipitated by adding 8 (il of 4M NaCl and 
then 40jil of filter sterilised 13% PEGgooo overnight at -20°C. Plasmid DNA was pelleted 
by centrifuging at 13000rpm for 15 min at 4°C, the supernatant removed and the pellet 
washed in 500|il o f 70% ethanol by spinning at 13000rpm for 15 min at 4°C. After 
vacuum drying the pellet was resuspended in 20fil SDW and the quantity of DNA 
measured by using a RNA/DNA calculator (Pharmacia Biotech).
Linearisation o f plasmid DNA
Plasmid DNA was incubated with appropriate restriction enzymes to linearise the plasmid. 
EcoRl restriction was used to confrim that the tau cDNA was cloned in at this site on the 
vector. Restriction enzyme Sma 1 was used to confirm the orientation of the tau cDNA in 
the plasmid and the template for the generation of the anti-sense tau riboprobe. Xho 1 was 
used to provide the template for the generation of the sense ribopobe (Fig. 9 and 10). 
Restriction reactions consisted of 5p.g plasmid DNA, 20U restriction enzyme and the 
appropriate reaction buffer, incubated for 2-3 h at 30°C for Sma 1 or 37°C for Xho 1 and 
EcoR l. 1% agarose gels were prepared using ultra pure electrophoresis grade agarose 
(Gibco BRL). Agarose was melted in the presence of Tris acetate EDTA (TAE) buffer 
with a final concentration of 0.04M Tris acetate, 0.001M EDTA and 0.5|lg/ml ethidium
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bromide. The melted agarose was cooled slightly and poured into a mini gel rig, a comb 
inserted and allowed to set. The solidified gel was then immersed in TAE buffer. 500ng 
of linearised product was loaded with 6 x TAE gel loading buffer (6 x TAE, 30% glycerol 
(Sigma), 0.25% bromophenol blue (BDH) and 0.25% xylene cyanole FF (Sigma)) and 
electrophoresed at 50mV for 1.5 h to confirm linearisation of plasmid DNA (see Fig. 9). 
Gels were viewed using a "Fotoprep I" ultraviolet transilluminator (Fotodyne Inc.) and 
photographed using a Polaroid MP4 land camera (Polaroid), a T2201 transilluminator 
(Sigma), a Wratten 22A filter (Kodak) an Polaroid 667 (ASA 3000) film.
Following conformation of linearisation, the digestion product from each reaction was 
ethanol precipitated by adding 1/10 x volume 3M sodium acetate (pH 5.2) and 3 x volume 
of ethanol (-20°C) overnight at -20°C. The solution was then centrifuged at 13000 rpm at 
4°C for 30min, the supernatant removed using a finely pulled glass pipette and the pellet 
washed with 500|il of 70% ethanol/SDW by spinning at 13000rpm for 15 min. The 
supernatant was removed, the pellet air-dried and resuspended in SDW at 500ng/pl and 
stored at -20°C until use.
2.3.3 Preparation of 35 S labelled riboprobes
Sense and anti-sense 35s riboprobes were generated using a SP6/T7 transcription kit 
(Boehringer Mannheim). Labelling reactions contained 2ng linearised plasmid DNA, 
0.5mM ATP, 0.5mM GTP, 0.5mM UTP, 50pCi 3 5 S-CTP (specific activity 37TBq/mM; 
<1000Ci/mM; Amersham), 20U RNase inhibitor, 20U SP6  or T7 RNA polymerase and 
transcription buffer and were carried out in a DEPC treated sterile eppendorfs. The 
mixture was incubated at 37°C for 30 min, a further 20U of polymerase was then added 
and the incubation repeated. 20U RNase free DNase was added to this mixture and 
incubated at 37°C for 15 min to remove the DNA template. To deproteinise the sample an 
equal volume of phenol chloroform was added and the sample, vortexed for 1 0  s, 
centrifuged at 13000rpm for 3 min and the aqueous layer (containing nucleic acid) 
removed into a DEPC treated eppendorf. The solvent was then back extracted by adding 
an equal volume of DEPC SDW. The sample was centrifuged at 13000rpm for 3 min and 
the aqueous phase harvested and added to other aqueous phase. The RNA was 
precipitated using 1/10 volume 7.5M ammonium acetate and 2.5 x volume of ethanol (- 
20°C) for 3 h at -20°C. A 5|il aliquot was removed prior to centrifugation and placed in 
5ml "Ecoscint" in a scintillation vial (total amount of isotope present). Following 
centrifugation at 13000rpm for 30min at 4°C, 5jil of the supernatant was removed and 
placed in 5ml "Ecoscint" (amount of isotope unincorporated). The remaining supernatant 
was discarded and the pellet resuspended in 100|il DEPC .SDW, 5jil of resuspended pellet 
was removed and placed in "Ecoscint" (amount of incorporated isotope). The vials were
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counted on a Beckman LS 1801 scintillation counter and the percentage of incorporated 
isotope calculated. RNA was then re-precipitated overnight at -20°C with 1/10 x volume 
3M sodium acetate (pH5.2) and 3 x volume of ethanol (-20°C). The preparation was 
centrifuged at 13000rpm at 4°C for 30min the pellet washed with 70% ethanol/DEPC 
SDW, air dried and resuspended at lng/pl/kb. The probes were stored at -20°C and used 
within 6-8weeks.
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Figure 9. 1% agarose gel showing plasmid digests used for tau 35S riboprobe preparation. 
Lane 1; lamda Hind III fragments (Gibco, BRL). Lane 2 ; lOObp ladder (Gibco, BRL). 
Lane 3; Xhol digestion products (4308 - linearised plasmid and 1441 bp - tau cDNA), used 
for antisense riboprobe preparation. Lane 4; Sm al digestion products, bands were 
detected at approximately 3792 (linearised plasmid), 1441 (tau cDNA) and 516bp (small 
tau fragment), confirming that the tau inserts were positioned head to tail 5'-3'5'-3' as 
expected (see Fig. 10). Sma 1 was used to linearise cDNA for the preparation of the tau 
sense riboprobe. Lane 5; undigested plasmid containing tau insens (5794bp). Lane 6; 
EcoRl digestion products show linearised plasmid (3792bp) and tau DNA (1441bp).
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Orientation of tau fragments Fragments resulting from Smal digest
5’-3,5,-3’ 3792, 1441,516
5 '-y y -5 ' 3792,986, 971
3,-5'3'-5' 3337, 1441,971
3'5,5'-3' 3337, 1996,516
Figure 10. Linearisation of plasmid DNA with Sm al. a) A schematic representation of 
the location of the two tau cDNA fragments within the pGEM3 plasmid and the site of 
linearisation of the plasmid with the restriction enzyme Sma 1. b) Shows the fragment 
sizes resulting from digestion of the plasmid containing tau cDNA (pGTau) with Smal 
depending on the orientation of the tau inserts. Linearisation of pGTau with Smal 
resulted in fragments approximately 4000, 1400 and 500bp (see Fig. 9) confirming that tau 
cDNA was inserted within the plasmid 5'-3'5'-3\
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2.3.4 In situ hybridisation procedure
Pre-treatment o f tissue
Pre-treatment of the tissue involved several steps that increased the availability of RNA to 
the riboprobe, while maintaining tissue morphology. Frozen rat brain sections were 
mounted onto APES coated slides and allowed to dry. Sections were rinsed in PBS and 
fixed for 20 min in 4% paraformaldehyde in PBS. After rinsing in PBS, sections were 
placed in a solution of 0.1M triethanolamine and 0.25% acetic anhydride for 5 min. A 
further 0.25% acetic anhydride was then added for a further 5 min, this decreases non­
specific binding of the probe to the tissue through electrostatic interactions. Sections were 
then place in PBS (5 min), 0.85% saline (5 min), methylated spirits (5 min) and 
dehydrated in absolute alcohol (2 x 5  min).
Hybridisation
Hybridisation buffer (50% formamide, 10% dextran sulphate, 1 x Denhardt's, 20mM Tris 
HC1 pH8 , 0.3M NaCl, 5mM EDTA, lOmM NaPC>4 pH8  and 0.5mg/ml yeast tRNA) was 
heated to 50°C to reduce viscosity. Hybridisation mixture, consisting of hybridisation 
buffer, ImM dithiothreitol (DTT) and appropriate amount of probe (1:10 dilution) was 
heated to 80°C for 2 min to denature the RNA and then placed on ice. 8 }il of diluted 
probe was placed at the edge of each section and covered with a siliconised coverslips 
(clean coverslips soaked in Repelcot™ (BDH) for 20 min, rinsed and baked at 130°C for 
90 min). Slides were placed horizontally in a slide box containing tissue paper soaked in 
50% formamide and 5 x SSC (0.75M sodium chloride, 0.075M sodium citrate) to prevent 
dehydration of the sections. The box was sealed with tape and placed in two vacuum 
sealed bags and incubated at 50°C overnight in a waterbath.
Post hybridisation treatment
Stringency washes remove unbound or poorly hybridised probe therefore reducing non­
specific labelling of tissue. Sections were placed in : 5 x SSC/lOmM DTT at 50°C for 30 
min to remove coverslips; 2 x SSC in 50% formamide/lOmM DTT at 65°C for 20 min; 
500mM N aC l, 5mM EDTA , lOmM Tris HC1 pH7.5 at 37°C for 10 min (x3); 0.02mg/ml 
RNase A, 500mM NaCl , 5mM EDTA , lOmM Tris HC1 pH7.5 at 37°C for 30 min to 
remove single stranded RNA; 500mM N aC l, 5mM EDTA , lOmM Tris HC1 pH7.5 at 
37°C for 15 min; 2 x SSC in 50% formamide/lOmM DTT at 65°C for 20 min; 2 x SSC at 
room temperature for 15 min and finally 0.1 x SSC at room temperature for 15 min.
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Dehydration
Sections were dehydrated through graded alcohols - 30%, 60%, 80%, 95% containing 
0.3M ammonium acetate, and finally absolute alcohol. The presence of ammonium 
acetate prevents denaturation of the hybridisation. Sections were then allowed to air dry 
and exposed to Cronex (DuPont) medical screen film inside a radiographic cassette at 
room temperature overnight. Sections were then dipped in Ilford K5 emulsion (1:1 
dilution with distilled water containing 1% glycerol) at 42°C. Slides were air dried for 4-6 
h and stored at 4°C in light tight boxes containing a sachet of silica gel, for the required 
exposure time (determined by intensity of film image), between 1 and 7 days. This 
procedure was carried out by Prof. I.R. Griffiths. Sections were washed in water, allowed 
to air dry, counter-stained with haematoxylin and permanently mounted using DPX 
mountant for microscopic analysis.
PART II - PREPARATION OF TISSUE
Tau was examined by the methods described in Part I in brain tissue from either rat 
models of acute brain injury or human post-mortem brain tissue and in oligodendrocyte 
cultures.
2.4 Intracortical perfusion of monosodium glutamate in vivo 
A model of glutamate toxicity in vivo was developed in this laboratory by Bullock and 
collegues (Fujisawa, et. al. 1993a; 1993b; 1996). This model was used to determine the 
effects of high extracellular glutamate concentrations on tau immunoreactivity in vivo.
2.4.1 Surgical preparation of animals
Twenty-three adult male Sprague-Dawley rats, each weighing between 322-424g were 
used in this study. Animals were initially anaesthetised with a mixture of 5% halothane, 
70% nitrous oxide and 30% oxygen. A tracheostomy was performed to allow artificial 
ventilation and anaesthesia subsequently maintained between 1 and 1.25% halothane. 
Cannulation of a femoral artery and vein allowed the monitoring o f blood pressure and 
arterial blood gases. Blood gas analyses was performed immediately after arterial 
cannulation, prior to glutamate perfusion and at 1 h intervals thereafter until the end of the 
experiment. Animals were maintained normocapnic (pCC>2 38-42mmHg), normoxic (pC>2 
> lOOmmHg) and normothermic (37°C ± 1 )  throughout the experimental period by 
adjusting the volume of gases delivered to the animal and controlling rectal temperature 
using a heat lamp (Table 1).
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TABLE 1 Physiological Variables - Glutamate toxicity study
TREATMENT GROUPS
PHYSIOLOGICAL PARAMETER Glutamate NaCl CSF
(n=8 ) (n=10) (n=5)
Temperature °C
at probe placement 36.8 ± 0.1 36.8 ± 0.1 36.8 ±  0.1
4 h after probe placement 36.9 ± 0 .0  37.0 ±0.1 36.8 ±0.1
Blood Pressure (mmHg)
at probe placement 91 ± 1 90 ± 2  93 ± 1
4 h after probe placement 92 ± 1 92 ± 1 93 ± 1
Arterial pH
at probe placement 7.44 ± 0.01 7.43 ±0.01 7.41 ± 0.02
4 h after probe placement 7.44 ±0.01 7.42 ±0.01 7.40 ±0.01
p C 0 2 (mmHg)
at probe placement 40 ± 1 40 ±  1 40 ±  1
4 h after probe placement 39 ± 1 39 ±0 39 ±  1
p 0 2 (mmHg)
at probe placement 182 ± 5  177 ± 6  179 ± 5
4 h after probe placement____________ 188 ± 5________ 180 ± 3________ 183 ± 5
Animals were maintained normocapnic (p C 0 2  38-42m m Hg), norm oxic (p 0 2  > 
lOOmmHg) and normothermic (37°C ± l)throughout the experimental period. Values are 
mean ± SEM. No differences in these physiological variables were seen between 
experimental groups.
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2.4.2 Microdialysis probe implantation
Animals were turned prone and mounted onto a Kopf stereotaxic frame (Clark 
Electromedical, London, UK.). Using an operating microscope, the left parietal skull was 
exposed and a burr hole made with a saline cooled dentist drill (stereotactic co-ordinates 
anterior -1.0mm, lateral +4.0mm relative to bregma). The microdialysis probe (CMA/12 
membrane length 1mm, outside diameter 0.5 mm, Biotech Instruments Ltd.) was angled at 
15° to the saggital plane and lowered 1mm into the cortex through the burr hole after the 
dura-arachnoid had been carefully incised using a fine dental needle (for schematic 
representation see Fig. 11). Once in position, the probe was perfused with CSF for 30 min 
prior to the perfusion of 1M monosodium glutamate or 1M NaCl.
Perfusate
1M monosodium glutamate 
_ /  1M NaCl 
1.5|il/min
Microdialysis
probe
 ^dialysis 
membrane
f ;; j Schematic representation of the area of tissue damage
— 1 resulting from the perfusion of 1M monosodium glutamate
Figure 11. Schematic representation of microdialysis probe placement in the parietal 
cortex. 1M monosodium glutamate or 1M NaCl was the perfused at L5|il/min for 90 min 
using a microinjection pump. Intracortical perfusion of 1M monosodium glutamate 
resated in a sizeable lesion which extended in anterior and posterior directions and was 
characterised by an area of pallor as shown by H&E staining (see Figure 15).
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2.4.3 Glutamate and sodium chloride perfusion *
1M monosodium glutamate (pH7.4) was prepared in artificial cerebrospinal fluid (CSF) 
(NaCl 135mM, KC1 ImM, KH2 PO4  2mM, CaCl2  1.2mM, MgCl2  ImM, pH7.4). 1M
glutamate was selected for this study on the basis of a prior investigation of dose 
dependency and lesion size (Landolt, et. al. 1993). The concentration of glutamate being 
delivered to the CNS is less than that within the fibre, being approximately lOOmM due to 
the dynamics of the dialysis membrane. The vehicle control solution consisted of 1M 
sodium chloride in artificial CSF (pH7.4). Mechanical damage induced by probe 
placement was assessed by the perfusion of artificial CSF (pH7.4) alone. After placement 
in the cortex, the probe was perfused with the appropriate solution at a flow rate of 
1 .5 (il/min for 90 min using a Carnegie Medicine CMA 100 infusion pump (Biotech 
Instruments, Luton, UK). After 90 min of perfusion, the probe was removed from the 
cortex and the scalp wound closely sutured. Two-and-a-half hours after the removal of the 
probe (i.e. 4 h from the start of perfusion), the animals were killed by transcardiac 
perfusion as described below.
2.4.4 Transcardiac perfusion
At the end of the experimental procedure anaesthesia was deepened using a mixture of 2% 
halothane, 70% nitrous oxide and 30% oxygen, the heart exposed and a needle inserted 
through the left ventricle to the aorta. Animals were exsanguanated by perfusing 0.9% 
heparinised saline at 120mmHg (approximately 150mls) then fixed by perfusing 150- 
200mls of ice cold 4% paraformaldehyde until the animal was rigid.
2.4.5 Processing of brain tissue for histology and immunohistochemistry
Following transcardiac perfusion, brains were removed and post-fixed in 4% 
paraformaldehyde at 4°C for 48 h and cryoprotected in 30% sucrose in 50mM phosphate 
buffer at 4°C for 2-3 days. The brains were then frozen in isopentane chilled on dry-ice to 
-42°C for 2 min and 30|im coronal sections cut on a cryostat. Sections were stored in 
multiwell plates containing cryoprotectant (30% glycerol /  30% ethylene glycol in 50mM 
sodium phosphate buffer) at -20°C until use. Sections for H&E staining were washed in 
50mM PBS, mounted onto poly-L-lysine coated slides, allowed to dry and stained using 
standard methods. Free floating sections were rinsed in PBS and immunostained as 
described in section 2 .1 .
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2.4.6 Processing of tissue for electron microscopy
Four additional animals each weighing 338g & 380g were used to produce tissue for 
electron microscopy. Two animals received intracortical perfusion of 1M monosodium 
glutamate and 2 received 1M NaCl as described above. At the end of the experimental 
procedure, the animals were killed by transcardiac perfusion of 150 ml, 0.9% saline 
followed by 150-200 ml of strong fix (4% paraformaldehyde; 5% gluteraldehyde; 0.05% 
calcium chloride in 0.08M sodium cacodylate buffer, pH7.2). Once removed, brains were 
post-fixed in strong fix for 24 h. A coronal section was cut through the resulting cortical 
lesion using a scalpel blade and a triangular section cut through the cortical lesion to the 
underlying corpus callosum. This section was embedded in araldite and processed on a 
Lynx tissue processor.
In collaboration with Prof. I.R. Griffiths, ultra thin sections were cut at 70nm on a 
Riechart-Jung Ultracut E ultratome and mounted onto copper grids. Sections were then 
stained by covering grids with saturated solution of uranyl acetate in 50% ethanol for 5-15 
min at room temperature and then rinsed in 50% and 75% ethanol, distilled water (x2) and 
air-dried. Grids were then stained with Reynold’s lead citrate for 5-10 min inside a NaOH 
moisturised chamber and washed 3 times in 1M NaOH and 5 times with distilled water.
2.5 Human post-mortem brain tissue
2.5.1 Sources of post-mortem brain tssue 
Head injury
Formalin-fixed post-mortem brain tissue was obtained from 11 patients dying within <1 
and 23 h following severe head injury (Table 2). The age of the patients ranged from 12 
to 58 years and the post-mortem delay (i.e. the time between death and tissue fixation) 
ranged from 24 - 72 h. The corpus callosum was the brain area of choice in this study, 
since this area of the brain is commonly affected by diffuse axonal injury following head 
injury (Adams and Graham, 1989). Head injury in these patients occurred during a road 
traffic accident. The accumulation of APP immunoreactivity within axons was used as a 
marker for the early stages of axonal bulb formation and all patients used in this study had 
an APP score of at least 1 (McKenzie, et. al. 1995). In patients surviving for more than 2 h 
following head injury axonal swellings were detected with antibodies directed towards 
APP, 23 h following head injury many axonal bulbs were detected. APP immunostaining 
and classification of axonal injury was carried out by Prof. D.I. Graham in the Dept, of 
Neuropathology, University of Glasgow.
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Stroke
Formalin fixed post-mortem brain tissue was obtained from 4 patients dying between 2 
days and several weeks following a stroke (Table 2). The age of these patients ranged 
from 70 - 95 years. Post-mortem delay ranged from <24 - 48 h, with one patient 
outstanding at 6  days, however, no significant differences were detected within this tissue 
compared to other cases and was therefore included in this study. The corpus callosum, 
cingulate cortex and thalamus was selected for this study as these were areas affected by 
ischaemic brain injury. All strokes were occlusive, with no evidence of haemorrhage.
Controls
Formalin fixed post-mortem tissue from 7 patients with no known history of neurological 
or psychiatric disorders and no significant neuropathological abnormalities served as 
controls in this study (Table 2). The distribution of MAPs has been shown to be altered by 
post-mortem delay in the rat (Irving and Dewar, in press). This highlights the importance 
of using control tissue closely matched for post-mortem delay when extrapolating 
information from post-mortem tissue of brain injured patients. The control patients in this 
study were therefore selected according to both age and post-mortem delay. The age of 
control cases ranged from 1 2 -5 9  years for comparison with head injured patients and 71 - 
84 years for comparison to stroke patients. Post-mortem delay in the control cases ranged 
from 19 - 72 h.
2.5.2 Histology and immunohistochemistry
At post-mortem the whole brain was removed and immersed in 4% formalin for 48 h. 
Dissected blocks were then embedded in paraffin wax, 1 2 (im sections cut on a microtome 
and mounted onto microscope slides. Prior to histological or immunohistochemical 
staining paraffin wax was removed by heating the sections at 60°C in an oven for 60 min 
and then placing in histoclear for 10 min. Sections for H&E staining were rehydrated and 
stained with H&E by standard methods. Sections for immunohistochemical staining were 
immersed in: 100% alcohol (2 x 10 min); methanol containing 0.5% hydrogen peroxide 
for 30 min to inhibit endogenous peroxidase activity and water for 10 min. At this stage 
microwave antigen retrieval was carried out on sections to be stained with Tau 1 (see 
below). Following two rinses in PBS all sections were incubated with PBS containing 
0.2% Triton X-100. Sections were then rinsed in PBS (2 x 10 min) and immunostained as 
described in section 2.1.3. In addition to those antibodies described in section 2.1.3, 
human brain tissue sections were also stained using AD2, an antibody raised against PHF 
tau. The concentration curve to determine the optimum concentration of AD2 was 
therefore carried out using formalin-fixed paraffin embedded post-mortem tissue from a 
patient diagnosed with AD. The concentration found produce the best signal was 1:2000
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and this dilution was therefore used throughout the investigations carried out in this thesis. 
As a positive control, an A lzheim er brain section was included in every 
immunohistochemical experiment (see Fig. 12). Following antigen detection the sections 
were rinsed and allowed to dry. Once dry, sections were dehydrated using graded alcohols 
and coverslipped using DPX mountant ready for microscopic analysis.
F igure  12. Photomicrograph showing NFTs immunostained with AD2 in the 
hippocampus of a patient diagnosed with AD. AD2 is a monoclonal antibody raised 
against PHF tau (see section 2.1.1) and therefore fails to detect normal tau, 
immunoreactivity is therefore specifically localised to NFTs in AD tissue. Staining of 
Alzheimer tissue was included in each immunohistochemistry experiment involving AD2, 
as a positive control. Scale bar = 50pm.
2.5.3 Antigen retrieval
M icrowave pre-treatm ent was carried out on tissue being used for Tau 1 
immunohistochemistry as this antibody does not react well with formalin fixed paraffin 
embedded tissue. lOmM citric acid pH6 or distilled water was heated for 5 min in a 
65watt microwave at 70% power. The sections were then placed in the warmed solutions 
and heated for a further 5 min at 70% power. The solution volumes, lowered through 
heating, were topped up using distilled water and the tissue heated for a further 5 min. 
The sections were then removed from the microwave and allowed to stand in their solution 
for 20 min, rinsed in PBS and immunostained as described above. Citric acid gave a 
better antigen retrieval than water and so experiments were carried out using this method.
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TABLE 2 Case details
Cases Age (yrs) Survival PM delay
Head injury 2 0 < 1  h 48 h
Head injury 2 0 < 1  h 48 h
Head injury 18 1.5 h N/K
Head injury 39 2  h 48 h
Head injury 36 6  h 60 h
Head injury 14 7 h 48 h
Head injury 23 8  h 48 h
Head injury 58 1 0  h 24 h
Head injury 25 17 h 24 h
Head injury 46 19 h 72 h
Head injury 1 2 23 h 24 h
Stroke 84 2  days 24 h
Stroke 77 5 days < 24 h
Stroke 95 1 2  days 6  days
Stroke 70 > 2 1  days 48 h
Control 1 2 N/A 36 h
Control 18 N/A 24 h
Control 25 N/A 31 h
Control 34 N/A 72 h
Control 59 N/A 19 h
Control 71 N/A 24 h
Control 84 N/A 69 h
Post-mortem brain tissue was obtained from 11 patients dying following severe head 
injury and 4 patients dying following stroke. Survival time of patients following severe 
head injury ranged from <1-23 h, while that of stroke patients was 2->21 days. Seven 
patients with no history of neurological deficit served as controls. Control tissue was 
matched for age and post-mortem delay. The corpus callosum of head injured patients 
was examined as this area is commonly affected in head injury. For stroke patients, the 
cingulate cortex and thalamus was utilised as these were the areas affected by ischaemic 
brain damage. Both the corpus callosum and cingulate cortex were examined in the 
control brain tissue. N/A: not appropriate; N/K: not known.
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2.6 Permanent focal cerebral ischaemia
The MCAO model of permanent focal cerebral ischaemia in the rat was used (Tamura, et. 
al. 1981). In this model both glutamate toxicity and free radical mediated mechanisms 
have been shown to be involved in the mechanisms underlying neuronal degeneration 
which occurs following decreased cerebral blood flow within the territory of the MCA 
(see section 1.2.3).
2.6.1 Surgical preparation of animals
Thirty adult male Fischer-344 rats, each weighing between 250-300g were used in this 
study. Animals were initially prepared as described in section 2.4.1. Arterial blood gas 
and glucose analyses was performed prior to and immediately following middle cerebral 
artery occlusion and prior to transcardiac perfusion. Animals were maintained 
normocapnic, normoxic and normothermic throughout the experimental period by 
adjusting the volume of gases delivered to the animal and controlling temperature using a 
heat lamp (Tables 3 ,4  & 5).
2.6.2 Induction of cerebral ischaemia
The left middle cerebral artery (MCA) was exposed using a subtemporal approach based 
on the method originally described by Tamura et. al. (1981). This surgical procedure was 
performed by Dr. K. Yatsushiro. The animals were placed on their left side and a 2cm 
vertical incision made between the left orbit and the external auditory canal. The 
temporalis muscle was dissected from the cranium and retracted to expose the infero- 
temporal fossa. The zygomatic arch was left intact throughout the procedure. Under a 
high magnification operating microscope, a small craniectomy was made using a saline 
cooled dentist drill, at the junction between the medial wall and the roof of the infero- 
temporal fossa. The underlying dura was opened by an incision using a fine needle and 
retracted to reveal the main branch of the MCA. The exposed MCA was occluded by 
bipolar electrocoagulation from the area where it crossed the inferior cerebral vein to 
proximal to the origin of the lenticulostriate branch. All side branches including the 
lenticulostriate were coagulated and the artery transected. The muscle and skin was then 
sutured and the animals maintained under anaesthesia for appropriate intervals. Separate 
groups of animals were used for three distinct studies : 1 ) to determine the time of the 
induction of tau-positive oligodendrocytes following the onset of focal cerebral ischaemia; 
2 ) to investigate the effect of drug intervention on the induction of tau-positive 
oligodendrocytes and 3) to determine whether increased tau-immunoreactivity in 
oligodendrocytes following focal cerebral ischaemia reflects increased de novo synthesis 
o f the protein.
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TABLE 3 Physiological variables - Time course study
Physiological Param eter Time after M CAO
20 min 40 min 80 min
M ABP (mmHg)
Pre 93 ± 4  88 ± 7 102 ± 6
Post 88 ± 4 90 ± 5 85 ± 5
Rectal Tem perature (°C)
Pre 37.0 ±0 .2  37.2 ±0.1 36.8 ± 0.3
Post 36.8 ±0.1 37.0 ± 0 .0  37.0 ± 0.3
A rterial pH
Pre 7.45 ±0.01 7.42 ±0.01 7.39 ±0 .02
Post 7.44 ±0.01 7.44 ±0.03 7.40 ±0.01
p C 0 2 (mmHg)
Pre 38 ± 1  40 ± 1  44 ± 1
Post 36 ± 2 37 ± 1 40 ± 0
p 0 2 (mmHg)
Pre 156 ± 8  151 ± 10 175 ± 12
Post 155 ± 4  179 ± 1 4  160 ± 1 7
Plasm a Glucose (mM)
Pre 8.6 ±0 .8  9.2 ± 0 .6  9.4 ±0 .3
Post 7.3 ±0 .9  7.8 ± 0 .6  9.1 ±0.3
M ean arterial blood pressure (MABP) and physiological parameters were recorded both 
immediately after femoral vessel cannulation (pre) and after MCAO (post). Groups of 
rats were killed : 20 min (n=3); 40 min (n=4) and 80 min following MCAO. There were no 
significant differences in the physiological parameters detected throughout the experimental 
period between experimental groups.
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TABLE 4 Physiological variables - Drug intervention study
Drug Pretreatm ent
Physiological Param eter MK-801 NBQX PBN
M ABP (mmHg)
Pre 84 ± 7 91 ± 1 8 8  ± 5
Post 82 ± 1 89 ± 5 85 ± 4
Rectal Tem perature (°C)
Pre 37.1 ±0 .2 37.1 ± 0 .2 36.8 ±0.1
Post 37.2 ±0 .2 37.0 ±0.1 37.4 ±0.3
A rterial pH
Pre 7.45 ± 0.02 7.42 ±0.02 7.40 ± 0.02
Post 7.38 ±0.02 7.39 ±0.02 7.40 ±0.01
p C 0 2 (mmHg)
Pre 39 ± 1 40 ± 1 39 ± 1
Post 39 ± 1 39 ± 2 38 ± 1
p 0 2 (mmHg)
Pre 166 ± 7 167 ± 13 171 ± 7
Post 160 ± 9 164 ± 12 175 ± 5
Plasm a Glucose (mM)
Pre 8.5 ±0 .4 1 0 . 0  ± 0 . 6 9.5 ± 0 .8
Post 8.3 ±0.3 11.8 ± 0.9 9.1 ±0 .5
Mean arterial blood pressure (MABP) and physiological parameters were recorded both 
immediately after femoral vessel cannulation (pre) and after MCAO (post). Rats received 
drug pretreatment 30 min prior to MCAO and were killed 40 min after MCAO. The 
following pre-treatments were examined: MK-801 (0.5 mg/kg, i.v.), n=5; NBQX (30 
mg/kg, i.v.; 30 min prior to and 30 min after MCAO), n=5; PBN (100 mg/kg, i.p.), n=5. 
There were no significant differences detected throughout the experimental period between 
experimental groups, with the exeption of increased plasma glucose levels following NBQX 
administration.
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TABLE 5 Physiological variables - In situ hybridisation study
Physiological Param eter Time after MCAO
40 min 120 min 240 min
M ABP (mmHg)
Pre 80 ± 0  90 ± 5 83 ± 3
Post 75 ± 0  87 ± 7  75 ± 0
Rectal Tem perature (°C)
Pre 37.2 ±0 .3  36.9 ±0.3 36.8 ±0 .2
Post 36.9 ±0.1 36.6 ± 0.2 36.8 ±0.1
A rteria l pH
Pre 7.39 ±0 .04  7.37 ±0.05 7.44 ± 0.03
Post 7.40 ±0.01 7.39 ±0.03 7.36 ± 0.04
p C 0 2 (mmHg)
Pre 44 ± 1  40 ± 1  37 ± 1
Post 38 ± 2 42 ± 1 37 ± 1
p 0 2 (mmHg)
Pre 145 ± 1 4  148 ±11 168 ± 5
Post 145 ± 6  144 ± 3  156 ±11
Mean arterial blood pressure (MABP) and physiological parameters were recorded both 
immediately after femoral vessel cannulation (pre) and prior to kill (post). Animals 
remained normocapnic, normoxic and normothermic during the experimental period. 
Groups of rats were killed : 40 min (n=2); 120 min (n=2) and 240 min (n=2) after MCAO.
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2.6.3 Immunohistochemical studies
To determine the earliest time at which tau-positive oligodendrocytes could be detected 
following permanent focal cerebral ischaemia, animals were killed by transcardiac 
perfusion of 4% paraformaldehyde, at 20 min (n=3); 40 min (n=4) or 80 min (n=3) after 
MCAO. In order to investigate the effect of drug intervention on the induction of tau 
immunoreactivity in oligodendrocytes 40 min following MCAO rats were treated with : 
MK801 (0.5mg/kg, i.v.)(n=5); NBQX (30mg/kg, i.v.)(n=4) or PBN (lOOmg/kg i.p)(n=5). 
All drugs were administered 30 min prior to MCA occlusion, NBQX was administered 
again 30 min after MCA occlusion. MK801 was prepared as a lmg/ml solution in 0.9% 
saline and PBN as a 25mg/ml solution in distilled water. NBQX was prepared as a 
15mg/ml solution by dissolving 15mg of compound in 20|il 1M NaOH and adding 9.98ml 
of 5.5% glucose (made in distilled water). The doses for each drug used in this study has 
previously been shown to reduce infarct volume following focal cerebral ischaemia in the 
rat (Cao and Phillis, 1994; Gill, et. al. 1992; Park, et. al. 1988). For the drug intervention 
studies animals were killed, by transcardiac perfusion of 4% paraformaldehyde, 40 min 
after MCAO.
Following transcardiac perfusion, brains were removed and processed for histology and 
immunohistochemistry as described in section 2.4.5. Free floating sections were 
immunostained as described in section 2 .1 .
2.6.4 Quantification of tau positive oligodendrocytes following cerebral ischaemia
For each animal from both the time course study and the drug intervention study, the total 
number of tau-positive oligodendrocytes in the entire subcortical white matter, extending 
from that underlying the perirhinal cortex to that underlying cingulate cortex was counted 
in one section from each of the two brain levels shown in Fig. 13. Sections were viewed 
at x40 magnification, blind to the drug treatments of each animal. The area of subcortical 
white matter in each section counted was measured using an MCID image analyser and 
the number of tau-positive oligodendrocytes /  mm2  calculated for the white matter of each 
brain level. From this the average number of tau-positive oligodendrocytes /  mm2  present 
in the 2 sections counted was calculated for each individual animal. The mean number of 
tau-positive oligodendrocytes / mm 2 in each treatment group was calculated and data 
expressed as mean ± SEM. The same quantitative analysis was performed in both 
hemispheres, ipsilateral and contralateral to the occluded MCA. To determine the 
reproducibility of this quantitative approach, the number of tau-positive oligodendrocytes 
was determined and the area of corpus callosum measured in one animal from each 
treatment group 1 week later (see Fig. 14). The coefficient of variance for repeated 
measurements 1 week apart was 7%. For comparison of drug treated groups statistical
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analyses consisted of an ANOVA followed by Students one-tailed t-test with appropriate 
Boneforroni correction. The a priori hypothesis which was tested was that drug-treatment 
would reduce the number of tau-positive oligodendrocytes present following 40 min 
MCAO as compared to untreated animals.
Area of contralateral white 
matter where tau-positive 
oligodendrocytes were counted
Area of ipsilateral white matter 
where tau-positive 
oligodendrocytes were counted
H Area of ischaemic damage as detected with loss of MAP2 immunoreactivity
Figure 13. Schematic representation of the sections in which the number of tau-positive 
o ligodendrocytes/m m ^ was determined in subcortical white matter. The sections 
corresponded to those approximately 1.2 mm and 0.7 mm to Bregma in the atlas of 
Paxinos and Watson. The arrow indicates the region of subcortical white matter from 
which photographs shown in Fig. 36 were taken.
ihotomicrographs
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Linear regression analysis o f  repeated m easures
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Figure 14 Relationship between the number of oligodendrocytes / mm2 subcortical white 
matter calculated on day 1 and day 2 (1 week later). The number o f oligodendrocytes / 
mm2 was calculated at two brain levels for each animal in the study as described above. 
This analysis was repeated for 1 animal from each treatment group 1 week later, the 
correlation coefficient for repeated measures was 7%. The line o f linear regression is 
shown in the graph and the correlation coefficient (r2) is presented.
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2.6.5 In situ hybridisation studies
In situ hybridisation studies were carried out to determine whether increased tau 
immunoreactivity in oligodendrocytes following permanent focal cerebral ischaemia 
represents increased de novo synthesis of the protein. Animals were killed by decapitation 
: 40 min (n=2); 120 min (n=2) or 240 min (n=2) following the induction o f cerebral 
ischaemia. One animal was anaesthetised and decapitated without any surgical 
intervention. Following decapitation, the brains were rapidly removed and submerged in a 
small volume of tissue mountant contained within a small cup made with aluminum foil. 
This was then lowered into isopentane chilled in liquid nitrgen until the tissue mountant 
solidified. 15|im sections were then cut using a cryostat, mounted on to APES coated 
slides and processed for tau in situ hybridisation using 35s riboprobes as described in 
section 2.3.
2.7. Oligodendrocyte cultures
Pure oligodendrocyte cultures, were derived from an 0-2A  cell line kindly provided by 
Dr. S.C. Barnett (Department of Neurology, University of Glasgow). This cell line has 
recently been described by Barnett and Crouch, (1995) and preparation of cultures for 
immunohistochemistry and immunoblotting experiments was kindly carried out by Dr. 
S.C. Barnett.
2.7.1 Preparation of oligodendrocyte cultures
Cell line clones were maintained in 25cm2 flasks (NUNC) at -70°C until use. Cells were 
detached from the flasks by washing in 2.5mg/ml trypsin (bovine pancreas, Sigma) for a 
few minutes at room temperature. Cells were then pipetted into a centrifuge tube and 
trypsin activity inhibited using an equal volume of Soya bean trypsin inhibitor: 0.52mg/ml 
soya bean trypsin inhibitor; 0.4mg/ml bovine pancreas DNase; 3mg/ml BSA fraction V 
(Sigma). The suspension was spun and the cells resuspended in modified Sato medium 
(Bottenstein and Sato, 1990) containing 5ng/ml platelet derived growth factor (PDGF) and 
5ng/ml basic fibroblast growth factor (bFGF) - PF medium (Barnett and Crouch, 1995). 
The presence of these growth factors allows self-renewal of 0-2A  progenitor cells while 
preventing their differentiation (Bogler et. al. 1990). Cells were counted using a 
haemocytometer and approximately 7,000 placed on poly-L-lysine coated coverslips in 24 
well plates for immunohistochemical experiments. For immunoblotting experiments an 
equal number of cells were placed on the surface of individual 25cm2 NUNC flasks. All 
cells were incubated at 37°C in a CO2 incubator until they had adhered to the coverslips or 
flasks respectively. PF medium was added and cells were incubated at 37°C in a CO2  
incubator until the cells had reached 80% confluency. PF medium was then replaced with 
Sato medium to allow differentiation of the cells into oligodendrocytes. Every second day
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half the medium was removed and replaced with fresh Sato's medium. Following 4-5 days 
in culture oligodendrocyte cultures for immunocytochemical analysis were exposed to 
cytotoxic injury, as described below, and processed for tau immunocytochemistry. Batch 
cultures for immunoblotting experiments were washed in cold PBS and frozen on dry ice. 
Cultures were stored at -70°C until use for western blot analyses.
2.7.2 Exposure of oligodendrocytes to glutamate and sodium chloride
In a laminar flow hood, using sterile techniques, oligodendrocyte cultures prepared on 
coverslips as described above, were exposed to 10|iM, lOOpM or ImM  monosodium 
glutamate or sodium chloride (made up in Sato medium) for 4 h at 37°C in a CO2  
incubator. Controls were maintained in Sato medium during this time. Some cultures 
were dephosphorylated prior to immunostaining, this was carried out in the multiwell 
plates as described in section 2.1.3.
2.7.3 Immunocytochemistry
A control culture from each experimental run was stained with 01 antibody to confirm the 
presence of mature oligodendrocytes within the cultures. On removal from the incubator 
cells were rinsed with Hanks balanced salt solution (HBSS; 3 x 1 0  min) and 01 added (1 : 
3 in HBSS) or 30 min at room temperature. Following 2 x 10 min washes with HBSS 
rhodamine labelled IgG was added (1 : 3) in HBSS for 30 min. Cells were then fixed and 
stained for tau as described below.
Following incubation, the cells were removed from the incubator washed in Hanks Hepes, 
fixed with ice cold 4% paraformaldehyde for 15 min, washed with PBS ( 2 x 5  min) and 
permeabilised in 0.2% Triton X-100 for 30 min. Following two washes with PBS ( 2 x 5  
min) endogenous peroxidase activity was blocked with 0.5% hydrogen peroxide in PBS, 
and the cells immunostained for tau as described in section 2.1.3 using 3 different 
antibodies : Tau 1, 1:1250; T P 70 ,1:3000; TP007 1:750. Following immunostaining, cells 
were dehydrated in 70%, 90% and 100% alcohol (10 min each), immersed in histoclear for 
10-15 min and permanently mounted onto poly-L-lysine coated slides using DPX, for 
microscopic analysis.
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CHAPTER 3 RESULTS
3.1  Intracortical perfusion of glutamate in vivo
Glutamate excitotoxicity has been implicated in the pathogenesis o f a variety of 
neurodegenerative conditions in which NFT pathology is observed. However, whether 
increased extracellular concentrations of glutamate are involved in the mechanisms 
underlying tangle formation is unknown. This study was designed to investigate the effects 
of high extracellular concentrations of glutamate on the distribution of tau within neurons to 
determine if glutamate induces any changes in tau similar to those occurring in NFT 
formation. In vivo microdialysis was used to perfuse 1M monosodium glutamate or the 
control solution, 1M NaCl into the rat parietal cortex at 1.5|il/min for 90 min. Four h from 
the start of perfusion the animals were killed and the brain processed for histology and 
immunohistochemistry.
3.1.1 Histology - light microscope
Intracortical perfusion of 1M monosodium glutamate resulted in a sizeable lesion which 
extended in anterior and posterior directions and was characterised by an area of pallor as 
shown by H&E staining. In agreement with previous studies (Fujisawa, et. al. 1993a; 
1993b; 1996; Landolt, et. al. 1993) the histopathological features of the lesion included a 
loss of H&E stained neurons, triangulation of the nucleus and shrinkage of neurons and 
neuropil. There was a sharp boundary between the area of the lesion and histologically 
normal tissue observed in the H&E stained sections (Fig. 15). In contrast, intracortical 
perfusion of the control solution, 1M NaCl, resulted in a smaller area of pallor on H&E 
stained sections compared to that resulting from glutamate perfusion. The boundary between 
the area of pallor and histologically normal tissue in the NaCl perfused brains was less well 
delineated than in glutamate perfused animals (Fig. 15). Within the core of the NaCl 
induced lesion, the number of H&E stained neurons appeared to be reduced compared to 
histologically normal tissue, while towards the edge of the lesion nuclei had undergone 
triangulation. The perfusion of artificial CSF did not cause significant neuronal 
degeneration (Fig. 16) and failed to show any significant alteration to the normal distribution 
of immunostaining obtained for all the antibodies used in this study, therefore only the 
results obtained with glutamate and NaCl perfusion are presented.
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Figure 15. H&E stained coronal sections showing the area of pallor characterising the 
lesioned area produced by the intracortical perfusion of 1M monosodium glutamate (a) or 
1M NaCl (b). Note the sharp boundary between lesioned and histologically normal tissue 
following 1M monosodium glutamate perfusion (a). This boundary was less well 
delineated after 1M NaCl perfusion (b). Both photographs are the same magnification; bar 
= 250p.m. A - necrotic core; B - boundary region of the lesion; cort - parietal cortex; wm - 
subcortical white matter.
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Figure 16. H&E stained coronal sections showing the area of damage resulting from the 
intracortical perfusion of artificial CSF. In comparison to intracortical perfusion of 1M 
monosodium glutamate or 1M NaCl, the perfusion of artificial CSF did not induce 
significant neuronal damage. Only mechanical damage caused by microdialysis probe 
placement was evident. Scale bar = 400|im.
In addition to histological damage present in the cortical grey matter, areas of pallor were 
detected in the subcortical white matter immediately underlying glutamate induced lesions, 
as compared to histologically normal tissue (Fig. 17). In contrast the white matter 
underlying NaCl induced cortical lesions appeared to be histologically normal as compared 
to that of the contralateral hemisphere. This suggests that the neuropil of the subcortical 
white matter is damaged by the perfusion of glutamate but not NaCl. Examination of H&E 
stained sections using light microscopy failed to detect significant histological changes in 
oligodendrocytes within the subcortical white matter following intracortical perfusion of 
glutamate or NaCl (Fig. 17), although ultrastructural changes in oligodendrocytes were 
detected using electron microscopy (see section 3.1.4).
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F igure 17. H&E stained coronal sections showing the subcortical white matter 
immediately underlying cortical lesions induced by the perfusion of 1M monosodium 
glutamate (b) or 1M NaCl (c). Areas where H&E staining was decreased in the neuropil 
were detected within the subcortical white matter immediately underlying the lesion induced 
by intracortical perfusion of 1M monosodium glutamate (a). Reduced staining of the 
neuropil, probably due to the swelling of axons, dendrites and astrocytic processes, 
suggests that in addition to the cortex, the subcortical white matter is also affected by the 
intracortical perfusion of glutamate. In contrast, H&E staining of the subcortical white 
matter immediately underlying the lesion induced by the intracortical perfusion of 1M NaCl 
(c) was not significantly different ffom that of the contralateral subcortical white matter (a). 
No significant alteration in glial cell morphology was detected in the subcortical white matter 
immediately underlying 1M monosodium glutamate or 1M NaCl induced cortical lesions. 
Scale bar = 50|im.
73
3 . 1 . 2  The effect of intracortical glutamate perfusion on the distribution of 
tau, MAP2 and MAP5 immunoreactivity in neurons
Tau
The Tau 1 antibody detects tau dephosphorylated between residues 199-202 and therefore in 
normal rat brain immunoreactivity was detected predominandy within axons where tau is 
dephosphorylated at this epitope. In contrast Tau 1 immunoreactivity was not detected in 
neuronal perikarya where tau is phosphorylated at this epitope. This pattern of Tau 1 
immunoreactivity in histologically normal tissue is similar to that described previously 
(Binder, et. al. 1985; Papasozomenos and Binder, 1987). Following intracortical glutamate 
perfusion this pattern of Tau 1 immunoreactivity was altered (Fig. 18). At the core of the 
lesion, Tau 1 immunoreactivity was increased within neuronal perikarya and decreased in 
the neuropil compared to histologically normal tissue. Furthermore, it should be noted that 
perikaryal staining induced by intracortical glutamate perfusion was much more intense than 
that of histologically normal tissue incubated with alkaline phosphatase. In contrast to 
glutamate, NaCl perfusion did not increase Tau 1 immunoreactivity within neuronal 
perikarya, however neuropil staining was reduced (Fig. 18). Alkaline phosphatase pre­
treatment failed to alter the pattern of Tau 1 immunostaining present within the neurons 
following glutamate or NaCl perfusion (Fig. 19), suggesting that decreased Tau 1 staining 
was not due to phosphorylation of the protein at this epitope. In contrast to Tau 1, AT8 
detects tau phosphorylated at residue 200 and therefore predominantly detects tau within 
neuronal perikarya in histologically normal tissue (Fig. 18). Following intracortical 
perfusion of either glutamate (Fig. 18) or NaCl (Fig. 18), AT8 immunoreactivity was 
decreased in neuronal perikarya, confirming that tau present within neuronal perikarya 
following glutamate perfusion is dephosphorylated at this epitope.
The distribution of B19 (directed towards full-length tau), TP70 (directed towards C- 
terminal o f tau) and TP007 (directed towards N-terminal of tau) in histologically normal 
tissue is shown in Fig. 20. These antibodies are phosphorylation independent and therefore 
detect tau present in both neuronal perikarya and axons. In contrast to Tau 1? B19, TP70 
and TP007 immunoreactivity was decreased within neuronal perikarya following glutamate 
perfusion (Fig. 20) compared to histologically normal tissue. Similarly to Tau 1, neuropil 
staining with B19 and TP007 was reduced following both glutamate and NaCl perfusion, 
however TP70 remained relatively unchanged. B19, TP70 and TP007 staining of neuronal 
perikarya was reduced following NaCl perfusion (Fig. 20).
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Figure 18. Distribution of Tau 1 and AT8 immunoreactivity in rat cerebral cortex. Tau 1 
immunoreactivity, most abundant in axons in histologically normal tissue, was increased in 
neuronal perikarya at the core of the lesion produced by the intracortical perfusion of 1M 
monosodium glutamate. In contrast, AT8 immunoreactivity, most abundant within neuronal 
perikarya in histologically normal tissue, decreased following glutamate perfusion. Tau 1 
immunoreactivity was decreased in axons following glutamate or NaCl perfusion compared 
to histologically normal tissue. AT8 immunoreactivity was not detected following glutamate 
or NaCl perfusion. In addition to the alterations in neuronal immunoreactivity, increased 
Tau 1 immunoreactivity was detected in small cells with the morphological appearance of 
glia within the cortical lesion induced by 1M NaCl perfusion (arrows) (see section 3.1.3). 
Scale bar = 50pm
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F ig u re  19. The effect of alkaline phosphatase pre-treatment on the distribution of Tau 1 
immunoreactivity in neurons and glia following intracortical perfusion of 1M monosodium 
glutamate or 1M NaCl. Following intracortical perfusion of 1M monosodium glutamate, 
increased Tau 1 immunoreactivity was detected in neuronal perikarya while staining was 
decreased in the axons. Intracortical perfusion of 1M NaCl resulted in increased Tau 1 
immunoreactivity within small cells with the morphological appearance of glia. This pattern 
of Tau 1 immunoreactivity described within the cortex following glutamate or NaCl 
perfusion was not altered by dephosphorylation of the tissue prior to immunostaining. This 
data confirms that decreased Tau 1 immunoreactivity within the neuropil detected following 
the perfusion of glutamate or NaCl was not due to phosphorylation of tau at the Tau 1 
epitope. Scale bar = 50|im.
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Figure 20. Distribution of B19, TP007 and TP70 immunoreactivity in rat cerebral cortex. 
B19, TP70 and TP007 detect tau in both axons and neuronal perikarya of histologically 
normal tissue. Following intracortical perfusion of 1M monosodium glutamate or 1M NaCl, 
B19, TP70 and TP007 immunoreactivity was decreased in neuronal perikarya. Similarly, 
B19 and TP007 staining of axons was reduced following both glutamate and NaCl 
perfusion however TP70 immunoreactivity remained relatively unchanged. Increased tau 
immunoreactivity was detected in small cells with the morphological appearance of glia 
within the cortical lesion resulting from the perfusion of 1M monosodium glutamate or 1M 
NaCl (see section 3.1.3). Scale bar = 50pm.
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MAP2 and MAP5
To compare the changes in tau immunoreactivity with that of other MAPs, adjacent sections 
to those stained with tau, were labelled using antibodies directed towards MAP2 and MAP5. 
MAP2 immunoreactivity was detected mainly in dendrites and neuronal perikarya in 
histologically normal tissue (Fig. 21) as described previously (Caceres, e t  al. 1984; Huber 
and Matus, 1984). At the core of the lesion produced by the intracortical perfusion of 1M 
monosodium glutamate neuronal perikaryal staining with the MAP2 antibody was increased 
while dendritic staining was reduced (Fig. 21). In contrast to glutamate, 1M NaCl 
perfusion did not increase neuronal perikaryal immunostaining, instead both dendritic and 
perikaryal MAP2 immunoreactivity was reduced (Fig. 21). MAP5 immunoreactivity was 
detected in both perikarya and neuropil in histologically normal tissue (Fig. 21). Similarly 
to MAP2, MAP5 immunoreactivity increased within neuronal perikarya and decreased in 
neuropil within the core of the lesion produced by glutamate perfusion (Fig. 21). NaCl 
perfusion resulted in decreased MAPS immunostaining in both perikarya and neuropil (Fig. 
21). Thus the effects of intracortical perfusion of glutamate or NaCl on the immunostaining 
of MAPs within neurons were not specific for tau, but also included MAP2 and MAP5.
3 . 1 . 3  MAPs in oligodendrocytes following intracortical glutam ate perfusion
In addition to changes in the distribution of tau, MAP2 and MAP5 immunoreactivity 
detected in neurons, tau immunoreactivity was detected in small cells with the morphological 
appearance of oligodendrocytes following intracortical glutamate or NaCl perfusion. This 
was an unexpected finding since tau is thought to be a neuron specific protein. However 
increased tau immunoreactivity was detected in oligodendrocytes within the cortical lesion 
and the subcortical white matter immediately underlying this area, both in glutamate and 
NaCl perfused animals. In light of this novel and unexpected finding o f increased tau 
staining in glial cells, it was decided to persue this finding. Unravelling this response 
became the focus of future studies.
Tau
Within the subcortical white matter contralateral to the glutamate or NaCl induced cortical 
lesion, tau, as detected with Tau 1, TP70, TP007 and B19 was localised predominantly 
within axons (Fig. 22 & 23). Following intracortical perfusion o f 1M monosodium 
glutamate or 1M NaCl, tau immunoreactivity was observed in small cells with the 
morphological appearance of glia. These tau-positive glial cells were found scattered 
throughout the cortical lesion (Fig. 18 & 20) but also abundantly within the subcortical 
white matter immediately underlying this area (Fig. 22 & 23). Following intracortical 
perfusion o f 1M monosodium glutamate or 1M NaCl, tau positive glial cells were detected 
using B19, TP70 and TP007 suggesting the presence of full-length protein.
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Figure 21. Distribution of MAP2 and MAP5 immunoreactivity in neurons following 
intracortical perfusion of 1M monosodium glutamate or 1M NaCl. MAP2 and MAP5 
immunoreactivity was detected within neuronal perikarya and neuropil of histologically 
normal tissue. Following intracortical glutamate perfusion, both MAP2 and MAP5 
immunoreactivity increased in perikarya and decreased in neuropil within the resulting 
cortical lesion. By contrast, MAP2 and MAP5 immunoreactivity was decreased in both 
neuronal perikarya and neuropil within the cortical lesion induced by the perfusion of 1M 
NaCl. Scale bar = 50pm.
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Figure 22. Tau immunoreactivity in glial cells of the subcortical white matter following 
intracortical perfusion 1M monosodium glutamate or 1M NaCl in the rat. B19, TP70 and 
TP007 immunoreactivity was localised within the axons of the contralateral subcortical 
white matter. However, following intracortical perfusion of 1M monosodium glutamate or 
1M NaCl, increased tau immunoreactivity was detected within cells with the morphological 
appearance of glia both within the resulting cortical lesion and in the subcortical white matter 
immediately underlying this area. These glial cells were detected using B19, TP70 and 
TP007, suggesting the presence of full length tau protein. Scale bar = 50p.m.
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Tau-positive glia were also detected with the Tau 1 antibody, both within the cortical lesion 
induced by the perfusion of 1M monosodium glutamate or 1M NaCl and in the subcortical 
white matter immediately underlying this area. This suggests that tau present in these cells 
is dephosphorylated at the Tau 1 epitope. In support of this finding, the phosphorylation 
dependant antibody AT8 failed to detect these glial cells (Fig. 23), confirming that tau 
present within these cells is dephosphorylated at the Tau 1 epitope. Tau immunoreactivity 
was not detected within glial cells in histologically normal tissue with any of the tau 
antibodies used in this study with (Fig. 24) or without alkaline phosphatase pretreatment 
(Figs. 22 & 23).
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Figure 23. Distribution of Tau 1 and AT8 immunoreactivity in the subcortical white 
matter following intracortical perfusion of 1M monosodium glutamate or 1M NaCl. Tau 1 
immunoreactivity was predominantly localised to axons within the contralateral subcortical 
white matter. However following the intracortical perfusion of either 1M monosodium 
glutamate or 1M NaCl, Tau 1 immunoreactivity was detected in glial cells both within the 
resulting cortical lesion and in the subcortical white matter immediately underlying this area. 
AT8 failed to detect glial cells prior to, or following intracortical perfusion of 1M 
monosodium glutamate or 1M NaCl. Scale bar = 50p.m.
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F igu re  24. Tau immunoreactivity in the subcortical white matter following alkaline 
phosphatase pre-treatment of histologically normal rat brain tissue using Tau 1, B19, TP70 
or TP007. Tau 1, B19, TP70 and TP007 immunoreactivity is located predominantly within 
axons of the subcortical white matter in histologically normal tissue. Alkaline phosphatase 
pre-treatment of rat brain tissue prior to immunostaining failed to alter this pattern of 
immunoreactivity as detected with all 4 tau antibodies. Glial cells were not detected using 
Tau 1, B19, TP70 or TP007 before, or after dephosphorylation of the tissue. This data 
suggests that the epitopes of tau recognised by these antibodies are not masked by 
phosphorylation within glial cells present in control tissue. Furthermore, the presence of tau 
immunoreactivity in glial cells, as detected with all 4 antibodies, following intracortical 
perfusion of 1M monosodium glutamate or 1M NaCl cannot be explained simply by the 
dephosphorylation of existing tau protein within these cells. Scale bar = 50|im.
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Tau-positive cells displayed a small perikaryon and lacked visible processes consistmt with 
the morphological appearance of oligodendrocytes in situ. Within the subcorticd white 
matter tau-positive cells were aligned in rows, a feature characteristic of intrafisicular 
oligodendrocytes. Moreover, tau-positive oligodendrocytes, detected following intra;ortical 
perfusion of glutamate or NaCl, stained negative for GFAP and positive for traisferrin 
therefore showing that these tau-positive cells were itntnunologically sinilar to 
oligodendrocytes (Fig. 25). Together this data confirms that tau-positive glial cells (etected 
in response to intracortical perfusion of lM  monosodiutn glutamate or 1M NaCl were 
oligodendrocytes.
Figure 25. Confocal images showing Tau 1, GFAP and transferrin immunorcac ivity in 
the subcortical white matter immediately underlying cortical lesions induced by the perfusion 
of 1M monosodium glutamate (a,c) or lM  NaCl (b,d). (a&b) GFAP shown in red md Tau 
1 shown in green. Tau-positive cells were GFAP negative and morphologically distinct 
from astrocytes which displayed an elaborate array of processes, (c&d) Transferrin shown 
in red and Tau 1 shown in green. Yellow staining represents areas of overlapping 
immunoreactivity, showing that tau-positive cells are also positive for transferrin. Tau- 
positive cells were therefore immunologically and morphologically similar to 
oligodendrocytes. Confocal images were kindly provided by Prof. I.R. Griffiths. Scale 
bar = 5()|lm.
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MAP 2 and MAP5
Neither MAP2 nor MAP5 immunoreactivity was detected in glial cells of the hemisphere 
contralateral to the occluded MCA. In contrast to tau, MAP2 and MAP5 immunoreactivity 
was not detected in oligodendrocytes following intracortical perfusion of 1M monosodium 
glutamate or 1M NaCl neither in the resulting cortical lesion nor in the subcortical white 
matter underlying this area (Fig. 26). In contrast to neurons, where tau, MAP2 and MAP5 
underwent marked alteration in response to intracortical perfusion of both glutamate and 
NaCl, changes in MAPs within oligodendrocytes following injury appears to be specific for 
t a u . _________      _
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Figure 26. Distribution of MAP2 and MAP5 immunoreactivity in the subcortical white 
matter following intracortical perfusion of 1M monosodium glutamate or 1M NaCl. MAP2 
and MAP5 immunoreactivity was localised predominantly within axons and dendrites of the 
contralateral subcortical white matter. In contrast to tau, neither MAP2 nor MAP5 
immunoreactivity was detected in glial cells of the ipsilateral subcortical white matter 
following either 1M monosodium glutamate or 1M NaCl perfusion. Scale bar = 50pm.
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3.1.4 Electron microscopy
Structural changes in glial cells present within the subcortical white matter immediately 
underlying the glutamate or NaCl induced lesion could not be detected by light microscopy. 
In order to determine if such changes could be detected at the ultrastructural level, the brains 
from animals which received intracortical perfusion of either 1M monosodium glutamate 
(n=2) or 1M NaCl (n=2) were processed for electron microscopy. The white matter of the 
corpus callosum immediately underlying cortical lesions induced by glutamate or NaCl 
perfusion, was markedly oedematous. Astrocytic swelling was marked, involving both 
nuclei and cytoplasm, while oligodendrocytes were involved to a lesser degree. 
Oligodendrocytes of the contralateral corpus callosum, had an electron dense nucleus and 
abundant microtubules (Fig. 27). Following the intracortical perfusion of 1M monosodium 
glutamate, the most obvious ultrastructural changes were that the oligodendrocyte nucleus 
became swollen and less electron dense as did the cytoplasm, as compared to 
oligodendrocytes in the contralateral hemisphere (Fig. 27). Oligodendrocyte processes were 
swollen however all cytoplasmic organelles were recognisable (Fig. 27). The 
ultrastructural changes in oligodendrocytes reported following intracortical perfusion of 1M 
monosodium glutamate were also seen following 1M NaCl perfusion, there were no 
significant differences detected between the two treatment groups. The swelling of 
oligodendrocytes and their processes confirmed that these cells, present within the 
subcortical white matter, were affected by the intracortical perfusion of glutamate or NaCl. 
Electron microscopy was performed by Prof. I.R. Griffiths.
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Figure 27. Electron micrograph showing oligodendrocyte morphology in the contralateral 
(a) and ipsilateral (b) subcortical white matter following intracortical perfusion of 1M 
monosodium glutamate. Oligodendrocytes present in the contralateral subcortical white 
matter had an electron dense nucleus and cytoplasm which contained abundant 
microtubules. Following intracortical perfusion of 1M monosodium glutamate (b) or 1M 
NaCl, the oligodendrocyte nucleus and cytoplasm became swollen and less electron dense, 
compared to those oligodendrocytes present in the contralateral hemisphere. Magnification 
factor = x 20,000.
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3 .2  Human post-mortem brain studies
Increased tau immunoreactivity was detected in oligodendrocytes following glutamate 
toxicity in rat brain. Previously, extracellular concentrations of glutamate were shown to be 
increased immediately following both traumatic brain injury and stroke in the rat (Butcher, 
et. al. 1990, Bullock, et. al. 1990). Therefore in the next study, human post-mortem brain 
tissue from patients dying following stroke or head injury was examined for the presence of 
tau-positive oligodendrocytes, in order to determine whether or not the presence of tau- 
positive oligodendrocytes following excitotoxic brain injury was a phenomenum peculiar to 
the rat brain.
3.2.1 Tau positive glial cells following severe head injury
For this study, cases of head injury were selected in which there was evidence of diffuse 
axonal injury within the corpus callosum. The accumulation o f APP immunoreactivity 
within axons was used as a marker for the early stages of axonal bulb formation and all 
patients used in this study had an APP score of at least 1 (McKenzie, et. al. 1995). APP 
immunostaining and classification of axonal injury was carried out by Prof. D.I. Graham in 
the Dept, of Neuropathology, University of Glasgow. In the corpus callosum of control 
cases, tau immunoreactivity as detected with TP70, TP007 and Tau 1 was localised 
predominantly within axons (Fig. 28 & 29). However, in the corpus callosum from 
patients dying following head injury, in addition to its presence in axons, tau 
immunoreactivity was also detected within cells with the morphological appearance of glia 
(Fig. 28 & 29). The alignment of these glial cells in rows within the corpus callosum 
suggests that these tau-positive cells were oligodendrocytes. These tau-positive glia were 
detected using Tau 1, TP70 and TP007 suggesting the presence of full-length protein which 
was dephosphorylated at the Tau 1 epitope in these cells. It should be noted however that 
the number of oligodendrocytes detected with Tau 1 was less than that detected by TP70 and 
TP007 in all cases examined. The Tau 1 epitope is normally phosphorylated in NFTs, 
therefore in order to confirm that tau present in glial cells reported here was 
dephosphorylated, rather than hyperphosphorylated as seen in NFTs, sections were stained 
with the AD2 antibody. AD2 is an antibody raised against tau proteins found in Alzheimer's 
disease which recognises tau phosphorylated at Ser-396 and Ser-404 (BueeScherrer, et. al. 
1996). The lack of staining of glial cells in the corpus callosum of head injured patients 
with AD2 suggests that in contrast to that of PHF tau, tau present in these cells is not 
phosphorylated at the AD2 epitopes (Fig. 28). The possibility that tau may be 
phosphorylated at different residues, similar to that in of PHF tau however, cannot be ruled 
out. Tau was detected within a few glia in the corpus callosum of patients surviving <1 h 
following head injury and the number of these tau-positive cells appeared to increase with 
survival time after injury, although quantitative analyses were not undertaken (Fig. 28 &
8 7
29). In patients surviving for 6 h or more, areas of pallor within the corpus callosum were
detected in H&E stained sections outlining areas of tissue affected by injury (Fig. 29). In
these patients tau-positive glia were localised within and immediately surrounding the area 
* •
of tissue delineated by reduced H&E staining. In tissue distant from these affected areas 
where there was no histological evidence of brain injury, tau-positive glia were not detected. 
Tau-positive glia were detected in all brain injured patients examined in this study however, 
it should be noted that only a proportion of the glial population became tau-positive within 
damaged areas especially at early times following head injury.
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F igure 28. Tau 1 and AD2 immunoreactivity within the corpus callosum of control 
patients and 6 h and 23 h following head injury. In control tissue, Tau 1 immunoreactivity 
was localised predominantly within the axonal compartment where tau is dephosphorylated 
at this epitope. AD2 recognises PHF tau and therefore fails to detect tau in histologically 
normal tissue. 6 h following head injury Tau 1 immunoreactivity was increased in small 
cells with the morphological appearance of oligodendroglia, however the number of these 
cells detected was less than that detected by TP70 and TP007 (Fig. 29). 23 h following 
head injury Tau 1 positive oligodendrocytes were difficult to detect. AD2 immunoreactivity 
was not detected in glial cells of histologically normal or head injured tissue. Scale bar = 
50p.m.
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In one patient surviving for 23 h following severe head injury, TP70 and TP007 
immunoreactivity was intense in the cytoplasm of glial cells to one side of the cell (Fig. 29), 
within the corpus callosum where H&E staining was markedly decreased (Fig. 30). The 
morphological appearance of these tau-positive glial cells was similar to that reported 
previously for glial inclusions in neurodegenerative conditions such as MSA (Iwatsubo, et. 
al. 1994; Kato, et. al. 1991; Yamada, et. al. 1992). In this single case, glial cells were not 
detected with the Tau 1 antibody (Fig. 28), although they were stained with TP70 and 
TP007, suggesting that tau may be phosphorylated at the Tau 1 epitope. AD2 failed to 
detect these tau-positive cells showing that in contrast to PHF tau, tau present in these 
oligodendrocytes was not phosphorylated at the AD2 epitope (Fig. 28).
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F igu re  29. Distribution of TP70 and TP007 immunoreactivity in the corpus callosum of 
control and head injured patients 6 and 23 h following injury. In control tissue, 
immunoreactivity is localised predominantly within the axonal compartment. Following 
head injury however TP70 and TP007 immunoreactivity was increased in small cells with 
the morphological appearance of oligodendroglia. In the patient surviving for 23 h 
following head injury, TP70 and TP007, immunoreactivity was intense within the 
cytoplasm of some oligodendrocytes, showing a morphology similar to that of glial 
inclusions (arrows). Scale bar = 50p.m.
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Figure 30. Corpus callosum of control and head injured patients stained with H&E. In 
patients surviving for 6 h or more after head injury, areas where H&E staining was 
decreased within the neuropil outlined the regions of the corpus callosum affected by brain 
injury. 6 and 23 h following head injury the number of glial cells present in the corpus 
callosum decreased as compared to histologically normal tissue. In addition nuclei appeared 
eosinophilic. 23 h following head injury H&E staining was markedly reduced within the 
neuropil as compared to that of control tissue. Scale bar = 100p.m.
3.2.2 T au-positive glia following stroke
Post-mortem brain tissue was obtained from patients who died following occlusive stroke. 
Brain areas examined encompassed the cingulate cortex and thalamus, depending on the 
location of the ischaemic injury. In brain tissue obtained from all four patients who died 
following a stroke, tau-positive glia were detected within and immediately surrounding areas 
of tissue in which there was histological evidence of ischaemic brain damage (Fig. 31). 
Tau-positive glia were detected at the core of the infarct, however were most abundant in the 
grey matter immediately surrounding the infarcted tissue (Fig. 32 & 33) and in the white 
matter lying in close proximity to the infarcted tissue. The detection of tau-positive glia with 
TP70 and TP007 suggests the presence of full-length protein in these cells (Fig. 32). 
Detection of glial cells with the Tau 1 antibody shows that, similarly to that occurring 
following head injury, tau is dephosphorylated at the Tau 1 epitope (Fig.33). AD2 failed to
9 0
to detect tau present within glial cells showing that in contrast to PHF tau, tau present in 
these cells is not phosphorylated at the AD2 epitope (Fig. 33).
In the patient surviving for several weeks following stroke, many glia within the infarcted 
tissue contained intense tau staining within the cell cytoplasm to one side of the cell as 
detected with TP70 and TP007 (Fig. 32). The morphological appearance of these tau- 
positive glial cells was similar to that reported previously for glial inclusions in 
neurodegenerative conditions such as MSA (Iwatsubo, et. al. 1994; Kato, et. al. 1991; 
Yamada, et. al. 1992). This pattern of tau immunoreactivity was not detected with the Tau 1 
antibody (Fig. 33) suggesting that tau present in these cells may be phosphorylated at the 
Tau 1 epitope. Similarly to oligodendrocytes detected 23 h following head injury, AD2 
failed to detect tau accumulations within the oligodendrocyte cytoplasm showing that in 
contrast to PHF tau, tau present within these inclusions was not phosphorylated at the AD2 
epitope (Fig. 33). Tau present in glial inclusions can be detected with antibodies raised 
against PHF tau which is phosphorylated at many sites including the Tau 1 epitope, the 
possibility that tau present in these cells is phosphorylated at other residues of the tau protein 
similar to those occurring in glial inclusions cannot be ruled out.
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Figure 31. Cingulate cortex from control and stroke patients stained with H&E. In all 
cases areas where H&E staining was decreased outlined the regions of tissue affected by 
ischaemic brain injury. 5 days and following stroke, neurons showed triangulation of the 
nucleus and eosinophilic cytoplasm, in addition neuropil staining was decreased. In the 
patient surviving for several weeks following stroke, infarcted tissue was characterised by 
decreased H&E staining, of all cellular elements. In all cases neuropil staining was reduced 
within areas of tissue affected by ischaemic brain injury. Scale bar = 100p.m.
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Figure 32. Distribution of TP70 and TP007 immunoreactivity in the cingulate cortex 
from control and stroke patients. In post-mortem brain tissue obtained from control 
patients, TP70 and TP007 immunoreactivity was localised predominantly within the axonal 
compartment. However, following stroke tau immunoreactivity was increased within 
oligodendrocytes in, and immediately surrounding the region of infarct. Figure shows tau- 
positive oligodendrocytes in the cingulate cortex 5 days and several weeks following stroke. 
In the patient surviving several weeks following a stroke, tau-positive glia displaying 
morphological features similar to that of glial inclusions, were detected with TP70 and 
TP007 (arrows) within the region of infarct. Scale bar = 50p.m.
9 2
control *
Tau 1
AD2
Figure 33. Distribution of Tau 1 and AD2 immunoreactivity in the cingulate cortex from 
control and stroke patients. In post-mortem brain tissue obtained from control patients, Tau 
1 immunoreactivity was localised predominantly within the axonal compartment. However, 
following stroke Tau 1 immunoreactivity was increased within oligodendrocytes in, and 
immediately surrounding the region of infarct. Figure shows tau-positive oligodendrocytes 
in the cingulate cortex 5 days and several weeks following stroke. AD2 failed to detect tau- 
positive oligodendrocytes in both control and stroke tissue Scale bar = 50fim.
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3.2.3 Identification  of tau-positive glia
Sections double immunostained with GFAP, as a marker for astrocytes, and Tau 1 showed 
that tau-positive glial cells present in the corpus callosum following both head injury and 
stroke did not stain with a GFAP antibody and were morphologically distinct from 
astrocytes (Fig. 34). In contrast to the large cell body and elaborate array of processes 
displayed by astrocytes, tau-positive glial cells had small perikarya, limited cytoplasm and 
lacked visible cellular processes. This morphology is consistent to that described for 
oligodendrocytes. In addition, tau-positive glial cells also stained positive for transferrin, a 
specific marker for oligodendrocytes (Fig. 34) confirming that tau-positive glial cells were 
both immunologically and morphologically similar to oligodendrocytes.
Figure 34. Identification of tau-positive glia in human post-mortem tissue. Sections of 
the corpus callosum of a patient dying 10 h following severe head injury were 
immunostained with A) GFAP as a marker for astrocytes shown in grey and Tau 1 shown 
in purple. Tau-positive cells were GFAP negative and morphologically distinct from 
astrocytes which displayed an elaborate array of processes (arrows) or B) transferrin as a 
marker for oligodendrocytes shown in grey and Tau 1 shown in purple. Tau-positive glial 
were positive for transferrin and Tau 1, the dark purple colour showing areas a overlapping 
immunostaining. Tau-positive cells detected in human post-mortem tissue after acute brain 
injury were therefore immunologically and morphologically similar to oligodendrocytes. 
Scale bar = 50|im.
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3 .3  Tau-positive oligodendrocytes following permanent focal 
cerebral ischaemia in the rat.
The presence of tau-positive oligodendrocytes in human brain following acute brain injury 
confirmed that the appearance of tau in oligodendrocytes was not a phenomenon unique to 
rat brain, but a response of these cells to acute brain injury. In order to further characterise 
the presence of tau in oligodendrocytes, the next study was designed to determine the 
earliest time following focal cerebral ischaemia in the rat that tau-positive oligodendrocytes 
could be detected. In addition, in order to determine whether the number o f tau-positive 
oligodendrocytes increased over time, quantitative analysis of cell density was performed. 
Permanent MCAO in the rat was performed by Dr. K. Yatsushiro as originally described by 
Tamura et. al. (1981). Twenty min (n=3), 40 min (n=4) and 80 min (n=3) following the 
induction of cerebral ischaemia, the animals were killed by transcardiac perfusion and the 
brains processed for tau, MAP2 and MAP5 immunohistochemistry. The distribution of 
tau, MAP2 and MAP5 immunoreactivity in neurons was also investigated for comparison.
3.3.1 MAP2 as a marker of ischaemic damage
MAP2 immunostaining has been shown to be a sensitive marker of ischaemic damage in 
animal models of cerebral ischaemia (Dawson and Hallenbeck, 1996; Kitagawa, et. al. 
1989; Yamamoto, et. al. 1986; Yanagihara, et. al. 1990). Although traditional histological 
stains such as H&E have been employed within 4 h of permanent focal ischaemia at shorter 
survival times, these stains are difficult to interpret. Therefore, in this study involving very 
short survival times following MCAO, the anatomical extent of ischaemic damage was 
detected using MAP2 immunostaining (Fig. 35). Twenty min post-MCAO, an area where 
MAP2 immunostaining was decreased was detected within the caudate nucleus in the 
ipsilateral hemisphere. Forty and 80 min post-occlusion, MAP2 immunostaining was 
decreased within the caudate nucleus within the territory ipsilateral to the occluded MCA. In 
addition, areas of decreased immunoreactivity were also detected within the ipsilateral 
cortex, however this was variable and patchy in its distribution. Decreased MAP2 
immunostaining was detected in all animals used in this study. For a more detailed 
description of altered MAP2 distribution in neurons following ischaemic brain injury see 
section 3.3.3.
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Figure 35. Photomicrograph of a rat brain section stained with MAP2 showing the area of 
ischaemic damage following 40 min MCAO. Immunoreactivity was markedly reduced in 
perikarya and neuropil of the caudate nucleus ipsilateral to the occluded MCA. The 
boundary of ischaemic tissue could also be detected in the cortex (arrow). All animals used 
in this study showed areas of decreased MAP2 immunoreactivity within the caudate 
nucleus, two animals also showed patches of decreased immunoreactivity in the cortex. 
Scale bar = 50p.m.
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3.3.2 Time course o f increased tau immunoreactivity in oligodendrocytes 
following permanent MCAO in the rat.
In the hemisphere contralateral to the occluded MCA of all animals in this study the 
distribution of Tau 1, TP70 and TP007 immunoreactivity within the cortex and caudate 
nucleus was predominantly located within neurons. In previous studies no tau-positive 
oligodendrocytes were detected in rat tissue with any of the tau antibodies before or after 
dephosphorylation of the tissue (see section 3.1). In this study however, occasional tau- 
positive oligodendrocytes were detected in the subcortical white matter of the contralateral 
hemisphere 20 min following MCAO, using Tau 1, TP70 and TP007. This number 
increased slightly with time, however the number of tau-positive oligodendrocytes /  mm2 of 
subcortical white matter remained low compared to the contralateral hemisphere (Fig. 37). 
This suggests that the mechanisms underlying increased tau immunoreactivity in 
oligodendrocytes are induced throughout the entire corpus callosum following MCAO. 
Twenty min following MCAO, only a few tau-positive oligodendrocytes were detected 
within the ipsilateral subcortical white matter however this was greater than that in the 
contralateral hemisphere. In rats subjected to 40 min (Fig. 36 & 37) or 80 min of focal 
ischaemia, the number of tau-positive oligodendrocytes in the ipsilateral subcortical white 
matter, detected with all three tau antibodies, was increased compared to the contralateral 
white matter (Fig. 37). While increased tau immunoreactivity was most prominent within 
intrafasicular oligodendrocytes located in the subcortical white matter, oligodendrocytes 
were also present to a lesser extent in the grey matter of the caudate nucleus and the 
neocortex ipsilateral to the occluded MCA. These oligodendrocytes, detected using all three 
tau antibodies, were present in grey matter only within the boundary of ischaemic damage as 
determined by MAP2 immunostaining. Double label immunohistochemistry confirmed that 
similarly to the previous studies, these tau-positive glial cells with the morphological 
appearance o f oligodendrocytes present in the subcortical white matter ipsilateral to the 
occluded MCA were morphologically and immunologically similar to oligodendrocytes 
(Fig. 38).
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Figure 36. Tau immunostaining of subcortical white matter 40 min following MCAO in 
the rat. Tau immunostaining was localised mainly within the axons of the contralateral 
subcortical white matter 40 min following MCAO as detected with Tau 1, TP70 and TP007. 
In contrast, ipsilateral to the occluded MCA, numerous tau-positive oligodendrocytes were 
present in the subcortical white matter 40 min following the induction of cerebral ischaemia. 
Tau-positive oligodendrocytes in the ipsilateral hemisphere were detected with Tau 1, TP70 
and TP007. Scale bar = 50p.m.
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Figure 37. Quantification (described in section 2.6.4) showed the number of tau-positive 
oligodendrocytes to increase with time following MCAO. Twenty min following MCAO 
the number of tau-positive oligodendrocytes /  mm2 in the ipsilateral subcortical white matter 
was increased slightly as compared to contralateral white matter. The number of tau- 
positive oligodendrocytes / mm2 increased significantly 40 and 80 min following MCAO in 
the white matter ipsilateral to the occluded MCA. Increased cell density was detected with 
all three antibodies : Tau 1, TP70 and TP007. Data are presented as Mean ± SEM, 20 min 
(n=3), 40 min (n=4) and 80 min (n=3).
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Figure 38. Identification of tau-positive glia present after MCAO as oligodendrocytes. A: 
Section labelled with Tau 1 shown in purple and GFAP shown in grey. Tau-positive cells 
were clearly GFAP-negative and therefore immunologically distinct from astrocytes. In 
addition tau-positive cells were morphologically distinct from astrocytes, which displayed 
an elaborate array of processes (arrows), having a compact, rounded appearance consistent 
with that of oligodendrocytes. B: Section double labelled with Tau 1 shown in purple and 
transferrin shown in grey. Tau-positive cells stained positive for transferrin, the coincident 
staining appears black. These cells were therefore immunologically and morphologically 
similar to oligodendrocytes. Scale bar = 50|im.
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In contrast to those directed towards tau, oligodendrocytes were not detected with antibodies 
directed towards MAP2, MAP5 or c-fos in the subcortical white matter contralateral or 
ipsilateral to the occluded MCA at any time following the induction of cerebral ischaemia 
(Fig. 39).
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F igure  39. MAP2, MAP5 and c-fos immunostaining of subcortical white matter 40 min 
following the induction of focal cerebral ischaemia in the rat. In contrast to tau, MAP2, 
MAP5 or c-fos immunoreactivity was not detected in oligodendrocytes of the ipsilateral 
subcortical white matter 40 min following MCAO. Together this data suggests that the 
induction of tau immunoreactivity in oligodendrocytes following MCAO in the rat is a 
specific response of these cells to injury. Scale bar = 50pm.
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3.3.3 Neuronal distribution of MAPs following permanent focal cerebral 
ischaemia in the rat
The purpose of the study described above was to examine tau immunostaining in 
oligodendrocytes in response to MCAO. However, in addition to changes in tau described 
within oligodendrocytes in the previous section, changes in the neuronal distribution of tau 
were also observed. Alteration to the neuronal distribution of tau were distinct from those 
observed in oligodendrocytes and therefore for comparison the following section describes 
these changes.
Tau
The distribution of Tau 1 immunoreactivity was predominantly located within axons of the 
hemisphere contralateral to the occluded MCA (Fig. 40). Twenty min following MCAO, 
Tau 1 immunoreactivity was increased within neuronal perikarya of both the cortex and 
caudate nucleus ipsilateral to the occluded MCA (Fig. 40). In contrast, there was no 
significant alteration in Tau 1 staining of the neuropil within these areas. Forty min after 
MCAO, Tau 1 immunoreactivity was increased within neuronal perikarya of both the cortex 
and caudate nucleus. In addition, increased immunoreactivity was detected within the 
neuropil of the caudate nucleus (Fig. 40). Eighty min following MCAO, the number of Tau 
1 positive neuronal perikarya detected within the cortex, ipsilateral to the occluded MCA, 
decreased as compared to that present 40 min after MCAO. Within this area o f the cortex, 
decreased neuropil staining was also detected as compared to the contralateral hemisphere. 
Tau 1 staining remained increased within the neuropil of the caudate nucleus ipsilateral to the 
occluded MCA.
TP70 and TP007 detected tau both within neuronal perikarya and axons in the hemisphere 
contralateral to the occluded MCA (Fig 41 & 42). TP70 and TP007 immunoreactivity 
remained relatively unchanged within neuronal perikarya and neuropil of the cortex and 
caudate nucleus ipsilateral to the occluded MCA, 20 min following the induction of cerebral 
ischaemia. In contrast to Tau 1, TP70 (Fig. 41) and TP007 (Fig. 42) staining of neuronal 
perikarya was decreased in the cortex and caudate nucleus, ipsilateral to the occluded MCA, 
40 and 80 min following the induction of cerebral ischaemia, as compared to the 
contralateral hemisphere. TP70 immunostaining was decreased slightly within the neuropil 
of the cortex and caudate nucleus, ipsilateral to the occluded MCA (Fig. 41), in contrast 
TP007 immunoreactivity remained relatively unaltered (Fig. 42).
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Figure 40. Tau 1 immunoreactivity within neurons 40 min following MCAO in the rat. 
Tau 1 immunoreactivity was increased in neuronal perikarya of the cortex and caudate 
nucleus in the hemisphere ipsilateral to the occluded MCA, 40 min after the induction of 
cerebral ischaemia as compared to controls. Axonal staining was not significantly altered 
within the cortex as compared to controls, however increased axonal staining was detected 
in the caudate nucleus 40 min after MCAO as compared to controls. Scale bar = 100p.m.
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Figure 41. TP70 immunoreactivity within neurons 40 min following MCAO in the rat. In 
contrast to Tau 1, TP70 immunoreactivity was decreased within neuronal perikarya of the 
cortex and caudate nucleus ipsilateral to the occluded MCA, 40 min following the induction 
of cerebral ischaemia, as compared to control. Axonal staining was decreased within the 
cortex and caudate nucleus ipsilateral to the occluded MCA 40 min following MCAO. Note 
the tau positive glia (arrows) within the caudate nucleus. Scale bar = 100p.m.
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Figure 42. TP007 immunoreactivity within neurons 40 min following MCAO in the rat. 
Similarly to TP70, TP007 immunoreactivity was decreased within neuronal perikarya of the 
cortex and caudate nucleus ipsilateral to the occluded MCA, 40 min following the induction 
of cerebral ischaemia as compared to control. Axonal staining was not significantly altered 
in the cortex or caudate nucleus ipsilateral to the occluded MCA. Scale bar = 100pm.
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Twenty min following MCAO, MAP2 immunoreactivity was increased in neuronal 
perikarya of both the cortex and caudate nucleus ipsilateral to the occluded MCA as 
compared to the contralateral hemisphere (Fig. 43). An area where MAP2 staining was 
decreased within neuropil outlined the boundary of tissue affected by MCAO within the 
caudate nucleus and cerebral cortex. Forty or 80 min following MCAO, decreased MAP2 
immunoreactivity was detected within neuronal perikarya and neuropil of the caudate 
nucleus within the hemisphere ipsilateral to the occluded MCA (Fig. 43). MAP2 
immunoreactivity was increased in neuronal perikarya and decreased in the neuropil of the 
cortex, however the number of positive cells was decreased compared to that present 
following 20 min MCAO (Fig. 43).
M AP 5
MAP5 immunoreactivity was detected both within neuronal perikarya and neuropil of the 
cortex and caudate nucleus contralateral to the occluded MCA (Fig. 44). Twenty min 
following MCAO, increased MAP5 immunoreactivity was detected in neuronal perikarya of 
both the cortex and caudate nucleus ipsilateral to the occluded MCA as compared to the 
contralateral hemisphere. No significant difference in MAP5 immunostaining was detected 
within the neuropil. Forty and 80 min after MCAO MAP5 immunoreactivity remained 
increased in perikarya of the cortex and caudate nucleus ipsilateral to the occluded MCA, 
however the number of cells stained with MAP5 was decreased in the cortex as compared to 
that following 20 min MCAO (Fig. 44). Decreased staining o f the neuropil was detected 
within the cortex ipsilateral to the occluded MCA, as compared to that of the contralateral 
hemisphere.
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Figure 43. MAP2 immunoreactivity within neurons 40 min following MCAO in the rat. 
Increased MAP2 immunoreactivity was detected in neuronal perikarya, while neuropil 
staining decreased within the cortex ipsilateral to the occluded MCA 40 min following the 
induction of cerebral ischaemia. In the hemisphere ipsilateral to the occluded MCA, MAP2 
staining was decreased within both the neuronal perikarya and neuropil of the caudate 
nucleus, as compared to the contralateral hemisphere. Scale bar = 100pm
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Figure 44. MAP5 immunoreactivity in neurons 40 min following MCAO in the rat. 
Increased MAP5 immunoreactivity was detected in neuronal perikarya within the cortex and 
caudate nucleus, in the hemisphere ipsilateral to the occluded MCA 40 min following the 
induction of cerebral ischaemia as compared to control. In the hemisphere ipsilateral to the 
occluded MCA, MAP5 immunoreactivity was decreased in neuropil within the cortex and 
caudate nucleus as compared to the contralateral hemisphere. Scale bar = 100pm.
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3 . 3 . 4  Mechanisms underlying increased tau immunoreactivity in 
oligodendrocytes following focal cerebral ischaemia.
Glutamate excitotoxicity is involved in the mechanisms underlying the neurodegeneration 
which occurs following ischaemic brain injury (for review see McCulloch, et. al. 1991) 
and intracortical perfusion in the rat induced tau-positive oligodendrocytes. Therefore it 
might be speculated that the presence of tau immunoreactivity within oligodendrocytes in the 
focal ischaemia model may be induced by the actions of elevated extracellular concentrations 
of glutamate (Butcher, et. al. 1990). However the ability of intracortical NaCl perfusion to 
induce a similar response suggests that additional mechanisms may be involved in the 
induction of tau immunoreactivity within these cells. In addition to glutamate receptor 
activation, free radical mediated mechanisms have also been implicated in the pathology of 
cerebral ischaemia (see section 1.2.3). In vitro studies employing pure oligodendrocyte 
cultures have shown that oligodendrocytes are susceptible to both glutamate toxicity and free 
radical mediated damage (see section 1.5.7). The next study was therefore designed to 
determine whether the presence of tau immunoreactivity within oligodendrocytes following 
focal cerebral ischaemia in the rat, was initiated through glutamate receptor activation or free 
radical mediated mechanisms. In order to do this, rats were pre-treated with the NMDA 
receptor antagonist MK-801, the AMPA receptor antagonist NBQX or the spin trap agent 
PBN. Previous studies using the MCAO rat model of focal ischaemia have shown these 
agents at the doses used in this study reduced the volume of infarcted tissue following 
permanent MCAO in the rat (Cao and Phillis, 1994; Gill, et. al. 1992; Park, et. al. 1988).
The time course study described in section 3.3.2 demonstrated that the number of tau- 
positive oligodendrocytes / mm2 detected in the subcortical white matter ipsilateral to the 
occluded MCA was markedly increased 40 min after the induction of focal cerebral 
ischaemia in the rat. This was the earliest time point following MCAO that significant 
numbers of tau-positive cells were detected within the subcortical white matter ipsilateral to 
the occluded MCA and was therefore selected for the drug intervention study. Similarly to 
the previous quantitative study, for each animal the total number o f tau-positive 
oligodendrocytes in the entire subcortical white matter, extending from that underlying the 
perirhinal cortex to that underlying cingulate cortex was counted at two distinct brain levels, 
as described in section 2.6.4. The area of subcortical white matter within which tau-positive 
cells were counted was measured for each animal and the number of tau-positive cells /  mm2 
subcortical white matter was calculated for both the ipsilateral and contralateral hemispheres. 
Thirty min prior to MCAO rats received PBN (lOOmg/kg; n=5), MK801 (0.5mg/kg, n=5) 
or NBQX (30mg/kg; n=4), NBQX was administered again 30 min following MCAO. 
Forty min following MCAO animals were killed by transcardiac perfusion of 4%
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paraformaldehyde, and the brains processed for tau immunohistochemistry. Animals 
subjected to 40 min MCAO with no therapeutic intervention served as controls in this study.
Ipsilateral hemisphere
Pre-treatment with the spin trap agent PBN reduced the number of tau-positive 
oligodendrocytes /  mm2 by approximately 50% within the subcortical white matter ipsilateral 
to the occluded MCA of animals subjected to 40 min cerebral ischaemia as compared to 
untreated animals (Fig. 45). This marked reduction in the number of oligodendrocytes / 
mm2 subcortical white matter ipsilateral to the occluded MCA was consistendy detected 
using all 3 tau antibodies : Tau 1 (recognises a dephosphorylated epitope between residues 
199-202); TP70 (directed towards the C-terminal of tau) and TP007 (directed towards the 
N-terminal of tau) (Fig 45).
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Figure 45. Effect of PBN pre-treatment on the number of tau-positive oligodendrocytes 
present in the ipsilateral sucortical white matter 40 min following MCAO. Pre-treatment 
with the spin trap agent PBN (lOOmg/kg) significantly reduced the number of tau-positive 
oligodendrocytes /  mm2, as detected with Tau 1, TP70 and TP007, in the ipsilateral 
subcortical white matter as compared to untreated animals (* p<0.05). Data is presented as 
Mean ± SEM. Statistical analysis consisted of ANOVA followed by Student's r-test with 
Bonferroni correction.
11 0
By contrast, pre-treatment with the glutamate receptor antagonists MK801 or NBQX failed 
to decrease the number of tau-positive oligodendrocytes / mm2, as detected with Tau 1, 
TP70 and TP007, in the subcortical white matter ipsilateral to the occluded MCA compared 
to untreated animals (Fig. 46). Moreover, pre-treatment with MK801 and NBQX increased 
the number of tau-positive oligodendrocytes in the ipsilateral subcortical white matter by up 
to 50% and 25% respectively. The statistical significance of this increase was not tested due 
to the a priori hypothesis being tested i.e. that drug intervention would decrease the 
response in the ischaemic hemisphere. Together these data suggest that the mechanisms 
which lead to increased tau immunoreactivity in oligodendrocytes following focal cerebral 
ischaemia at least in part involve free radicals but not glutamate receptor activation.
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Figure 46. Effect of MK801 and NBQX pre-treatment on the number of tau-positive 
oligodendrocytes 40 min following MCAO. Pre-treatment with the NMDA receptor 
antagonist MK801 (0.5mg/kg) or the AMPA receptor antagonist NBQX (30mg/kg, x2) 
failed to significantly reduced the number of tau-positive oligodendrocytes / mm2, as 
detected with Tau 1, TP70 and TP007, in the ipsilateral subcortical white matter compared 
to untreated animals. Data is presented as Mean ± SEM. Statistical analysis consisted of 
ANOVA followed by Student's f-test with Bonferroni correction.
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Contralateral hemisphere
Due to the unilateral nature of the ischaemic brain damage resulting from MCAO, the 
contralateral hemisphere served as a control for the effect of drug treatment alone on tau 
immunoreactivity in oligodendrocytes. In animals pre-treated with PBN, the number of tau- 
positive oligodendrocytes /  mm2 in the contralateral hemisphere 40 min following MCAO 
was not significantly different from that present in untreated animals (Fig. 47). This shows 
that PBN alone did not have an effect on tau immunoreactivity within oligodendrocytes 
distant from the area of ischaemic brain injury.
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Figure 47. The effect of PBN pre-treatment on tau-positive oligodendrocytes within the 
contralateral subcortical white matter 40 min following MCAO. Pre-treatment with PBN 
(lOOmg/kg) did not significantly alter the number of tau-positive oligodendrocytes /  mm2, as 
detected with Tau 1, TP70 or TP007 as compared to untreated animals. This shows that 
PBN alone at this concentration does not have an effect on tau immunoreactivity in 
oligodendrocytes. Data is presented as Mean ± SEM.
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Pre-treatment with MK801 or NBQX however increased the number of tau-positive 
oligodendrocytes in the contralateral subcortical white matter compared to untreated animals 
(Fig. 48). Thus treatment with these glutamate receptor antagonists alone at the 
concentrations employed in the present study have an effect on tau in oligodendrocytes 
distant from the area of ischaemia. Again the statistical significance of this increase was not 
tested due to the a priori hypothesis being tested i.e. that drug intervention would decrease 
the response in the ischaemic hemisphere.
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Figure 48. The effect of MK801 and NBQX pre-treatm ent on tau-positive 
oligodendrocytes within the contralateral subcortical white matter 40 min following MCAO. 
Following pre-treatment with MK801 (lOOmg/kg) or NBQX (2 x 30mg/kg), the number of 
tau-positive oligodendrocytes /  mm2 subcortical white matter increased by up to 300% and 
100% respectively as compared to untreated animals. This increase was detected with each 
of the 3 tau antibodies used : Tau 1; TP70 and TP007, showing that MK801 and NBQX 
alone have an effect on tau immunoreactivity in oligodendrocytes. Data is presented as 
Mean ± SEM.
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3.4 The effect of permanent focal cerebral ischaemia on the 
synthesis of tau in oligodendrocytes
In all the experimental models used so far and in the human post-mortem brain tissue, 
increased tau immunoreactivity was detected by antibodies directed towards the N- and C- 
terminals, as well as the middle portion of the protein. This suggests that full-length tau 
may be present in oligodendrocytes and that increased staining represents increased protein 
levels. The next question to be addressed therefore, was whether tau synthesis was 
increased under the same pathological circumstances as those in which increased 
immunoreactivity was present. In situ hybridisation studies were performed in order to 
determine whether tau immunoreactivity detected within oligodendrocytes following 
permanent MCAO in the rat reflects increased de novo synthesis of the protein. In this 
study rats were killed 40 min (n=2), 120 min (n=2) and 240 min (n=2) after the induction of 
permanent cerebral ischaemia and the brains processed for in situ hybridisation.
An anti-sense 35S labelled riboprobe was synthesized from a 1031 bp fragment generated 
from the coding region of rat tau cDNA (see section 2.3). Dark field microscopy, revealed 
neurons of the cerebral cortex as the most intensely labelled cells in rat brain sections (Fig. 
49). High signal was also detected in neurons of the caudate nucleus and other areas of 
grey matter, however these were labelled to a lesser extent than cortical neurons. Low 
levels of signal were detected in the subcortical white matter, however the cellular 
localisation of this signal was difficult to distinguish. The level of signal detected in the 
white matter was only slightly higher than that detected in sections labelled with a sense 
riboprobe, suggesting that this signal may represent non-specific hybridisation (Fig. 49).
Forty, 120 or 240 min following the induction of ischaemia, no significant difference in the 
distribution of tau mRNA in oligodendrocytes was detected within the white matter 
ipsilateral to the occluded MCA, as compared to the contralateral hemisphere (Fig. 50). 
However, 120 or 240 min after MCAO tau mRNA was decreased within the neurons of the 
cortex within the region of ischaemic tissue (Fig. 51)
cortex
white matter
sense probe
Figure 49. Distribution of tau mRNA in normal rat brain tissue. Tau mRNA was 
detected using a 35S labelled riboprobe directed towards the coding region of rat tau cDNA. 
Dark field microscopy revealed that tau mRNA was detected predominantly within neurons 
of the cerebral cortex in histologically normal tissue. Signal present in the subcortical white 
matter was, by contrast, much lower than that present in grey matter. In situ hybridisation 
using a sense riboprobe resulted in similar levels of signal within the subcortical white 
matter, suggesting that signal detected in the subcortical white matter using the antisense 
ripboprobe represent non-specific hybridisation of the probe. Scale bar = 200|im.
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Figure 50. Distribution of tau mRNA in the subcortical white matter following MCAO in 
the rat. No significant increase in tau mRNA was detected in the subcortical white matter 
ipsilateral to the occluded MCA, 40 min (b), 120 min (c) or 240 min (d) following MCAO 
as compared to the contralateral white matter (a). Scale bar = 200|im.
40mincontrol
120min 240min
Figure 51. The distribution of tau mRNA in neurons following MCAO in the rat. Tau 
mRNA as detected with a 35S riboprobe directed against the coding region of tau, was 
decreased in the ipsilateral hemisphere 120 min (c) and 240 min (d) following MCAO as 
compared to control (a).No significant alteration in the pattern of tau mRNA was seen 40 
min following MCAO as compared to controls. Scale bar = 200p.m.
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3 .5  Tau protein in an 0-2A  oligodendrocyte cell line
The previous experiments show that the induction of tau im m unoreactivity in 
oligodendrocytes is a rapid response of these cells to acute brain injury and is initiated 
through free radical mediated mechanisms. However, whether the presence of tau in 
oligodendrocytes results through direct injury to these cells or is mediated through neuronal 
degeneration is not known. Pure oligodendrocyte cultures derived from an 0-2A  cell line, 
kindly prepared by Dr S.C. Barnett were therefore utilised to investigate the direct effects of 
pathological stimuli on tau immunoreactivity.
3 . 5 . 1  Western blot analysis of tau in oligodendrocyte cultures
In normal rat brain tau exists as six isoforms. To determine whether tau was present in 
oligodendrocytes in culture, extracts from these cultures were resolved on SDS-PAGE and 
blotted with Tau 1 and TP70 antibodies. Both antibodies detected multiple isoforms of tau 
in oligodendrocyte cultures, however each resulted in a different banding pattern. TP70 
detected four major bands between 40kDa and 60kDa (Fig. 52). Tau 1 detected five bands 
within a similar molecular weight range, however the highest molecular weight band 
(~60kDa) detected with TP70 was not detected with this antibody, suggesting that this 
isoform may be phosphorylated at the Tau 1 epitope. These results show that 
oligodendrocyte cultures used in this study contain tau protein.
3.5.2 Tau immunoreactivity in oligodendrocyte cultures 
Tau immunoreactivity in control cultures
In contrast to oligodendrocytes in normal rat brain tissue, oligodendrocyte cultures derived 
from an 0-2A  cell line, maintained under normal culture conditions, stained positive for tau 
as detected with Tau 1, TP70 and TP007 (Fig. 53, 54 & 55). This is in agreement with 
western blot analysis of these cultures which showed the presence of multiple tau isoforms 
in control cultures and suggests that full length tau protein is present in these cells. Each 
antibody showed a distinct pattern of immunoreactivity. TP70 and Tau 1 stained the cellular 
cytoplasm within the cell body and processes, while TP007 immunoreactivity appeared to 
be within the nucleus. Nuclear staining often represents non-specific binding, it is possible 
therefore that TP007 may recognise an unrelated epitope in the nucleus of these cells. 
TP007 immunoreactivity remained nuclear following exposure to glutamate and NaCl (Fig. 
55) and the results were therefore disregarded.
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Figure 52. Western blot analysis of tau in cultured oligodendrocytes, using TP70 and 
Tau 1. Similarly to tau present in whole rat brain homogenates (lanes 1 & 3), tau extracted 
from oligodendrocyte cultures consisted of multiple isoforms (lanes 2&4). Rat brain 
homogenates displayed tau isoforms between 52 & 68kDa as described previously (Drubin, 
et. al. (1984). In oligodendrocyte extracts, TP70 detected 3 major bands ranging from 44- 
66kDa (lane 2). Tau 1 however detected 5 bands ranging from 44-60kDa (lane 4).
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M onosodium glutam ate dose response curve
All experiments described below were carried out in duplicate on three occasions using 
different batches of oligodendrocyte cultures. Pure oligodendrocyte cultures were exposed 
to IOjxM, lOOpM or ImM monosodium glutamate for 4 h at 37°C in a CO2  incubator. 
Immediately following incubation, the cells were rinsed and immunostained with Tau 1 
(Fig. 53). Tau 1 immunoreactivity remained relatively unchanged following exposure of 
oligodendrocyte cultures to 10|iM monosodium glutamate as compared to control cultures. 
Following exposure to 100|iM monosodium glutamate Tau 1 immunoreactivity was 
significantly increased both within the cytoplasm of the cell body and processes. Tau 1 
immunoreactivity was increased following exposure to ImM monosodium glutamate as 
compared to those treated with lOOfiM monosodium glutamate. However, these tau- 
positive oligodendrocytes exhibited signs of degeneration, the cells were swollen in 
appearance and disintegration of processes was detected. From these results IOOjiM 
monosodium glutamate was selected to investigate the effect of sublethal glutamate induced 
injury on tau immunoreactivity in pure oligodendrocyte cultures.
E ffect o f  100 pM  monosodium glutamate and NaCl on tau im m unoreactivity 
in oligodendrocyte cultures
As a control for these studies, oligodendrocyte cultures were exposed to 100|iM NaCl for 4 
h prior to tau immunostaining. Increased Tau 1 immunoreactivity was detected in 
oligodendrocyte cultures treated with either lOOpM monosodium glutamate or lOOfiM NaCl 
(Fig. 54). However, the intensity of Tau 1 staining was less in NaCl treated cultures as 
compared to those treated with glutamate (Fig. 54). Dephosphorylation of control cultures 
prior to Tau 1 immunostaining resulted in a similar increase in the intensity of Tau 1 staining 
following treatment with IOOjiM monosodium glutamate and NaCl (Fig. 54). In contrast to 
the increased Tau 1 immunoreactivity detected following exposure of cultures to 100|iM 
monosodium glutamate or NaCl, TP70 staining remained largely unchanged as compared to 
controls (Fig. 55). Together these results suggest that, in contrast to the accumulation of tau 
in oligodendrocytes detected in vivo following glutamate or NaCl perfusion, tau undergoes 
dephosphorylation following cytotoxic injury in vitro. All results were obtained in duplicate 
on three separate occassions.
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Figure 53. Tau 1 immunoreactivity in oligodendrocyte cultures treated with 10p.M, 
IOOjiM or ImM monosodium glutamate for 4 h. Similarly to that present in control cultures 
(a), Tau 1 immunoreactivity was detected within the cytoplasm of the cell body and 
processes of oligodendrocytes following exposure of these cultures to 10p.M monosodium 
glutamate (b). However, following exposure to IOOjiM monosodium glutamate (c), Tau 1 
immunoreactivity was increased both within the cell body and processes. Treatment of 
cultures with ImM monosodium glutamate resulted in increased Tau 1 imunoreactivity, 
however cells showed signs of degeneration, such as the disintegration of cellular processes 
(arrows) and swelling of the cell body (d). Scale bar = 100p.m.
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Figure 54. Tau 1 immunoreactivity in oligodendrocyte cultures derived from an 0-2A 
cell line. Tau 1 immunoreactivity was detected within the cytoplasm of the cell body and 
processes of oligodendrocytes maintained in Sato's growth medium. Following exposure 
o f these cultures to IOOjiM monosodium glutamate or IOOjiM NaCl, Tau 1 
im m unoreactivity  was increased both within the cell body and processes. 
Dephosphorylation of control cultures prior to immunostaining resulted in a similar pattern 
of Tau 1 immunoreactivity within these cells as detected following treatment with IOOjiM 
monosodium glutamate or NaCl. Scale bar = lOOjim.
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Figure 55. TP70 and TP(X)7 immunoreactivity in oligodendrocyte cultures derived from 
an 0-2A  cell line. TP70 immunoreactivity was detected in oligodendrocyte cultures 
maintained in Sato's growth medium. Immunoreactivity was detected within the cytoplasm 
of the cell body and processes, while TP007 was localised mainly to the cell nucleus. 
Following treatment of cultures with 100|iM monosodium glutamate or IOOjiM NaCl, the 
distribution of TP70 and TP007 immunoreactivity was relatively unchanged. The 
localisation of TP007 immunoreactivity to the nucleus, suggests that this antibody may bind 
non-specifically to an unrelated protein within these cells. Scale bar = lOOjim
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CHAPTER 4 DISCUSSION
The original aim of my thesis was to investigate the possible mechanisms underlying 
cytoskeletal breakdown in neurons following acute brain injury. However, in the first study 
investigating the possible role of glutamate excitotoxicity in this process, tau 
immunoreactivity was detected within oligodendrocytes. This intriguing finding indicated 
that cells other than neurons within the CNS may respond to acute brain injury with changes 
in tau protein. My studies were therefore directed at further characterising the presence of 
tau in oligodendrocytes following acute brain injury and determining the mechanisms 
underlying this response. Until recently oligodendrocytes have been considered to be 
relatively inactive during cerebral ischaemia, however the work in this thesis shows that 
oligodendrocytes have the ability to respond rapidly to acute brain injury and may therefore 
play an important role in the progression of ischaemic brain damage. I will firstly describe 
changes in the oligodendrocyte cytoskeleton that occur following acute brain injury and then 
go on and compare these to the alterations of the cytoskeleton which occur in neurons.
4 .1  Detection of the 11 neuronal" protein tau in oligodendrocytes 
following acute brain injury
4 . 1 . 1  Distribution of tau in histologically normal brain tissue
The normal distribution of tau in the CNS has been well documented (see section 1.4.2) and
it is generally accepted that tau is predominantly located within neurons where it is most
abundant in the axonal compartment (Binder, et. al. 1985; Brion, et. al. 1988;
Papasozomenos and Binder, 1987; Trojanowski, et.al. 1989). Moreover, tau mRNA was
shown to be located specifically within neurons in situ (Goedert, et. al. 1989; Kosik, et. al.
1989a; 1989b). In the studies carried out throughout this thesis, tau immunoreactivity was
found located mainly within neurons in histologically normal rat and human brain tissue,
supporting a predominantly neuronal localisation of tau. Tau immunoreactivity was not
detected within glia in histologically normal tissue using antibodies directed towards various
regions of tau : Tau 1 (recognises a dephosphorylated epitope in the middle portion of the
protein); TP70 (raised against C-terminal portion of tau); TP007 (raised against the N-
terminal portion of tau) and B19 (raised against full-length tau). In addition,
dephosphorylation of histologically normal rat or human brain tissue failed to induce Tau 1
immunoreactivity in glial cells, suggesting that the lack of Tau 1 immunoreactivity in these
cells is not due to masking of the protein by phosphorylation. In support of this TP70,
TP007 and B19 antibodies, which detect tau independent of its phosphorylation state, also
failed to detect tau in glial cells in normal rat or human brain tissue. These results suggest
that tau may be absent from glial cells in histologically normal human and rat brain tissue, or
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may reflect very low levels of tau within mature glia in vivo which are undetectable using 
standard immunohistochemical techniques. This is in contrast to a previous study which 
reported the presence of tau immunoreactivity in glial cells and neurons (Migheli, et. al. 
1988). In addition, Tau 1 immunoreactivity was detected in perineuronal oligodendrocytes 
and astrocytes but not intrafasicular oligodendrocytes in rat brain following enzymatic 
dephosphorylation o f the tissue (Papazosomenos and Binder, 1987). However, in 
agreement with the present study, Lopresti, et. al. (1995) failed to detect oligodendrocytes 
in normal rat brain using Tau 1 however did detect tau in intrafasicular oligodendrocytes 
using Tau 5, an antibody raised specifically towards glial tau. The possibility that tau 
present in intrafasicular oligodendrocytes in normal brain may be folded in a particular 
conformation within the oligodendrocyte thus preventing antibody binding cannot be ruled 
out. However, it is difficult to envisage that epitopes located in the middle of the protein 
and at the N- and C- terminals of the protein would all be masked under normal conditions 
and all uncovered following injury. Furthermore the immunostaining detected using the 
polyclonal antibodies TP70 and TP007 raised against synthetic fragments of tau is unlikely 
to be altered by conformational change in the protein.
4 . 1 . 2  Tau immunoreactivity in oligodendrocytes following acute brain 
injury
Due to the vast amount of evidence suggesting that tau is a neuron-specific protein and the 
inability of the tau antibodies used throughout this thesis to detect tau in glial cells in 
histologically normal brain tissue, the most intriguing and novel finding of this thesis was 
the induction of tau immunoreactivity in small cells with the morphological appearance of 
glia following acute brain injury. Double label immunohistochemistry, utilising GFAP as a 
cellular marker for astrocytes and transferrin as a cellular marker for oligodendrocytes, 
identified these tau-positive glial cells as oligodendrocytes. Tau-positive oligodendrocytes 
were detected in all animal models of acute brain injury and in post-mortem brain tissue 
from patients who died following a stroke or head injury. These tau-positive cells were 
found located in both white and grey matter depending on the location of the brain injury. 
In white matter these cells were arranged in rows with the appearance of intrafasicualr 
oligodendrocytes, while those in grey matter were found located around neurons and were 
therefore assumed to be perineuronal oligodendrocytes. Tau immunostaining was observed 
with antibodies directed towards full length tau, and the N- and C-terminals of the protein 
suggesting the accumulation of full-length tau protein within these cells. Tau-positive 
oligodendrocytes were also detected using the Tau 1 antibody, showing that tau present in 
these cells following injury was dephosphorylated at the Tau 1 epitope. It is possible that 
injury to oligodendrocytes may result in a conformational change in tau which results in 
increased antigenicity, however as discussed above it is unlikely that all the epitopes
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examined in this study would be masked and unmasked equally before and after injury. 
Together these findings do not support the complete absence of tau in intrafasicular or 
perineuronal oligodendrocytes within the adult rat and human brain. In addition, to the 
evidence described above showing tau within oligodendrocytes in normal rat brain tissue, 
glial inclusions characteristic of chronic neurodegenerative conditions such as MSA, PSP 
and PD (Abe, et. al. 1992; Iwatsubo, et. al. 1994; Nishimura, et. al. 1992; Yamada, et. al.
1992) have been shown to stain positive for tau. Tau present in these cells can be detected 
with antibodies directed towards PHF tau, suggesting that in addition to neurons, tangle 
formation may also occur in glial cells during chronic progressive degeneration of the brain.
Although oligodendrocytes contain abundant microtubules and would therefore be expected 
to contain many MAPs, in contrast to tau, neither MAP2 nor MAP5 immunoreactivity was 
detected in oligodendrocytes before or after acute brain injury in human or rat brain tissue. 
This is in contrast to previous studies which report the presence of both MAP2 and MAP5 
immunoreactivity in oligodendrocytes (Fischer, et. al. 1990; Ulloa, et. al. 1994b; 
Vouyiouklis and Brophy, 1995). The possibility that oligodendrocytes in situ express 
levels of these proteins below the detection limits of standard immunohistochemical 
techniques cannot be ruled out. However, mRNA for MAP2 and MAP5 has been located 
only within neurons in vivo (Gamer, et. al. 1988; Landry, et. al. 1994; Papadrikopoalou, 
et. al. 1986; Tucker, et. al. 1989) suggesting that glial cells in situ do not express these 
proteins. These studies highlight the caution that should be exercised when extrapolating 
events occurring in vitro to those occurring in vivo where the cellular milieu is more 
complex.
4 . 1 . 3  Tau in oligodendrocyte cell cultures
Further supporting the presence of tau in non-neuronal cells, the results presented in this 
thesis show the presence of tau in pure oligodendrocyte cultures derived from an 0-2A  cell 
line. In the adult rat brain, tau protein comprises six isoforms produced by alternative 
splicing of a single mRNA transcript Similarly, tau present in the oligodendrocyte cultures 
also comprised several isoforms. This finding is in agreement with those of Lopresti, et. al. 
(1995) who also showed the presence of multiple tau isoforms in primary oligodendrocyte 
cultures. Immunoblotting with TP70 detected 3 major bands ranging from 40-66kDa. In 
contrast Tau 1 detected 5 major bands within a similar molecular weight range, however 
failed to detect the highest molecular weight isoform detected with TP70. In addition to the 
multiple isoforms reported here, Lopresti, et. al. (1995) also showed the presence of a 
higher molecular weight band of approximately 80kDa. The distinct pattern of isoform 
detection with Tau 1 and TP70 suggests that, as with neuronal tau, isoforms present in 
oligodendrocytes are modified by phosphorylation. Together these results confirm the
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presence of tau in oligodendrocytes maintained in normal culture conditions. To ascertain 
whether these bands represent an oligodendrocyte specific isoform pattern or whether each 
band represents differentially phosphorylated forms of a single isoform would require 
isolation and characterisation of the tau protein and characterisation of the tau transcripts 
present within these cells.
In contrast to oligodendrocytes present in the normal rat CNS, tau as detected with Tau 1 
and TP70 was present within oligodendrocytes in vitro maintained in normal growth 
conditions. In addition, the distribution of tau was different in oligodendrocyte cultures as 
compared to those in situ following acute brain injury. In oligodendrocytes resident within 
adult rat brain, tau immunoreactivity was located only within the cell body, no staining was 
present in the cellular processes. This is probably not surprising however due to the 
intricate architecture of the mature CNS; oligodendrocyte processes are not readily detected 
in situ at the light microscope level. In vitro however TP70 and Tau 1 immunoreactivity 
was detected both within the cytoplasm of the oligodendrocyte cell body and the cellular 
processes. The possibility that discrepancies between in vivo and in vitro studies is due to 
the accesability of the tau epitopes to the antibodies cannot be ruled out.
Detection of tau with TP70 and to a lesser extent Tau 1, suggests the presence of full-length 
tau protein in these cells under normal culture conditions. It should be noted that although 
oligodendrocytes were detected with Tau 1, the intensity of this staining was far less than 
that of TP70, suggesting that a proportion of tau present in these cells is phosphorylated at 
the Tau 1 epitope. Immunostaining with Tau 1 and TP70 was continuous along the length 
of the oligodendrocyte processes. This contrasts with the findings of Lopresti, et. al. (1995) 
who reported discontinuous staining within the cellular processes. In their studies, tau 
staining was segmental, present at the tips of the processes and in the membrane expansions 
present at the end of each process. It is possible to speculate that discrepancies between 
these 2  studies may reflect differential stages of maturity of the cultures used in the 2  
studies, since cells used in the investigations carried out in this thesis did not show any 
membrane expansions present in their cultures. Alternatively this may reflect species 
differences since cultures used throughout this thesis were derived from rat tissue while 
those employed by Lopresti, et. al. 1995 were derived from ovine brain. In contrast to 
these 2 studies Vouyiouklis and Brophy (1995) failed to show the presence of tau in rat 
primary oligodendrocyte cultures using the monoclonal antibody Tau 2 directed towards 
full-length tau. This may be partly explained by the poor cross-reactivity of this antibody 
with rat tissue (Binder, et. al. 1985).
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The apparent lack of tau immunoreactivity in oligodendrocytes in situ may reflect levels of 
protein in these cells which are below the limits of detection using standard 
immunohistochemical techniques, however tau protein may be more abundant in 
oligodendrocyte cultures than those present in vivo. Cell cultures are derived from 
immature tissue and, although these cells were grown for 5 days and showed 
immunological characteristics of mature oligodendrocytes, it is possible that they may still 
be undergoing development. Oligodendrocytes have to extend multiple processes required 
for the effective myelination of axons and in addition, proteins required for myelin 
formation have to be transported to the site of myelinogenesis. There is a general consensus 
that the oligodendrocyte cytoskeleton is involved in oligodendrocyte process extension and 
myelin assembly (Brophy, et. al. 1993). Tau has been shown to be involved in process 
extension in neurons (Caceres and Kosik, 1990; Caceres, et. al. 1991) and presuming that 
tau has similar functional properties in both neurons and oligodendrocytes, tau may also 
play a key role in process extension in oligodendrocytes. Supporting this theory, the tips of 
growing oligodendrocyte processes, like neuronal growth cones are known to be actin rich 
(Kachar, et. al. 1986) and previous studies have shown that tau binds to actin in vitro 
(Seldon and Pollard, 1983). Taken together this data supports a role for tau in 
oligodendrocytes similar to that proposed for neuronal tau in the growth cones of cerebellar 
neurons. That is, mediating interactions between elements of the growth cone cytoskeleton, 
therefore maintaining its structural organization (DiTella, et. al. 1994). It is possible 
therefore that until the extension of processes and myelination is established, 
oligodendrocytes may express high levels of tau protein. Therefore, oligodendrocytes 
present in culture, although expressing markers of mature oligodendrocytes, may still be 
extending processes and thus contain high levels of tau protein. In contrast, fully developed 
oligodendrocytes present within the adult CNS may lack the necessity for high levels of tau 
protein.
The differential distribution of tau present in oligodendrocytes in vitro and in vivo highlight 
the care that should be exercised when extrapolating findings in vitro to events occurring 
within the adult CNS where the cellular milieu is more complex. To ascertain whether tau 
present in these cells is similar to that present in neurons requires further characterisation, 
however together the results presented in this thesis strongly indicate that tau is present in 
oligodendrocytes and therefore can no longer be viewed as a neuron-specific protein.
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4 .2  The induction of tau immunoreactivity in oligodendrocytes 
is a rapid response to acute brain injury
The results presented in this thesis provide compelling evidence that the induction of tau 
immunoreactivity in oligodendrocytes is a rapid response of these cells to acute brain injury. 
The first study in this thesis, showed the presence of tau-positive oligodendrocytes 4 h 
following intracortical perfusion of 1M monosodium glutamate both within the resulting 
cortical lesion and in the subcortical white matter immediately underlying this area. The 
presence of tau-positive oligodendrocytes in human post-mortem tissue from patients who 
died within 2  h following head injury confirmed that the induction of tau immunoreactivity 
in oligodendrocytes was not a phenomenum characteristic of rat brain, but also occurred 
rapidly in human brain. Tau-positive cells were detected within and immediately 
surrounding areas of tissue shown by decreased H&E staining to be damaged by the injury. 
Following severe head injury in the human, the proportion of tau-positive cells detected 
increased with survival time and it is possible to speculate that this pattern may reflect the 
evolution of brain damage over time following injury. The detection of tau-positive 
oligodendrocytes in post-mortem brain tissue of patients who died 23 h following head 
injury and several weeks following a stroke suggests that the induction of tau 
immunoreactivity in these glial cells is maintained over long periods of time. In order to 
determine just how rapidly the presence of tau-positive oligodendrocytes could be detected, 
animals were killed 20, 40 or 80 min following MCAO and the brains processed for tau 
immunohistochemistry. Twenty minutes following MCAO the number of tau-positive 
oligodendrocytes /  mm2  subcortical white matter was not significantly different in the 
ipsilateral hemisphere compared to the contralateral hemisphere. However, 40 and 80 min 
following MCAO the number of tau-positive oligodendrocytes / mm2  subcortical white 
matter in the ischaemic hemisphere, as detected with all three antibodies : Tau 1, TP70 and 
TP007, was increased compared to the contralateral hemisphere. Tau-positive 
oligodendrocytes were located predominantly within the subcortical white matter ipsilateral 
to the occluded MCA where they were found aligned in rows with the appearance of 
intrafasicular oligodendrocytes. In addition tau-positive perineuronal oligodendrocytes were 
also found scattered throughout the caudate nucleus and cortex within the area of ischaemic 
tissue as defined by decreased MAP2 immunostaining. Thus, tau immunostaining in 
oligodendrocytes increased within 40 min of the ischaemic challenge, indicating that these 
glial cells, like neurons, have the ability to respond rapidly to injury.
Proteins coded by proto-oncogenes such as c-fos, act to carry cytoplasmic signals to the 
nucleus where they interact with the DNA enhancing the expression of several genes 
(Morgan and Curran, 1989; 1991). C-fos mRNA expression has been shown to increase
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rapidly within neurons following ischaemic brain injury in the rat (Abe and Kogure, 1993; 
Hsu, et. al. 1993). Increased expression of c-fos and other immediate early genes 
following brain injury is thought to be involved in the ability of neurons to survive 
following injury (Magnusson and Wieloch, 1989), however, the real significance of this 
reponse is unknown. Since tau immunoreactivity in oligodendrocytes is detected rapidly 
following injury, it is possible to speculate that this may be part of a "stress” response of 
these cells to brain injury. C-fos has recently been shown to be induced in oligodendrocytes 
progenitor cells in vitro following exposure to glutamate (Liu and Almazan, 1995), 
suggesting that increased c-fos may occur in response to injury in these cells. The 
distribution of c-fos immunoreactivity in oligodendrocytes was therefore examined in the rat 
brain following MCAO this gene product was also increased in these oligodendrocytes 
following injury in vivo. In contrast to increased c-fos levels seen in neurons 20 min after 
MCAO, and in oligodendrocyte progenitor cells in vitro, c-fos was undetectable within 
oligodendrocytes in situ before or after MCAO. Together these results suggest that acute 
brain injury in the rat specifically alters tau protein in oligodendrocytes and the alteration is 
not due to a generalised "stress" response within these cells.
4 .3  Mechanisms underlying the induction of tau 
immunoreactivity in oligodendrocytes
4 . 3 . 1  Glutamate toxicity in vivo induces tau immunoreactivity in 
oligodendrocytes
The in vivo model of glutamate toxicity used in this study has been well characterised 
previously (Landolt, et. al. 1993; Fujisawa, et. al. 1993; 1996) and provides a means of 
studying the effects of glutamate toxicity without the interference of factors such as reduced 
blood flow, present in models of cerebral ischaemia. In the in vivo study described in 
section 3.1, 1M monosodium glutamate was perfused through the dialysis probe, at a 
concentration far in excess of those used in previous in vitro studies (|iM range). However, 
due to the dynamics of the dialysis membrane, only approximately 1 0 % of the solution 
being perfused reaches the tissue where glutamate uptake into astrocytes (Hertz, et. al. 
1992; Schousboe, et. al. 1988) further reduces the concentration of extracellular glutamate 
remaining in the tissue. The extracellular concentration of glutamate decreases further in 
relation to the distance from the probe as the glutamate diffuses through the tissue. The 
extracellular concentration of glutamate reaching the corpus callosum is therefore estimated 
to be within the pM-mM range.
Tau immunoreactivity was detected in intrafasicular and peri-neuronal oligodendrocytes 
within the subcortical white matter and the cortical lesion respectively, following
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intracortical perfusion of 1M monosodium glutamate, suggesting that glutamate may be 
involved in the accumulation of tau in oligodendrocytes following acute brain injury. 
Monosodium glutamate was chosen to avoid the use of glutamic acid which proves 
problematic when maintaining a neutral pH and 1M NaCl was therefore the control solution 
for this study. The ability of NaCl perfusion to induce tau immunoreactivity within 
oligodendrocytes however, suggests that mechanisms other than glutamate toxicity may be 
involved in this response. It is possible to speculate that the mechanisms underlying tau 
accumulation in oligodendrocytes involves the presence of excessive extracellular Na+. 
Glutamate excitotoxicity to neurons has been shown to consist of both a NaCl component 
and a Ca++ component (Dessi, et. al. 1994). Influx of NaCl results in neuronal swelling 
and can induce neuronal degeneration without concurrent influx of Ca++. In addition, 
increased extracellular sodium exacerbates the damage produced by glutamate, possibly 
through the disturbance of the Na+/K + glutamate transporter. Cells from the 
oligodendrocyte lineage have been shown to express many ion channels in vitro including 
two types of voltage dependant Ca++ channels (Blankenfield, et. al. 1992; Verkhratsky, et 
al. 1990), and Na+ channels (for review see Barres, et. al. 1990). In light of this it is 
possible to envisage that high extracellular concentrations of Na+ would result in Na+ influx 
through Na+/K+ channels, resulting in membrane depolarisation. Such depolarisation of the 
membrane may lead to the initiation of Ca++ influx through voltage gated Ca++ channels and 
through the mobilisation of intracellular Ca++ stores. Moreover, it is possible that glutamate 
toxicity in oligodendrocytes may also consist of both a NaCl and a Ca++ component, since 
glutamate and the non-NMDA receptor agonists, kainate and AMPA have been shown to 
cause an influx of Na+ in oligodendrocyte cultures (Borges and Kettenman, 1995). 
Furthermore glutamate toxicity in oligodendrocytes in vitro has also been shown to be Ca** 
dependent (Yoshioka, et. al. 1995). Disruption of Ca++ homeostasis is thought to be 
involved in the formation of free radicals (Siesjo, et. al. 1989). Once free radicals are 
formed these cause further disruption of calcium homeostasis and therefore a vicious circle 
continues. It is possible to speculate therefore that free radical mediated mechanisms 
initiated through increased intracellular Ca++ levels, whether through glutamate receptor 
activation or excess Na+ ions, may be involved in the induction of tau immunoreactivity in 
oligodendrocytes as outlined below.
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In support of this theory oligodendrocytes have been shown to be particularly susceptible to 
free radical damage (Kim and Kim, 1991; Oka, et. al. 1993; Thorbume and Juurlink, 
1996). Moreover, in the present studies pre-treatment of animals with the spin trap agent 
PBN significantly reduced the number of tau-positive oligodendrocytes /  mm2  present in the 
subcortical white matter following focal cerebral ischaemia. This will be discussed more 
extensively in section 4.3.3.
4 . 3 . 2  Increased Tau 1 immunoreactivity in oligodendrocytes is a direct 
response of these cells to cytotoxic injury
Experiments employing pure oligodendrocyte cultures provided evidence that changes in tau 
occurring in oligodendrocytes following cytotoxic injury are induced through a direct effect 
on oligodendrocytes and is not mediated through neuronal degeneration. Electron 
microscopy showed oligodendrocytes did not show significant signs of degeneration 
following in vivo perfusion of 1M monosodium glutamate or NaCl. The in vitro study was 
therefore designed to treat the cells with a sublethal dose of monosodium glutamate and 
NaCl. Exposure to 100|iM glutamate over 24 h has previously been reported to be sublethal 
to oligodendrocyte cultures (Oka, et. al. 1993). In the present study oligodendrocyte 
cultures were exposed to 10|iM, 100|iM and ImM monosodium glutamate for 4 h. 
Exposure of oligodendrocytes to 10|iM monosodium glutamate failed to induce changes in 
tau immunoreactivity within these cells, in contrast tau immunoreactivity was increased 
following exposure to 100 or ImM monosodium glutamate. However morphological signs 
of degeneration were detected oligodendrocyte cultures exposed to ImM  monosodium 
glutamate, therefore lOOpM monosodium glutamate was selected for this study.
Tau 1 immunoreactivity was increased in the cytoplasm of both the oligodendrocyte 
perikarya and processes following treatment of the cells with lOOpM monosodium 
glutamate or lOOpM NaCl for 4 h. In contrast to the in vivo study however, TP70 
immunoreactivity remained largely unchanged following exposure to IOOjiM monosodium
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glutamate or NaCl, although staining within the cellular processes became slightly more 
prominent with TP70. Dephosphorylation of cultures maintained in Sato's medium resulted 
in a similar intensity of Tau 1 immunoreactivity present following treatment with IOOjiM 
monosodium glutamate or NaCl. Together these results suggest that rather than 
accumulation of tau protein within these cells as seen in situ , increased Tau 1 
immunoreactivity reflects dephosphorylation of existing protein in response to glutamate or 
NaCl exposure. However the possibility that increased TP70 levels were not detected due 
to the high level of immunoreactivity present in control cells cannot be ruled out.
These results show that alterations to tau in oligodendrocytes following exposure to 
monosodium glutamate or NaCl is a direct response of these cells to injury. This suggests 
that the accumulation of tau in oligodendrocytes in vivo following acute brain injury is is not 
a consequence of neuronal degeneration. However they do highlight again the caution that 
must be exercised when relating events occurring in vitro to those occurring in vivo where 
the cellular milieu is more complex.
4 . 3 . 3  The spin trap agent PBN reduces the number of tau-positive 
oligodendrocytes following focal cerebral ischaemia in the rat
The presence of tau-positive oligodendrocytes following exposure to both glutamate and 
NaCl suggests that additional mechanisms other than glutamate receptor activation are 
involved in the initiation of this response. Both glutamate toxicity and free radical mediated 
mechanisms have been implicated in the evolution of ischaemic brain damage. 
Oligodendrocytes have been shown in vitro to be susceptible to both glutamate and free 
radical mediated toxicity therefore permanent MCAO in the rat was used to determine if 
glutamate receptor activation or free radical mediated events are involved in the mechanisms 
underlying the accumulation of tau in oligodendrocytes following ischaemic brain injury.
Pre-treatment of animals with the spin trap agent PBN prior to MCAO significantly reduced 
the number of tau-positive oligodendrocytes /  mm2  in the subcortical white matter ipsilateral 
to the occluded MCA as compared to untreated animals 40 min after the induction of focal 
cerebral ischaemia. This indicates that the initiating stimulus for the response involves 
events mediated by free radicals. Oligodendrocytes are thought to be particularly susceptible 
to free radical damage due to low levels of the free radical scavenger glutathione and high 
levels of iron which is a catalyst for free radical production (Thorbume and Juurlink, 1996). 
Primary cultures of bovine oligodendrocytes were shown to be susceptible to oxygen 
radicals derived from glucose/glucose oxidase and hypoxanthine/xanthine oxidase reactions 
(Kim and Kim, 1991). In that study, cytotoxicity was measured by tryptan blue exclusion 
and lactate dehydrogenase leakage, and it showed that oxygen radicals induce significant
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membrane damage to oligodendrocytes within 2  h of exposure. In addition, Oka, et. al.
(1993) showed in rat primary oligodendrocyte cultures that glutamate induced cell death was 
mediated, not through glutamate receptor activation, but through free radical mediated 
mechanisms. Excessive extracellular glutamate concentrations led to the efflux of cystine 
from these cells through the actions of the glutamate/cystine transporter which in turn 
resulted in glutathione depletion. Glutathione is an important protective agent against 
oxidative stress (for review see Bast et. al. 1991) and its depletion therefore renders the cell 
vulnerable to oxidative stress. PBN is a nitrone compound which reacts with many types 
of free radicals resulting in the formation of the stable nitroxide radical adducts (Oliver, et. 
al. 1990). Glutamate toxicity and free radical generation have been shown to be 
interdependent, many studies demonstrating that glutamate toxicity can be markedly 
reduced by treatment with free radical scavenger systems both in vitro (Bondy and Lee, 
1993; Dykens, et. al. 1987; Murphy, et. al. 1990; Miyamoto, et. al. 1989; Nakao, et. al. 
1996) and in vivo (Nakao, et. al. 1996; Schulz et. al. 1995). Extracellular glutamate 
concentrations peak at 40 min following MCAO in the rat (Butcher, et. al. 1990) and it is 
possible to speculate therefore that treatment with PBN protects oligodendrocytes indirectly 
from glutamate toxicity and directly from free radical mediated damage resulting from 
ischaemic injury and thus prevents accumulation of tau within these cells.
In contrast to PBN neither the NMD A receptor antagonist MK801 nor the AMPA receptor 
antagonist NBQX prevented increased tau immunoreactivity in oligodendrocytes following 
40 min cerebral ischaemia further indicating that glutamate receptor activation is not involved 
in the response. However, both primary oligodendrocyte cultures and immortalised cultures 
derived from rat brain express non-NMDA receptor subtypes (Patneau, et. al. 1994; 
Puchalski, et. al. 1994; Yoshioka, et. al. 1995). Moreover, damage to these cells was 
mediated by non-NMDA receptor activation. Thus in our in vivo experimental paradigm, 
while it is possible that activation of AMPA receptors by excessive extracellular glutamate 
concentrations may damage oligodendrocytes, this signalling pathway does not appear to be 
involved in the tau protein response. Alternatively, the rapid desensitisation of AMPA 
receptors in oligodendrocytes in response to glutamate (Yoshioka, et. al. 1995) may have 
masked any effect of receptor blockade by NBQX. Finally although the selection of the 
drug doses were based on those previously shown to reduce infarct volume following 
permanent focal cerebral ischaemia in the rat (Cao and Phillis, 1994; Gill, et. al., 1992; 
Park, et. al. 1988), the possibility that the concentration of NBQX used in this study may be 
too low to prevent ischaemia induced accumulation of tau in oligodendrocytes cannot be 
ruled out. Mature oligodendrocytes have been reported to contain non-NMDA receptors, 
although mRNA for NMDA receptors was not detected (Patneau, 1994; Puchalski, et. al. 
1994; Yoshioka, et. al 1995) and therefore it is perhaps not surprising that MK801 failed to
1 3 4
prevent increased tau immunoreactivity in these cells following ischaemic injury. However, 
the mean value of tau-positive oligodendrocytes present in both the ipsilateral and 
contralateral white matter was greater following MK-801 treatment compared to controls. 
This suggests that MK-801 alone may be able to induce increased tau in oligodendrocytes. 
In the absence of a direct effect on oligodendrocytes themselves, increased tau 
immunoreactivity within these cells may arise as an indirect consequence of neuronal 
changes both in proximity and distant to ischaemia. MK-801 and other NMDA ion channel 
blockers induce a range of marked neurochemical alterations within neurons which include 
glucose utilisation and heat shock protein gene expression (Kurumaji et. al., 1988; Sharp, 
et. al. 1992). In light of the growing literature on neuronal-glia communication it may be 
envisaged that MK-801-induced changes in neuronal activity in turn induce responses in 
associated oligodendrocytes. Alterations in the cytoskeletal protein tau may represent such a 
response. Together the results of these studies show that the induction o f tau 
immunoreactivity in oligodendrocytes is initiated through free radical mediated mechanisms.
4 .4  Functional significance of tau in oligodendrocytes 
following injury
4 . 4 . 1  Protective response ?
At this stage the functional significance of tau in oligodendrocytes following acute brain 
injury is unknown. If tau is a neuron-specific protein it is intriguing that oligodendrocytes 
express a neuronal protein following injury. It is possible to speculate the accumulation of 
tau in oligodendrocytes following injury may be part of a protective response in that 
dephosphorylated tau is able to bind to and stabilise microtubules (Brandt and Lee, 1994; 
Kosik, 1993; Trinczek, et. al. 1995). Increased tau immunoreactivity was detected with 
antibodies directed towards full length protein and both the N- and C-terminals of the 
protein suggesting the accumulation of full length protein within these cells following acute 
brain injury both in the rat and the human. In situ hybridisation studies were therefore 
carried out to determine if this increased immunoreactivity in oligodendrocytes following 
ischaemic brain injury reflects increased de novo synthesis of tau.
In situ hybridisation using a 35S-labelled riboprobe synthesized from a 103 lbp fragment of 
the coding region of adult rat tau cDNA revealed that tau mRNA was predominantly located 
within the neurons of the cerebral cortex in rat brain contralateral to the occluded MCA. A 
low level of message was detected in white matter tracts, however the cellular localisation of 
this signal was difficult to interpret. Control experiments using a sense riboprobe generated 
from the same coding region of tau cDNA revealed a similar level of signal within the 
subcortical white matter, suggesting that white matter signal reflects non-specific
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hybridisation of the riboprobe. This is in agreement with previous studies which detected 
tau mRNA in neurons, however failed to detect tau mRNA in glial cells (Goedert, et. al. 
1989; Kosik, et. al. 1989). Following 40, 120 or 240 min MCAO in the rat, no significant 
changes in the pattern of tau mRNA distribution was detected ipsilateral to the occluded 
MCA. This suggests that increased tau immunoreactivity within oligodendrocytes 
following ischaemic brain injury does not reflect increased de novo synthesis of the protein. 
This is maybe not surprising considering the rapidity of tau accumulation in 
oligodendrocytes following injury. However the possibility that our detection system was 
not sensitive enough to detect small increases in mRNA levels within these cells cannot be 
ruled out.
In addition, it is possible to speculate that mRNA present in oligodendrocytes may differ 
from that present in neurons. Recently a 2kb and 8 kb tau mRNA have been detected in a 
neuroblastoma cell line and the peripheral nervous system respectively, encoding nuclear tau 
and big tau, as opposed to the 6 kb mRNA originally described for neuronal tau (Couchie, 
et. al. 1992; Goedert, et. al. 1992; Loomis, et. al. 1990; Wang, et. al. 1993). The 
riboprobe used in the present study was derived from a 1031 bp fragment of the coding 
region of a tau cDNA encoding the 6 kb mRNA of tau which includes exons 2, 3 and 10 
(Kosik, et. al. 1989). However, it is unknown what type of tau mRNA is present in 
oligodendrocytes. Tau cDNA encoding the 8 kb mRNA, contains an extra 762bp region 
encoded by exon 4A situated down stream of exons 2 and 3 which encode the N-terminal 
inserts (Goedert, et. al. 1992). In addition exon 6  further downstream from exon 4A has 
also Ibeen reported to be expressed in this larger isoform of tau (Couchie, et. al. 1992). The 
riboprobe generated in the present study encompasses 1031 bp of the coding region from the 
3' end of the tau cDNA. It is possible to speculate therefore that the expression of exon 4A 
and // or 6  would reduce the strength of hybridisation of the probe with this area of the 
mRNA. Signal obtained from weaker hybridisation reactions between the probe and the 
mRNA therefore may be lost during the stringency washes designed to reduce non-specific 
hybridisation.
Recently increased ferritin synthesis was reported in oligodendrocytes following 6 h hypoxia 
in vitro (Qi and Dawson, 1992, 1994, 1995). In these studies the authors showed that 
increased protein levels were due to a post-transcriptional modification of protein synthesis. 
It is; possible to speculate therefore that increased tau immunoreactivity within 
oligodendrocytes following acute brain injury may also represent post-transcriptional 
modiification of protein synthesis, which may account for the rapid appearance of tau in 
these cells. If increased tau immunoreactivity does reflect a protective response of these
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cells to injury, it is possible to envisage that post-transcriptional modification of protein 
synthesis would result in the rapid increase in tau protein levels required for their protection.
There is growing evidence that the oligodendrocyte cytoskeleton is involved in process 
extension and the transport of myelin proteins to the site of myelin assembly (Brophy, e t  al.
1993). The tips of growing oligodendrocyte processes, like neuronal growth cones are 
known to be actin rich (Kachar, et. al. 1986) and previous studies have shown that tau 
binds to actin in vitro (Seldon and Pollard, 1983). Taken together this data supports a role 
for tau in oligodendrocytes similar to that proposed for neuronal tau in the growth cones of 
cerebellar neurons (DiTella, et. al. 1994). Tau has been shown to be involved in process 
extension in neurons (Caceres and Kosik, 1990; Caceres, et. al. 1991) therefore it is 
possible to speculate that tau also plays a key role in the extension of oligodendrocyte 
processes. Oligodendrocytes contain abundant microtubules which have been postulated to 
be key elements in the transportation of myelin proteins to the site o f myelin assembly 
(Barbarese, et. al. 1991; Brophy, et. al. 1993; Colman, et. al. 1982). Purified MBP can 
form complexes with tubulin and actin (Modesti and Barra, 1986), and using cell culture 
both MBP and CNP have been shown to associate with the cytoskeleton of 
oligodendrocytes (Colman, et. al. 1982; Gillespie, et. al. 1989). Both CNP and MBP are 
synthesized on free ribosomes and have to be transported into the processes for myelin 
formation. It is possible to speculate therefore that microtubular networks within these cells 
are essential for the transportation of the machinery required for myelin formation into the 
processes. Recently MBP and tau have been shown to co-localize within the cell soma, 
processes and myelin expansions of oligodendrocyte cultures (Lopresti, et. al. 1995) and 
tau has also been postulated to play a role in the transportation of MBP mRNA and protein 
to the site of myelinogenesis (Lopresti et. al. 1995). It is attractive to hypothesise therefore 
that increased levels of dephosphorylated tau in these cells following injury may act to 
stabilise existing processes and increase the transportation of myelin components to sites 
where myelin sheaths have been damaged.
Petito, et. al. (1985) showed that medium-light oligodendrocytes increased in size following 
permanent focal cerebral ischaemia in the rat (Petito, et. al. 1985). These cells showed 
increased microtubule profiles and accounted for approximately 50% of all glial cells within 
2 hr o f injury, however the number present decreased to 6.5% by 3 h. Petito, et. al. 
suggest that cell loss may represent a transition of medium-light oligodendrocytes to 
intermediate glia which have some characteristics of both oligodendrocytes and astrocytes. 
This may represent an "active” oligodendrocyte. Since tau is postulated to be involved in 
process expansion and therefore cell morphology, it is possible to speculate that increased 
tau levels within these cells following injury may be involved in the morphological changes
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described following ischaemia and may therefore represent a marker for "active" 
oligodendrocytes. In addition oligodendrocytes have been shown to proliferate 24 hr 
following trauma in the mouse (Ludwin, 1984). It could be envisaged that the accumulation 
of tau following acute brain injury may be involved in the proliferation of oligodendrocytes, 
which would require the extension of new cellular processes. Tau-positive 
oligodendrocytes found following acute brain injury may thus represent cells about to 
undergo or are undergoing proliferation.
4 . 4 . 2  Degenerative response ?
In contrast to a protective role, the accumulation of tau in oligodendrocytes may represent an 
early stage of cellular degeneration. Tau has recently been reported to be present in glial 
inclusions characteristic of chronic neurodegenerative conditions such as MSA, PSP and PD 
(Abe, et. al. 1992; Iwatsubo, et. al. 1994; Nishimura, et. al. 1992; Yamada, et. al. 1992). 
Tau present in these glial inclusions can be detected using antibodies directed towards PHF 
tau, suggesting that tau in these glial inclusions is abnormally phosphorylated. The 
detection of tau immunoreactivity in oligodendrocytes present in human post-mortem brain 
tissue from patients who died following a stroke or head injury indicates that the 
accumulation of tau occurs in both acute and chronic neurodegenerative conditions. In 
contrast to tau present in glial inclusions (Abe, et. al. 1992; Iwatsubo, et. al. 1994; Kato, e t  
al. 1991; Nishimura et. al., 1992; Yamada , 1992; Yamada and McGeer, 1990) however, 
tau present in oligodendrocytes early following acute brain injury is dephosphorylated at the 
Tau 1 epitope. In one patient who survived 23 h following severe head injury, and one 
patient surviving several weeks following stroke, TP70 and TP007 immunoreactivity was 
found accumulated to one side of oligodendrocyte cytoplasm with the morphological 
appearance similar to the tau-positive glial inclusions previously described in MSA (Abe, e t  
al. 1992; Iwatsubo, et. al. 1994; Kato, et. al. 1991). These cells were detected within areas 
of tissuie severely affected by head injury and within infarcted tissue of the stroke patient, as 
determined by decreased H&E staining. Together these results suggest that accumulation of 
tau in oligodendrocytes is an acute response of these cells to injury, however the formation 
of cytoplasmic inclusions may occur over time. However such tau-positive inclusions were 
not detected in tissue obtained from patients dying up to 1 2  days following a stroke, 
suggesting that factors other than survival time following injury may be involved in the 
form ation of these tau positive accumulations. Tau present in the cytoplasm of 
oligodendrocytes with a morphology similar to glial inclusions, were not detected with Tau 
1 and iin addition the number of tau-positive oligodendrocytes detected with Tau 1 was 
decreased 23 h following head injury, as compared to earlier survival times, within these 
areas olf tissue where these inclusion like accumulations were detected, suggesting that tau 
within these cells may be phosphorylated at this epitope. Failure of AD2, an antibody
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directed towards PHF tau, to detect tau in oligodendrocytes showed that tau present within 
these cells, in contrast to PHF tau, was not phosphorylated at the AD2 epitope. The 
possibility that tau is phosphorylated at other sites similar to PHF tau cannot be ruled o u t It 
is attractive to speculate therefore that tau accumulation in oligodendrocytes may be a rapid 
response of these cells to acute injury, however changes in antigenicity similar to those of 
PHF tau may occur over longer periods of time. NFT formation is thought to lead to 
neuronal degeneration in a variety of chronic degenerative disorders such as AD, PD and 
PSP, it is possible to speculate that tangle formation in oligodendrocytes will also lead to the 
subsequent degeneration of these cells.
4.5 The neuronal distribution of MAPs following acute brain 
injury
4 . 5 . 1  Tau
Following intracortical perfusion of glutamate, axonal Tau 1 staining was reduced while 
perikaryal staining was increased within the core of the lesion. This in vivo result concords 
with previous in vitro studies which showed increased Tau 1 immunoreactivity within 
cultured neuronal perikarya following glutamate exposure (Bigot and Hunt, 1990; Davis, et. 
al. 1995; Pizzi, et. al. 1993; 1994; 1995). Studies using antisense oligonucleotides 
suggested that increased tau immunoreactivity in vitro reflected increased synthesis of the 
protein supported by the increased Tau 2 staining which recognises full length tau protein 
(Pizzi, et. al. 1993; 1994; 1995). This is in contrast to the results presented in this thesis, 
which suggests that rather than accumulation of protein, increased Tau 1 immunoreactivity 
reflects dephosphorylation of existing protein in response to glutamate toxicity in vivo. In 
support of this theory AT8  immunoreactivity was lost from neuronal perikarya within the 
lesioned area which is consistent with dephosphorylation of tau at this epitope. In addition, 
accumulation of the protein was not indicated with B19, which labels full length tau, or with 
tau antibodies directed at the N- and C-terminals of the protein.
In contrast to the findings of the present study, other in vitro studies have shown the 
converse; increased AT8  immunoreactivity following glutamate exposure (Sindou, et. al.
1994). Although increased Tau 2 immunoreactivity was detected by Sindou and colleagues 
they suggested that the accumulation of phosphorylated tau was not due to increased 
synthesis of the protein (Sindou, et. al. 1992). Discrepancies between different in vitro 
studies may be related to the maturation stage of the neuronal cultures since immature tau 
has antigenic properties similar to that present in neurofibrillary tangles. It is interesting to 
note that in experiments employing neuronal cultures grown for 8 days or less (Mattson, et. 
al. 1990; Sautiere, et. al. 1992; Sindou, et. al. 1994) glutamate was proposed to induce
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changes in tau similar to those found in neurofibrillary tangles. However in cultures grown 
for more than 8 days tau was dephosphorylated at the Tau 1 epitope in response to glutamate 
(Bigot and Hunt, 1990; Pizzi, et. al. 1993; 1994; 1995). It is also interesting to note that 
these investigators showed using antisense oligonucleotides, that increased tau 
immunoreactivity within these older neuronal cultures did represent increased synthesis of 
the protein (Pizzi, et. al. 1993; 1994; 1995). Such discrepancies between in vitro and in 
vivo again highlight the care that should be taken when relating observations made in cell 
cultures to pathophysiological events proposed to occur in the intact CNS, where the cellular 
milieu is more complex.
Monosodium glutamate was used in the present study and it is possible therefore that some 
of the changes in tau immunoreactivity observed may be due to the presence of excessive 
sodium ions. NaCl however failed to induce increased Tau 1 immunoreactivity in perikarya 
seen following glutamate perfusion, indicating that glutamate was responsible for the altered 
pattern of Tau 1 immunoreactivity. However, NaCl perfusion resulted in decreased tau 
immunoreactivity within the neuropil, suggesting that this pattern of immunoreactivity also 
seen following glutamate perfusion may result from excessive levels of sodium ions. In 
addition, decreased B19, TP007 and TP70 was also detected in perikarya following NaCl 
perfusion in vivo further implicating a role for Na+ ions in the disruption of cytoskeletal 
proteins.
Increased Tau 1 immunostaining within neuronal perikarya of the cortex and caudate 
nucleus was detected within 20 min following MCAO in the ra t 40 min following the onset 
of cerebral ischaemia, TP70 and TP007 staining was decreased within neuronal perikarya of 
the cortex and caudate nucleus, ipsilateral to the occluded MCA. Together these results 
suggest that neuronal tau undergoes rapid dephosphorylation, which is closely followed by 
loss of C- and N- terminal immunoreactivity suggesting degradation of the protein, both of 
which may be mediated through glutamate excitotoxicity. In agreement with this, the in situ 
hybridisation studies carried out showed that tau mRNA was decreased early following 
ischaemic brain injury, which implies that tau mRNA is degraded following focal cerebral 
ischaemia. This is in agreement with a previous study showing increased Tau 1 and 
decreased TP70 immunoreactivity within neuronal perikarya of the cortex and caudate 
nucleus 2 h and 6  h following permanent MCAO in the rat (Dewar and Dawson, 1995). 
These results suggest that tau undergoes rapid alteration following MCAO in the rat and that 
these alterations are maintained up to 6  h or more following the induction of cerebral 
ischaemia. However in axons, while Tau 1 immunoreactivity was reduced by both 
glutamate and sodium chloride perfusion in vivo, Tau 1 immunoreactivity was increased in 
the axons of the cortex and caudate nucleus ipsilateral to the occluded MCA 40 min
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following the induction of cerebral ischaemia. A similar increase in Tau 1 staining of axons 
was reported in permanent MCAO in the rat by Dewar and Dawson, (1995). Together this 
suggests that mechanisms other than those involving high extracellular glutamate and /  or 
Na+ levels may be involved in the changes in tau occurring in the axonal compartment 
following ischaemic brain damage.
4 .5 .2  MAP2 and  MAPS
Both MAP2 and MAP5 immunoreactivity was increased in neuronal perikarya and 
decreased in neuropil within the lesion resulting from the intracortical perfusion of 1M 
monosodium glutamate. In contrast to tau which undergoes dephosphorylation and /  or 
degradation, MAP2 and MAP5 appear to undergo redistribution from the neuropil to the 
perikarya. This is in agreement with previous studies showing a similar redistribution of 
MAP2 within neurons in culture following exposure to glutamate (Bigot and Hunt, 1990). 
Similarly, MAP2 and MAP5 immunoreactivity was increased in neuronal perikarya 
ipsilateral to the occluded MCA 20 min following the induction of cerebral ischaemia in the 
rat. 40 min following the onset of ischaemia both MAP2 and MAP5 immunoreactivity was 
decreased in the neuropil of the cortex of the ipsilateral hemisphere, implicating glutamate 
excitotoxicity in the mechanisms underlying the redistribution of these proteins following 
focal cerebral ischaemia. In addition, MAP2 immunoreactivity was decreased within both 
neuronal perikarya and neuropil of the caudate nucleus and clearly delineated the region of 
ischaemic tissue. This is similar to the findings of Dawson and Hallenbeck, (1996) who 
reported decreased MAP2 immunoreactivity within neuropil and neuronal perikarya of the 
caudate nucleus and cortex 1 h following focal cerebral ischaemia in the rat. This study 
further demonstrates the sensitivity of MAP2 to cerebral ischaemia, highlighting its use as a 
sensitive marker for ischaemic damage as early as 40 min of MCAO. NaCl perfusion also 
resulted in reduced MAP2 staining in perikarya and dendrites suggesting that excess Na+ 
ions may be involved in the loss of MAP2 immunoreactivity following 40 min cerebral 
ischaemia.
In conclusion the present study demonstrates that neuronal tau, MAP2 and MAP5 undergo 
marked alteration in their cellular distribution as early as 20 min following MCAO in the rat 
indicating that the neuronal cytoskeleton is extremely vulnerable to ischaemic brain injury. 
Glutamate perfusion in vivo resulted in many of the alterations of tau, MAP2 and MAP5 
described following cerebral ischaemia in the rat; it is possible to speculate therefore that in 
conditions such as cerebral ischaemia and head injury, where excessive extracellular 
concentrations of glutamate are present, alterations in cytoskeletal proteins may be involved 
in the evolution of irreversible brain damage. These results have important implications for 
the development of neuroprotective strategies, since cytoskeletal abnormalities are detected
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within neurons as early as 2 0  min following the induction of cerebral ischaemia which may 
represent the initial stages of irreversible brain damage.
4 .6  Oligodendrocyte versus neuronal tau following acute brain 
injury
Following acute brain injury in the rat and the human, increased tau imunoreactivity was 
detected in oligodendrocytes using a variety of tau antibodies, suggesting the accumulation 
of full-length protein within these cells. In contrast, neuronal tau appears to undego 
dephosphorylation and/or degradation in response to acute brain injury. The accumulation 
of tau in oligodendrocytes was detected as early as 40 min following MCAO in the rat 
suggesting that the cytoskeleton within these cells undergoes rapid alteration following acute 
brain injury. As early as 20 min following MCAO in the rat, increased tau immunoreactivity 
was detected in neuronal perikarya with Tau 1, however this was not detected with 
antibodies raised against the N- and C-terminals of the protein. Together these results 
suggest that in contrast to the accumulation of full-length tau in oligodendrocytes, neuronal 
tau becomes dephosphorylated and/or degraded following acute brain injury in the rat. 
Dephosphorylation of tau in neurons was detected as early as 20 min following MCAO in 
the rat, however tau-positive oligodendrocytes were not observed until 40 min after the 
induction of cerebral ischaemia. In addition degradation of tau in neurons but not in 
oligodendrocytes suggests that tau present in neuronal perikarya may be more susceptible to 
ischaemic brain damage than that in oligodendrocytes.
Dephosphorylated tau has the ability to bind to and stabilise microtubules. It is therefore 
possible to speculate that increased Tau 1 immunoreactivity detected in both these cell types 
following acute brain injury is an attempt to try and stabilise the cytoskeletal architecture. 
The observation that tau may have undergone some degree of proteolysis within neurons 
may reflect a loss or modification of the C-terminal of the protein which encompasses the 
microtubule binding domain, dephosphorylated tau present in neurons following acute brain 
injury may therefore lack the ability to bind to and stabilise microtubules. In contrast, the 
presence of full length tau within oligodendrocytes following injury suggests that successful 
microtubule stabilisation may occur within these cells therefore helping to maintain their 
cytoskeletal integrity. In contrast to the accumulation of MAP2 and MAP5 in neurons 
following acute brain injury, these proteins were not detected in oligodendrocytes. It is 
possible to speculate that MAP2 and MAP5 remain unaltered in oligodendrocytes following 
injury, however the possibility that oligodendrocytes do not contain these proteins cannot be 
ruled out. Breakdown of the neuronal cytoskeleton is thought to represent a common final 
pathway of irreversible cell damage following ischaemic brain injury. Neurons are 
generally considered to be the most vulnerable cells of the CNS to cerebral ischaemia, while
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oligodendrocytes are thought to be fairly resistant. The differential sensitivities of the 
cytoskeleton to cellular injury in these two cell types may help explain their differential 
sensitivity to acute brain injury.
In addition, the mechanisms underlying the altered distribution of tau in neuronal perikarya 
and oligodendrocytes appear to be different. Glutamate excitotoxicity appears to mediate the 
changes in tau occurring within neurons, while free radical mediated mechanisms appear to 
be responsible for those occurring in oligodendrocytes. Activation of the NMDA receptor 
and subsequent influx of Ca++ is thought to be one of the most important mechanism 
underlying glutamate mediated neurotoxicity following cerebral ischaemia (see McCulloch, 
et. al. (1991) for review). In contrast to neurons which contain abundant NMDA receptors, 
oligodendrocytes only contain mRNA encoding non-NMDA glutamate receptors (for review 
see Gallo and Russell, 1995). Glutamate release occurs immediately following MCAO 
(Butcher, et. al. 1990) and is thought to lead to the release of free radicals (Bondy and Lee, 
1993; Dykens et. al. 1987; Miyamoto, et. al. 1989; Nakao, et. al. 1996; Schulz, et. al.
1995). It is tempting to speculate therefore that neurons are susceptible to the initial release 
of glutamate following the onset of ischaemia, however oligodendrocytes which lack the 
presence of NMDA receptors are more susceptible to the secondary release of free radicals. 
Indeed oligodendrocytes are thought to be particularly susceptible to free radical damage due 
to their high levels of iron and low levels of the endogenous antioxidant glutathione 
(Thorbume and Juurlink, 1996). Further supporting this theory glutamate toxicity has been 
shown to be mediated not through receptor activation, but through free radical mediated 
mechanisms in oligodendrocyte cultures (Oka, et. al. 1993; Yonezawa, e t  al. 1996).
In conclusion, the results of this thesis demonstrate that tau is present in oligodendrocytes, 
which undergoes rapid alteration in response to acute brain injury. Alterations in the 
distribution of microtubule-associated proteins in neurons following injury are thought to 
represent altered cytoskeletal integrity which may result in irreversible neuronal damage. It 
is possible to speculate therefore that alterations to tau in oligodendrocytes, following acute 
brain injury may also represent early stages of cytoskeletal breakdown within these cells. 
Oligodendrocytes have been until recently considered to be relatively unresponsive to 
ischaemic brain injury, and neuroprotective agents have been evaluated solely on their ability 
to reduce neuronal damage. One of the most successful strategies involves the blockade of 
glutamate receptor activation which was without effect in the reduction of the induction of 
tau immunoreactivity in oligodendrocytes following focal cerebral ischaemia. The 
protection of neurons without concurrent protection of glial cells following acute brain 
injury would lead to delayed neuronal death due to the degeneration of glia rather than 
complete protection of the brain following injury.
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Appendix
Growth media 
SOC medium
llitre - 20g tryptone, 5g yeast extract, 0.5g NaCl in distilled water. Add 10ml of 250mM 
KC1 and adjust to pH7 using NaOH and sterilise by autoclaving for 20 min at 151b/in2. 
Once cooled to <60°C 20ml of filter sterilised, 1M glucose solution was added.
Luria-Bertrani (LB) agar indicator plates
llitre- 20g Tryptone, 5g Yeast extract, lOg NaCl; dissolved in distilled water and adjusted to 
pH7; 12g agar/L added and the solution sterilised by autoclaving for 20 min at 151b/in2. 
Agar was allowed to cool to 50°C and the following added prior to pouring the plates: 
0.004% X-gal (5-Bromo-4-chloro-3-indoyl-6-L-galactoside), 0.012% IPTG (isopropylthio- 
6 -D-galactoside) and 100|ig/ml ampicillin.
Terrific Broth
500ml - 6 g Tryptone, 12g Yeast extract, 2ml glycerol, make up to 450ml on distilled water 
(soln A). O.I7 MKH2 PO 4 and 0.72M K2 H PO 4  in 100ml distilled water (soln. B). 
Autoclave both solutions separately for 20 min at 151b/in2, allow to cool and add 50ml of 
soln B and 100|!g/ml ampicillin to soln A.
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